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List of abbreviations
L is t  o f  a b b re v ia t io n s
AAC aminoglycoside dd (NMR) doublet of doublets
acetyltransferase d.e. diastereomeric excess
Ac acetyl DCM dichloromethane
AcOH acetic acid DIBAL diisobutylaluminum hydride
All allyl DIPEA diisopropylethylamine
ANT aminoglycoside DMAP 4-dimethylaminopyridine
nucleotidyltransferase DMF AA,A/-dimethylformamide
APH aminoglycoside DMP Dess-Martin periodinane
phosphotransferase DMSO dimethyl sulfoxide
aq. aqueous DNA deoxyribonucleic acid
Ar aryl dt (NMR) doublet of triplets
arom aromatic e.e. enantiomeric excess
ax axial e.g. exempli gratia (for example)
Bn benzyl eq equatorial
Boc tert-butoxycarbonyl equiv. equivalents
Bu butyl ESI electrospray ionization
Bz benzoyl Et ethyl
°C degrees Celcius (centigrade) et al. et alia (and others)
calcd calculated Fmoc 9-fluorenylmethoxycarbonyl
CAN ceric ammonium nitrate GC gas chromatography
Cbz b enzyl oxycarb onyl h hours
CI chemical ionization HPLC high performance liquid
m-CPBA meta-chloroperoxybenzoic acid chromatography
CSA camphorsulfonic acid HRMS high resolution mass
compd compound spectrometry
d days IBX 2-iodoxybenzoic acid
d (NMR) doublet i. e. id est (that is)
DBU 1,8-diazabicyclo [5.4.0]undec- IR infrared
7-ene m (NMR) multiplet
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List of abbreviations
M molar TEMPO 2,2,6,6-tetramethylpiperidine-
Me methyl 1-oxyl
MIC minimum inhibitory TES triethylsilyl
concentration Tf trifluoromethanesulfonyl
min minutes TFA trifluoroacetic acid
mp melting point THF tetrahydrofuran
MS mass spectrometry or TLC thin layer chromatography
molecular sieves TMS trimethylsilyl
m/z mass to charge ratio Trt trityl (triphenylmethyl)
N normal (equivalents per liter) Ts p-toluenesulfonyl
NBS A/-bromosuccinimide UV ultraviolet
NIS N-iodosuccinimide ITC isothermal titration calorimetry
NMR nuclear magnetic resonance
on overnight
PEG polyethyleneglycol
Ph phenyl
ppm parts per million
q quartet
quant. quantitatively
Rf retention factor
RNA ribonucleic acid
RRE Rev response element
rt room temperature
s singlet (NMR)
sat. saturated
t (NMR) triplet
TBDMS tert-butyldimethylsilyl
TBDPS tert-butyldiphenylsilyl
t-Bu tert-butyl
TCCA trichloroisocyanuric Acid
TEA triethylamine
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CHAPTER 1
Aminoglycoside Antibiotics: Synthetic Strategies to Overcome Clinical 
Limitations
Aminoglycosides, a family of structurally related broad-spectrum bactericidal compounds, have been 
used extensively for the treatment of aerobic gram-negative bacterial infection because of their rapid 
anti-bacterial activity, chemical stability and ability to work in combination with other drugs. However, 
toxic side-effects and growing bacterial resistance have narrowed the significance of aminoglycosides as 
antibiotics. Due to these limitations, extensive research on aminoglycosides has resulted in the 
development of a wide range of synthetic strategies to improve the overall characteristics of 
aminoglycosides. In this chapter, an overview is provided of the various approaches reported in the 
literature to (a) enhance binding affinity, (b) overcome resistance and (c) reduce the toxicity of 
aminoglycosides.
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1.1 I n t r o d u c t io n
Aminoglycosides are a group of structurally related, naturally occurring compounds obtained from 
actinomycetes of genus Streptomyces or Micromonospora1. Since the discovery2 of streptomycin in 
1944, a series of related compounds like neomycin (1949), kanamycin (1957), paromomycin (1959), 
gentamicin (1963) and tobramycin (1968) have been added to the family of aminoglycoside antibiotics. 
The members of the aminoglycoside family are in clinical use for the treatment of aerobic gram-negative 
bacterial infections because of their rapid anti-bacterial activity, chemical stability and ability to work in 
combination with other drugs. In addition, some synthetically modified derivatives of aminoglycosides 
i.e. amikacin, netilmicin, arbekacin, isepamicin, and dibekacin, are also in use as chemotherapeutic 
agents, in particular against resistant bacteria. The antibacterial activity of aminoglycosides stems from 
their binding with therapeutically significant RNA targets3. Moreover, studies have shown that a number 
of aminoglycosides have antiviral activity as a consequence of their specific interactions with viral 
RNA4.
Structurally, as the name suggests, aminoglycosides are composed of a variety of aminosugars. 
However, the most important feature of aminoglycosides is the presence of a central cyclohexitol ring 
(1,3-diamino-4,5,6-trihydroxycyclohexane) commonly known as 2-deoxystreptamine (2-DOS). The 
aminosugars are linked, via glycosidic bonds, to the central 2-deoxystreptamine ring either at the 4 and 5 
position (4,5-linked type), as in neomycin and paromomycin, or at the 4 and 6 position (4,6-linked type), 
as in kanamycin, gentamicin and tobramycin (Figure 1.1). According to the accepted nomenclature the 
aminosugar at position 4 of the deoxystreptamine is ring I and referred to as the primed ring. The central 
aminocyclitol (2-DOS) is ring II and unprimed, while ring III is a substituent at position 5 or 6 of 2- 
deoxystreptamine and is numbered as double primed. Ring IV (triply primed numbering) corresponds to 
any additional ring attached to ring III5. However, a few aminoglycosides are structurally atypical 
according to the above description i.e. streptomycin, spectinomycin. Streptomycin possesses a 
streptidine ring as the central aminocyclitol, and spectinomycin consists of three fused rings (Figure 
1.1).
12
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Figure 1.1 Representative naturally occuring aminoglycoside antibiotics. 2-Deoxystreptamine is indicated in the dashed 
elliptical.
1.2 M o d e  o f  a c tio n
Aminoglycoside antibiotics exert their antibacterial activity by binding to 16S ribosomal RNA at the 
tRNA acceptor A-site (aminoacyl site), and affect the ability of the ribosome to decode mRNA correctly 
during protein synthesis3. Binding of the aminoglycosides to the decoding region changes the orientation 
of two highly conserved adenine residues at position 1492 and 1493 of 16S rRNA. A similar
13
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conformational change during mRNA decoding signals the establishment of an accurate codon- 
anticodon pairing. Reorientation of A1492/1493 induced by aminoglycosides therefore issues a similar 
approval signal even on the binding of non-cognate tRNA, thus resulting in the production of non-sense 
proteins by incorporation of incorrect amino acids6. Recent studies have shown that in addition to 
prokaryotic rRNA, aminoglycosides also bind to a variety of other RNA targets like hammerhead 
ribozyme7, hepatitis delta virus HDV ribozyme8, bacterial RNase P9 and HIV-1 TAR10. The high RNA 
affinity of aminoglycosides is due to the polycationic nature of these antibiotics (since amino groups are 
predominantly protonated at physiological pH). The electrostatic interactions between the positively 
charged ammonium groups on aminoglycosides and the negatively charged phosphate groups on the 
RNA play a key role in RNA-aminoglycoside binding11. Hydroxyl groups of aminosugars also have a 
significant effect on the RNA affinity. A systematic study of deoxygenated tobramycin derivatives has 
shown that removing the neighboring hydroxyl group increased the basicity of an amino group and, in 
turn, increases the RNA affinity of the antibiotics12. Moreover, the conformational flexibility around the 
glycosidic bonds between the saccharide building blocks allows the small molecules to attain different 
conformations to form stable complexes with diverse RNA targets13.
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Figure 1.2. Interactions between typical aminoglycosides and the 30S ribosome. (A) Interactions between paromomycin 
and the 30S ribosome. (B) Interactions between tobramycin and the 30S ribosome.
1.3 R e s is ta n c e
An important obstacle in the clinical use of aminoglycosides is the development of microbial resistance 
against these antibiotics. Structural modification of aminoglycosides by bacterial enzymes is one of the
14
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most important resistance mechanisms, resulting in the loss of antibacterial activity due to reduced 
affinity of a drug for its target14. There are three classes of enzymes responsible for the inactivation of 
aminoglycosides, i.e. aminoglycoside acetyltransferases (AACs), aminoglycoside 
nucleotidyltransferases (ANTs), and aminoglycoside phosphotransferases (APHs), each of which will 
chemically convert one or more substituents of the aminoglycosides (Figure 1.3).
I —\>NH2
NH T  I DH -------  APH’ ANTi 2 I  J. 9H and AAC
OH J J  
h o ' ' " V ^ ’,/n h 2 ' y ' ,,o h
S h
Figure 1.3. Sites of modification of kanamycin B by aminoglycoside-modifying enzymes.
Decrease in the intracellular concentration of antibiotic within the bacterial cell is another mechanism of 
aminoglycoside resistance15. This may be due to a decreased uptake of the antibiotic or bacteria may 
express efflux systems that result in the reduced accumulation of the drug within the cell. In addition, 
some bacteria develop resistance by modifying their 16S rRNA molecule at specific positions critical for 
tight binding of aminoglycosides16.
1.4 T o x ic ity
Another disadvantage that has limited the clinical use of aminoglycisides is relatively frequent 
occurrence of nephrotoxicity and ototoxicity during aminoglycoside treatment. Although the exact 
molecular mechanism of toxicity is still unclear, nephrotoxicity is considered to result from the 
accumulation of antibiotic in the renal cortical cells resulting in tubular cell degeneration17. In the 
majority of cases, nephrotoxicity is dose-dependant and generally reversible when the drug is 
discontinued. Ototoxicity occurs due to the progressive damage of sensory cells of the cochlea and 
vestibular apparatus18. In contrast to the reversible nephrotoxicity, killed sensory cells do not regenerate, 
thus resulting in varying degrees of hearing loss. Finally, neuromuscular blockade is another rare but 
serious adverse effect of aminoglycoside therapy.
15
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1.5 O v e rv ie w  o n  s y n th e t ic  s t r a te g ie s  to  m o d ify  th e  a m in o g ly c o s id e s
Ever since their discovery, extensive research on aminoglycosides has resulted in the development of a 
wide range of synthetic strategies to improve the overall characteristics of aminoglycosides. In the 
introductory chapter of this Thesis, there will be a focus on the synthetic approaches reported in the 
literature to (a) enhance binding affinity, (b) overcome resistance and (c) reduce the toxicity of the 
aminoglycosides. Below, these three topics will be discussed consecutively.
19
Aminoglycoside derivatives to enhance RNA binding affinity
Some total syntheses of aminoglycosides and analogues thereof have been reported in literature. 
However, the most important approach for the synthesis of new aminoglycoside derivatives is by 
modification of naturally occurring aminoglycosides, due to their cheap and large-scale commercial 
availability. For example, Timor and coworker have synthesized a set of modified neomycin B 
analogues by adding an additional sugar at the C5''-OH of ring III and prepared a series of pseudo­
pentasaccharides 1a-d (Figure 1.4)20. In these structures, the neomycin constitution was kept intact as a 
recognition element to rRNA, while the extended sugar ring of each structure was designed to enhance 
the binding affinity. However, the MIC values showed that only compound 1d (MIC = 4.5-6 mg/mL) is 
as potent as neomycin B against E. coli strains while other derivatives were 5 to 10 times less effective 
than natural aminoglycosides. Furthermore, 1d demonstrated an improved antibacterial activity with 
respect to parent neomycin against the resistant strain APH(3').
h 2 n . . N H ,
NH2 Y Y
k^O . Y  ,0H R = h2N
H 0 ' S f  'N H 2
o h  o;
n h 2 o h
H ,N
H O  O H  
1d
Figure 1.4. Structure of 5''modified neomycin.
Based on structural data from X-ray crystallography, Hanessian and co-workers have synthesized 
modified paromomycin derivatives by diversifing the 2''-OH with different amino ethers in order to 
exploit uncharted areas of the A-site, with the possible location of new modes of binding21. The 
modified paromomycin derivatives 2a and 2c demonstrated the similar activity (MIC = 5 mM) as the
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parent paromomycin while compound 2b (MIC = 25 mM) exhibited a slightly reduced activity against E. 
coli strains (Figure 1.5).
H ,N
OH
NH2
"’ OH
OH Ov
rOs
n h 2 o h
Figure 1.5. Structures of paromomycin derivatives.
OH
2a  R =
b R :
A
c R = A
'N H 2
^ nh2
Similarly, Hanessian has reported the synthesis of a library of tobramycin analogues bearing various 
functionalities at 5-OH by the direct modification of tobramycin 3a-e (Figure 1.6)22. Some of these 
modified tobramycin analogues showed a reasonable activity against E. coli. The 5-O-(2-guanidylethyl) 
ether of tobramycin 3e (MIC = 0.6-1.2 mM) was the most active analogue in the series.
h2n^ Y ° >
h2nv / - ^ nh2
I I  0H
T >0V ^ S1-NH2
\  ° V ^ ' ' ' O H
T  S)H
R
3a H2N ^  
3b H
NH
i2i''
i n
3c H N ^ N ^ - ^
3d h 2n '
3e H2N N
NH
R 1
H
H
H ,N
NH
U
H2N N ' A
Figure 1.6. Structures of 5'-modified tobramycin.
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Figure 1.7. Structures of symmetrical and non-symmetrical dimers.
Another approach that has been utilized by various research groups to increase binding affinity is to 
make dimers of existing aminoglycosides23. Dimers are believed to interact with the target RNA in
18
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bivalent fashion while the conformationally adoptable linkers may allow the scanning for multiple 
binding sites on the RNA. Wang and Tor have reported the synthesis of both symmetrical and non- 
symmetrical dimers of aminoglycosides derived from neomycin, kanamycin and tobramycin (Figure 
1.7)24. The primary 5''-OH of neomycin and 6'-OH of kanamycin and tobramycin served as the point of 
modification. These covalently linked dimeric aminoglycosides were tested for their ability to inhibit the 
hammerhead ribozyme. The dimers (4a-e) showed an enhanced activity compared to their natural 
counterparts. For example, at 10 mM concentration, kanamycin-kanamycin dimer 4a was five times 
more active than natural kanamycin.
By employing surface plasmon resonance (SPR) and an immobilized 27-mer RNA construct 
corresponding to the ribosomal A-site, it was found that neamine (the pseudodisaccharide corresponding 
to rings I and II of neomycin B) binds the rRNA sequence in a 2:1 ratio. Relying on a favorable divalent 
interaction with the RNA target, Wong and co-workers synthesized several neamine dimers 5a-h 
(Figure 1.8)25. In order to improve the affinity of dimers for RNA, various points of attachment and 
different linkers were screened.
Linkers
Figure 1.8. Synthetic neamine dimers.
One more approach reported by various research groups to synthesize derivatives of natural 
aminoglycosides is glycodiversification. This approach involves the swapping of naturally attached 
aminosugars with some structurally modified carbohydrates. Based on the method of glycosylation, 
Chang and co-workers have reported the synthesis of a small library of kanamycin B analogues 6a-m 
(Figure 1.9)26.
19
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H2N y-yN H 2 
HO'' Y  ,NH2 " t 'R;■2
OH ^R.■4
Figure 1.9. Kanamycin analogues made by glycodiversification.
Likewise, Seeberger and co-workers have described the synthesis of a series of kanamycin analogues 
containing a simplified 2,5-dideoxystreptamine scaffold in place of the naturally occurring
2-deoxystreptamine core27. Following a similar approach, Wong et al. earlier synthesized a series of 
neamine analogues in which the position of the amino groups was varied around the glucopyranose ring 
in order to find the optimal substitution pattern while retaining the original stereochemistry28. In 
addition, heteroconjugation of aminoglycosides with a diverse sort of molecules like acridines29,
30 31 32 33nucleobases , nucleotides , peptides , and other antibiotics in order to combine the binding effect of 
both molecules by linking them in the same molecular system is another widely used methodology. 
Tor et al. synthesized a series of aminoglycoside-acridine conjugates with variable linker lengths (Figure 
1.10) and evaluated them for RNA, DNA and RRE affinity and specificity34. It was found that the neo- 
acridine conjugate with the shortest linker had optimal RRE specificity. Duplex DNA, on the other hand, 
prefers the acridine conjugate with the longest linker length, and RNA has the highest affinity for the 
conjugate with an intermediate linker length. Compared to neomycin B, heteroconjugates of tobramycin 
and kanamycin A have slightly lower RRE affinities, but better RRE specificities. These results illustrate 
how the binding affinity and specificity of aminoglycoside intercalator conjugates can be tuned by 
optimizing the linker length and by changing the identity of the aminoglycoside moiety.
20
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Figure 1.10 Conjugates of aminoglycosides to acridine.
Finally, the methodology of substituting the naturally attached carbohydrates with some aromatic rings 
or heterocycles has been explored. For example, Ding and co-workers have synthesized paromomycin 
mimetics with ring I replaced with a heterocyclic compound (Figure 1.11)35. Compound 8a exhibited 
good RNA-binding activity (Kd < 1 mM), higher than that of parent paromomycin (Kd = 110 nM). 
Similarly, Hanessian and co-workers have reported the synthesis of a diverse series of paromomycin 
analogues by replacing ring I with aromatic, heteroaromatic and aliphatic appendages36.
f , c
H2N,s^ y NH2
s^ o' y ^ '^oh
,sOH F,C
h2n, ^ ^ nh2 
S^O ' Y^'OH 
'  ,X>H
H O '
8a
'O
0 ^ " NH2 
NH2 ÖH
8b
o^ nh2 
NH2 ÖH
Figure 1.11. Structures of paromomycin mimetics.
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Aminoglycoside derivatives to overcome resistance
Many aminoglycoside derivatives have been synthesized over the years with the aim to overcome the 
resistance caused by aminoglycoside-modifying enzymes. An important method to revive lost 
antibacterial activity is by N-1 modification of aminglycosides, a methodology that early-on resulted in 
the development of semi-synthetic amikacin that has a 4-amino-2-hydroxybutyryl (AHB) group at the 
N-1 position (Figure 1.12).
Figure 1.12. Semi-synthetic aminoglycosides and year of development.
Since aminoglycoside are complex multifunctional molecules, selective modification at the desired 
functional group is not an easy task. However, various methods for selective N-1 modification have
regioselective carbamate cyclization followed by hydrolysis of cyclized carbamates. The resulting 
neomycin derivatives with an AHB group at the N-1 position exhibited an improved activity against the 
resistant strains of E. coli31.
OH of the kanamycin and neomycin-type of aminoglycosides are common sites of modifications for 
most of the aminoglycoside-modifying enzymes, Umezawa et al. dideoxygenated the 3' and 4' positions
semi-synthetic dibekacin and arbekacin aminoglycosides (Figure 1.12). Following the same strategy, 
Chang and co-workers recently synthesized 3',4'-dideoxy kanamycin analogues 10a and 10b (Figure
been the developed over the years. Torii et al. have synthesized N-1 modified neomycin derivatives by
Umezawa and co-workers employed the metal-chelating method for the introduction of AHB at the N-1 
position of kanamycin and synthesized a small set of kanamycin derivatives modified at N-1 position 
(Figure 1.13)38. Umezawa and co-workers have also reported an efficient strategy for the synthesis of 
aminoglycoside derivatives less prone to resistance by enzymatic modifications. Since the 3'-OH and 4'-
of kanamycin which proved effective against APH(3')39. Application of this concept resulted in the
22
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1.14)40. When assayed against resistant bacteria equipped with APA(3'), these analogues showed an 
enhanced activity.
9b h  OH H
9c  H H OH
9d H H H
9e OH H OH
Figure 1.13. Kanamycin derivatives with N-1 modified with AHB.
Mobashery et al. have reported a self-regenerating strategy to overcome the resistance caused by 
aminoglycoside-modifying enzymes41 by synthesizing a keto-derivative of kanamycin 11a (Figure 1.15). 
The ketone function exists in equilibrium with the more stable hydrated form 11b that is recognized and 
phosphorylated by APH(3'). The cunning design is based on the insight that the phosphorylated 
molecule is unstable: by dehydration the phosphate group is eliminated and the original keto-kanamycin 
is regenerated. The minimum inhibitory concentration (MIC) of this modified aminoglycoside was than 
evaluated and compared to kanamycin A. For the non-resistant E. coli the the MIC of compound 11a 
was higher than that of kanamycin. However, when tested against resistant bacterial strains, MIC for 
kanamycin A increased by 500- to 1000-fold, while in case of regenerating aminoglycoside 11a the 
increase in MIC was mere 4-fold.
Figure 1.14. 3',4'-dideoxy kanamycin analogues.
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Figure 1.15. Mechanism for regenerating keto-kanamycin 11a.
Mobashery et al. also reported another strategy to overcome resistance caused by the aminoglycoside- 
modifying enzyme APH(3')42. A 2'-NO2 kanamycin derivative was synthesized by selective oxidation of 
the 2'-NH2, thus increasing the acidity of 2'-proton. Upon phosphorylation at 3'-OH by APH(3'), it was 
reasoned that the phosphate group would eliminate by an E2 mechanism, resulting in the formation of an 
nitroalkene. The nitroalkene, due to its electrophilic nature, was expected to trap any nucleophilic 
residue of the aminoglycoside-modifying enzyme, thus resulting in the irreversible inactivation of the 
enzyme (Figure 1.16).
Figure 1.16. Mode of action of 2'-NO2 kanamycin derivative.
12c
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Aminoglycoside derivatives to reduce toxicity
Since the exact molecular mechanism of toxicity is not yet clear, there are few reports on the structure- 
toxicity relationship of aminoglycosides. Tsuchiya et al. synthesized 5-deoxy-5-fluoro and 5-deoxy-5,5- 
difluoro derivatives 13a-e of arbekacin and studied the structure-toxicity relationship of 
aminoglycosides. Compound 13a-e exhibited similar activity but a remarkable decrease in toxicity as 
compared to that of arbekacin. It was suggested that the decrease in toxicity may be due to a decrease in 
the basicity of 3-NH2 group, induced by the strongly electronegative fluoride substituent.
13a H H OH
13b H OH OH
13d F H OH
13e F H H
Figure 1.17. Fluorinated arbekacin derivatives.
Outline of the thesis
Aminoglycosides are among the oldest classes of antibiotics and have been used extensively for the 
treatment of various bacterial infections. Despite of their toxicity and resistance problems, various 
members of the aminoglycoside family, such as gentamicin, tobramycin, arbekacin and amikacin, are 
still in clinical practice. However, the aminoglycoside family has not expanded since the early 1970s 
when the last semi-synthetic derivative was developed. In the present situation when bacterial infections 
remains a serious threat to human lives, synthetic modifications of the existing antibiotics provides an 
opportunity to match the persistent need of new antibacterial compounds. This Thesis summarizes a 
variety of synthetic strategies to control and improve aminoglycoside derivatives with respect to 
antibacterial activity, susceptibility to resistance mechanism, toxicity, and as potential antiviral agents.
In Chapter 2, neomycin is truncated and modified into a morpholine-substituted 2-deoxystreptamine 
derivative, which is further elaborated with RNA-binding ligands. Both monomeric and dimeric 
derivatives are prepared and evaluated for antibacterial activity with a novel fluorescence-based assay.
25
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The synthesis of an orthogonally protected, enantiopure 2-deoxystreptamine building block is reported 
in Chapter 3. Key steps involve an enzymatic conversion of a meso diacetate into a highly enantiopure 
alcohol and chemoselective Staudinger reduction.
Chapter 4 describes a strategy, starting from the enantiopure 2-deoxystreptamine building block, to 
replace ring I of neomycin with a nucleobase (thymine). The nucleobase-aminoglycoside conjugate is 
designed as a selective ligand for the kissing-loop complex by complementary base-pairing of thymine 
with adenosine A280. Binding is evaluated by isothermal titration calorimetry.
Finally, in Chapter 5 it is demonstrated how paromomycin can be elaborated into C-6'(R)-methyl 
neamine and C-6'(R)-methyl neomycin, with the objective to reduce aminoglycoside toxicity.
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CHAPTER 2
2-Deoxystreptamine Conjugates by Truncation-Derivatization of 
Neomycin
A small set of truncated neomycin-conjugates is prepared by consecutive removal of 2,6- 
diaminoglucose rings, oxidation-reductive amination of ribose, oxidation-conjugation of 
aminopyridine/aminoquinoline and finally dimerization. The dimeric conjugates, as well as a second- 
generation library based on monomeric conjugates, were evaluated for antibacterial activity with a 
unique hemocyanin-based biosensor. The conjugates were evaluated for antibacterial activity, and some 
compounds were found more active than kanamycin against kanamycin-resistant E. coli.
neomycin B
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2.1 I n t r o d u c t io n
Aminoglycosides, a group of naturally occurring compounds obtained from actinomycetes of the genus 
Streptomyces or Micromonospora1 are in clinical use as antibiotics as a result of their broad 
antimicrobial spectrum and rapid bactericidal effects2. Aminoglycosides bind to 16S ribosomal RNA at 
the tRNA acceptor A-site (aminoacyl site), and affect the ability of the ribosome to decode mRNA 
correctly during protein synthesis3. Unfortunately, toxic side-effects and growing bacterial resistance4 
have narrowed the significance of aminoglycosides as antibiotics. The most common mechanism of 
resistance is the enzymatic modification of one or more functional groups of the aminoglycoside drug by 
bacterial enzymes5. Due to these limitations, aminoglycosides are the focus of attention of research 
groups around the world and numerous structural analogues of the aminoglycosides have been 
synthesized over the years6. The main objective of the synthetic modifications of the aminoglycosides is 
to circumvent the bacterial resistance without loss in binding affinity of these drugs. In the majority of 
studies, naturally occurring aminoglycosides are modified by regioselective diversifications of the 
appropriate functional groups while keeping the whole structure intact7. However, it is clear that 
structures with a high resemblance to the natural compounds are most likely to undergo modification by 
bacterial resistance enzymes. Therefore, unlike this strategy we intended to utilize a minimal core 
element for the development of new structural analogues. Because bacterial enzymes have evolved to 
modify the structures of naturally occurring aminoglycosides, stripping off the targeted alcohol and 
amino functions evades the problem of bacterial resistance. On the other hand, such a strategy will 
concomitantly also reduce antibacterial activity because the same heteroatoms are responsible for RNA 
binding. Therefore, in order to restore affinity lost by functional group removal, we envisaged 
conjugation of such a truncated aminoglycoside with a non-aminoglycoside type RNA ligand. Such a 
strategy has earlier proven successful for conjugation of native aminoglycosides to acridines,8 
nucleobases,9 nucleotides,10 peptides,11 and other antibiotics.12 Also, diversification of neamine as a 
structural motif for the synthesis of RNA ligands has been explored by several research groups.13 
However, neamine still contains the diaminosugar ring I of aminoglycosides, and is therefore a substrate 
for several resistance enzymes. Dimeric aminoglycoside have also divulged an improved RNA binding 
than individual aminoglycosides,14 therefore we made the dimers of our conjugates with 
conformationally adaptable linkers to further enhance binding affinity. Both dimeric and monomeric 
compounds were tested for antibacterial activity against E. coli with a fluorescence-based assay.
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2.2  R e s u lts  a n d  d iscu ss io n .
Synthesis of 5-O-morpholino-2-deoxystreptamine
Our strategy is based on the fundamental observation that the key structural feature of (nearly) all 
aminoglycosides is not a carbohydrate but a diaminocyclohexitol ring termed 2-deoxystreptamine.15 It 
was hypothesized that 2-deoxystreptamine is a crucial scaffold to build aminoglycoside libraries and that 
the all-equatorial substitution pattern is highly favorable to position other pharmacophores in the proper 
orientation. Although a large number of synthetic routes to 2-deoxystreptamine have been developed 
over the years,15 including contributions from our own lab16, we realized that the most straightforward 
and cheapest route to 2-deoxystreptamine commences from natural neomycin. Apart from that, we 
surmised that partial degradation of neomycin would leave the ribofuranoside as a suitable substituent at 
the 5-position of 2-deoxystreptamine, as in structure 2 (Scheme 1). Thus, N-Boc-protected neomycin 117 
was reacted with 12 equivalents of sodium metaperiodate resulting in the oxidative cleavage of vicinal 
diols on both 2,6-diaminosugars. The intermediate tetraaldehyde was not purified due to its instability, 
but upon base treatment underwent smooth ß-elimination under the influence of an amine base, to give 
5-O-ribosyl-2-deoxystreptamine 2. Use of different bases like n-butyl amine, ammonium hydroxide and 
triethylamine gave the same results in terms of yield and reaction time. Importantly, 2 was purified by
Scheme 1
OH '— BocHN O
1
Reagents and conditions: a) NaIO4, H2O, MeOH, on. b) Et3N, MeOH, o.n. (45-52%). c) i- NaIO4, MeOH, H2O, 2 h, ii- 
propargylamine, NaBH3CN, AcOH, MeOH, 1 h (41%).
direct recrystallization from dichloromethane leading to highly pure product 2 in a 48% average yield 
over the two steps. The resulting pseudodisaccharide 2 was once again subjected to sodium 
metaperiodate cleavage of the diol to give a dialdehyde, this time followed by reductive amination with
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propargylamine, to afford morpholine 3 substituted with an acetylene moiety. Unfortunately, the 
formation of open chain diamine side products could not be fully avoided, thus significantly suppressing 
the yield.
Synthesis and conjugation of aminopyridines and aminoquinolines
As aminoglycoside antibiotics function by selective recognition and binding to a specific RNA 
sequence, the removal of two of the aminoglycopyranosides is detrimental for RNA affinity. Therefore, 
we opted to restore the binding affinity by conjugation with other RNA ligands. To this end, we 
surmised that aminopyridines and aminoquinolines18 could nicely serve our purpose because these 
molecules are of low molecular weight and contain no aliphatic amine functionality, but nevertheless 
have been reported to bind with E. coli A-site RNA in micromolar range. We selected the two tightest 
binders from the series of aminopyridines, i.e. 2-(2-aminoethylamino)-4-methylpyridine and 2-(2- 
aminoethylamino)-5-methylpyridine, and the best aminoquinoline ligand 2-(2-aminoethylamino)-4- 
methylquinoline (Scheme 2). In order to be able to conjugate the arylamine ligands to our morpholine 
compound, we designed a route involving reductive amination via the primary alcohol of 3. Therefore, 
we first prepared derivatives of the arylamines by treating the commercially available chloropyridines 
and a chloroquinoline with 1,2-ethylenediamine at 150 °C for 18 hours as shown in the Scheme 2, to 
afford the desired 2-aminoethyl modified arylamines 5-7 in reasonable yield.
Scheme 2
Reagents and conditions: a) 1,2-ethylenediamine, 150 °C, 20 h (5: 46%, 6: 51%, 7: 48%).
Having the primary amines at hand, the next step involved the diversification of morpholine 3 by 
conjugation with the aminoethyl derivatives 5-7. For this purpose the primary hydroxyl of compound 3 
appeared most appropriate since it is most accessible and leaves the chiral secondary alcohols of 2­
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deoxystreptamine intact. Since reductive amination is such a robust conjugation technology, we aimed 
to selectively oxidize the primary alcohol of 3. Because it is known that Swern oxidations can be 
selectively executed at O-TES protected primary alcohols,19 we treated compound 3 with TESOTf and 
triethylamine in dichloromethane to protect all hydroxyls with the TES group. Subsequently, the triply 
TES-protected derivative was subjected to Swern oxidation conditions (oxalyl chloride, DMSO, -78  
°C® 0 °C), in order to selectively oxidize the primary hydroxyl. However, an inseparable mixture of 
compounds was obtained (Table 1, entry 1).
Scheme 3
BocHN
conditions RO' Y  '0R  
O N
NHBoc
BocHN
0=*
X2HO' Y  'OH
V.
0  N
NHBoc
R =
4a  R = TES 
b R = H
i—  8a-i
3
*—»- 9a-i
c  X = H 
c  X = Boc
Reagents and conditions: a) 5/6/7, NaBH3CN, AcOH, MeOH, 3 h. b) Boc2O, DMAP, CH2Cl2, 4 h (9a: 34%, 9b: 37%, 9c: 
32%, for two steps).
Table 1: Conditions for selective oxidation of primary alcohal.
Entry conditions product yield
1 i) TESOTf, EtsN, CH2Cl2, r.t., 3 h
ii) (COCl)2, DMSO, CH2Cl2, 4a mixture
-78 ° C ^ 0  °C
2 TCCA, TEMPO, CH3CN, r.t., 16 h 4b no reaction
3 IBX, DMF, r .t .^ 8 0  °C, 16 h 4b conversion <10%
4 DMP, DMF, r.t., 16 h 4b conversion 60%
Because Swern oxidation of TES ethers was not successful, we opted for a selective oxidation of the 
primary alcohol without protective groups. However, attempts to oxidize the primary hydroxyl with 
TCCA/TEMPO20 (entry 2) or IBX21 (entry 3) gave no or less than 10% conversion, respectively.
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Finally, we succeeded (entry 4) in oxidizing the primary hydroxyl group with Dess-Martin periodinane22 
to give selectively the desired aldehyde 4b. However, also in this case the reaction did not go to 
completion, reaching a maximum of about 60% conversion. Further attempts to optimize the reaction 
conditions, i.e. variation in temperature, solvents or stoichiometry of the oxidant did not improve the 
outcome. The resulting aldehyde 4b was subjected to the next reaction without purification on account 
of its instability. We therefore proceeded to couple crude aldehyde 4b with aminopyridine and 
aminoquinoline derivatives 5-7 (Scheme 3). Therefore, compounds 5-7 were condensed with aldehyde 
4b employing standard reductive amination conditions, i.e. NaBH3CN and AcOH in methanol. The 
relatively low yields of the resulting compounds 8a-c can be ascribed to incomplete oxidation of the 
compound 3 in the preceeding step, apart from the fact that accompanying dialkylation of amines was 
observed during the reductive amination. However, in this case the desired conjugates 9a-c could be 
readily purified by silica gel column chromatography. Both for this purpose and for follow-up 
chemistry, it was found most convenient to convert the resulting secondary amino functions of the initial 
products 8a-c into Boc-protected carbamates under the influence of Boc2O and DMAP in CH2Cl2. Thus, 
heteroconjugates 9a-c of truncated neomycin with non-aminoglycoside type RNA ligands were 
successfully prepared.
Scheme 4
9a-c
BocHN
HO'
»NHBoc B o c H N ^ ^ ^ N H B o c
XX ^
' T  " 0 H  H0 Y 0HN '' N '
)“ A _)~J  ) N—'
Boc Boc'—N
© © 
H3N ^ Y nh3
© © 
H3Ny ^Y»NH3
©
H2N
f ^ Y ^ o H  ,N ,  J ~ T U n A n  h 0 ' '  0 H
)= *  X=V©.r~V1 8TO N—' ,N„ P
H H ©
- J  — NH2
©
R R
Reagents and conditions: a) N3-L-N3, CH3CN, H2O, Cu-wire, o.n. b) CH2Cl2, TFA, 3 h (quantitative).
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Dimerization and deprotection of the conjugates
Obviously, the obtained arylamine-morpholine-2-deoxystreptamine conjugates contain a functional 
handle at the morpholine ring in the form of the propargyl moiety. Based on the popular copper(I)- 
catalyzed azide acetylene cycloaddition (CuAAC),23 it is clear that the propargyl moiety provides an 
excellent handle for the preparation of further conjugates. Therefore, we next utilized the copper- 
catalyzed (3+2) cycloaddition chemistry to make dimers with a range of mono- and bisazido- 
functionalized linkers. This approach provided maximum synthetic flexibility and proved effective for 
the synthesis of various monomers and dimers from the building blocks 9a-c. Thus, the synthetic 
heteroconjugates were treated with bisazides A-D (0.5 equiv.) or a monoazide E (benzyl azide, 1 equiv.) 
in a mixture of water and acetonitrile in the presence of copper-wire24 to make the respective monomers 
9a-cE and dimers 9a-cA to 9a-cD in reasonable to good yields (Table 2).
Table 2: Linkers used for synthesis of dimers 9aA-9cE.
Entry linker (L) starting
material
product yield (%)
1
2
3
4
5
6 
- j -
8
9
10 
11 
12
13
14
15
A
9a
9b
9c
9a
9b
9c
9a
9b
9c
9a
9b
9c
9a
9b
9c
9aA 
9bA 
9cA 
9aB 
9bB 
9cB 
9aC 
9bC 
9cC 
9a I) 
9bD 
9cD 
9a K 
9bE 
9cE
63
73
60
"57
65 
58 
61
66 
69 
60
65
66 
"87 
92 
90
\ ---------\
CKy
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Finally, acidic deprotection of the Boc protective groups was performed in a 1:2 mixture of TFA and 
DCM to afford the respective monomers and the dimers in quantitative yields, giving a final set of 15
arylamine-aminoglycoside conjugates (3 monomers, 12 dimers). For biological evaluation, all of the 
compounds were purified by reversed phase HPLC, giving the pure conjugates in 5-20 mg quantitities.
Evaluation of antibacterial activity
Having prepared the desired conjugates, we were interested to investigate the antibacterial activity of 
these compounds. Determination of antibacterial activity is normally expressed in MIC (minimal 
inhibitory concentration) by growing bacteria in medium containing increasing amounts of the presumed 
antibiotic. Such an assay typically requires substantial amounts of compounds (30-70 mg), clearly 
exceeding the amount of compound that we had prepared. With small amounts of substrate, antibacterial 
activity can also be determined with Kirby-Bauer disc test, but that provides only a qualitative measure 
of activity. Alternatively, a plethora of RNA-binding assays have been developed,25 but a strong 
drawback of such assays is that they do not include cell-wall penetration or resistance mechanisms, 
obviously key in determining the overall activity of an antibiotic.26 An alternative approach, recently 
reported by Canters et al.,27 determines MICs on whole bacteria in a simple and rapid assay and 
moreover requires only minimal amounts (<2 mg) of substrate. The technique relies on a fluorescence- 
based cell viability assay and involves a hemocyanin-based oxygen biosensor to monitor oxygen 
consumption of bacteria and subsequently bacterial cell growth (Figure 1).
Deoxy
400 500
Wavelength [nm]
—  Hemocyanin-Oxy
— Hemocyanin-Deoxy 
Cy3-Emission
600
Oxy
700
Figure 1. (A) Representation of Cy3-labeled hemocyanin. The Cy3 dye (cyan) is showed attached to the ^-terminus of a 
monomer hemocyanin. (B) Detail of hemocyanin active site showing the active site histidines (blue), copper ions (orange) 
and the binding oxygen molecule (red). (C) The absorption spectra of the deoxygenated (red) and oxygenated (blue) forms of 
hemocyanin together with the emission spectrum of Cy3 (green).
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Deoxygenated hemocyanin has no absorption in the visible spectrum but upon oxygenation a strong 
band centered at 340 nm and a weak band around 570 nm appear (Figure 1B). If a fluorescent label is 
attached to the N-terminus of hemocyanin, this change in absorption can be translated into a change of 
fluorescence intensity of an attached label (Cy3, Cyanine 3 fluorescent dye) through a Förster resonance 
energy transfer (FRET) mechanism (Figure 1A).28 The efficiency of this energy transfer depends on the 
distance and orientation between the donor and the acceptor and also on the overlap integral between the 
donor emission and acceptor absorption spectra (Figure 1C). In this way, when the protein is in its 
deoxygenated state (Cy3-Deoxy-Hemocyanin), all the energy absorbed by the label is emitted normally 
as fluorescence. Upon oxygenation of hemocyanin (Cy3-Oxy-Hemocyanin), energy is transferred from 
Cy3 by radiationless decay to the copper center of hemocyanin, resulting in a decrease in the 
fluorescence intensity. Thus, when a bacterial culture grows aerobically, oxygen in the medium is 
gradually consumed. This results in a drop of the oxygen concentration, eventually resulting in an 
anaerobic medium. When hemocyanin-based oxygen biosensor is present, this oxygen depletion results 
in an increase of the fluorescence intensity emitted by the Cy3 label attached to protein.27 Tests were 
carried out as described27 with an initial cell concentration of 105 cfu/ mL.
0 100 200 300 400
T im e  [m in ]
Figure 2. Fluorescence intensity time traces at 570 nm (excitation 550 nm) of cultures of E. coli containing Cy3-labeled 
hemocyanin as a function of antibiotic concentration. Antibiotic concentrations of 9cA and 9cB are stated.
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Table 3. MIC values (mg/ mL) as determind by the fluorescence-based cell growth assay.
Entry bacterial strain
MIC (mg/ mL)
kanamycin s.m.
linker
A
linker
B
linker
C
linker
D
linker
E
1
E. coli 10
9a 200-400 200-400 400-800 400-800 400-800
2 9b 400-800 400-800 400-800 400-800 400-800
3 9c 200-400 100-200 200-400 400-800 200-400
We determined the MICs of our heteroconjugates with the fluorescence-based cell viability assay 
against several bacterial strains (E. coli, E. coli kan.ri.e. kanamycin-resistant E. coli) using kanamycin as 
a positive control. As can be seen from Figure 2, using compound 9cA and 9cB as an example, the MIC 
is determined by performing the bacterial growth in medium containing increasing amounts of our 
compounds. The MIC values of our synthetic analogues can be determined from Figure 2 and are 
depicted in Table 3.
Second generation monomeric ligands
Unfortunately, our set of dimers of heteroconjugates exhibited lower antibacterial activity than that of 
natural kanamycin when tested against E. coli. In fact, only compound 9cB demonstrated some but weak 
antibacterial activity. Moreover, and in contrast to expectation, it is clear that the dimers do not show 
improved activity compared to the monomeric substrates 9a-cE. The lack of improved activity is in 
contrast to findings by other groups,14 which may be explained in our case by the relatively short linkers 
employed. It is not excluded that a short linker is precluding cooperative binding of the other end of the 
molecule to a second binding pocket. Whatever the reason, the fact that the MIC value of the monomeric 
compound 9cE was comparable to that of different dimers stimulated us to explore whether antibacterial 
activity of the more simple, monomeric heteroconjugates could be further raised by modification of the 
azide partner for cycloaddition to the acetylene. Thus, we selected a range of aromatic and aliphatic 
azides and coupled these to acetylene derivatives 9a-c with CuAAC to obtain a set of monomeric 
compounds 10a-g with different substituents (Scheme 5). Thus, compounds 10a-e were synthesized by 
simply treating 9c with different monoazides in a mixture of water and acetonitrile in the presence of 
copper wire. For the synthesis of amino-terminated compounds 10f and 10g, acetylene 9c was treated 
with an excess of 1,4-bis(azidomethyl)benzene or 1,5-diazidopentane, to give the respective
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monosubstituted triazole adducts, followed by Staudinger reduction of the unreacted azide group at the 
other chain terminus under the action of PMe3.
Scheme 5
Reagents and conditions: a) R-N3, CH3CN, H2O, Cu-wire, 16 h (70-80%). b) CH2Cl2, TFA, 3 h (quantitative). a Azides were 
reduced with PMe3 prior to Boc removal.
Again, all compounds 10a-g were purified to homogeneity by reversed-phased HPLC before evaluation 
of antibacterial activity. Next, we tested the antibacterial activity of this set of compounds employing the 
same fluorescence-based cell viability assay and the results are summarized in Table 4. As evident from 
MIC values, para-bromo substitution of the aromatic ring induced a small enhancement of antibacterial 
activity of compounds 10a and 10b. In contrast, the rest of the monomeric compounds, with a methoxy- 
or methylamino-substituent on the aromatic ring 10c-10f, or with the aliphatic chain 10g showed a 
reduced antibacterial activity compared to that of unsubstituted parent compound 9cE. Finally, in order 
to obtain a first indication of the viability of our strategy to reduce susceptibility to bacterial resistance 
enzymes, we tested the MIC of the most active compounds against the kanamycin-resistant strains of E. 
coli (Table 4, entry 2). As can be seen in Table 4, MICs remain moderate, but compounds 10a and 10b 
displayed an antibacterial activity against E. coli slightly higher than that of kanamycin. The latter 
effect, although small, may be taken as an indication that removal of the diaminoglycosides reduces
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susceptibility to resistance mechanisms. The search for further synthetic analogues of aminoglycosides 
with such improved traits, and validation of these analogues against a larger panel of susceptible and 
resistant isolates of different species, is currently ongoing in our laboratory.
Table 4. MIC values (mg/mL) as determined by fluorescence-based cell growth assay.
Entry Bacterial
strains
MIC (mg/mL)
kanamycin 10a 10b 10c 10d 10e 10f 10g 9cB 9cE
1 E. coli 10
100­
200
100­
200
400­
800
400­
800
400­
800
400­
800
400­
800
100­
200
200­
400
2
E. coli 
kanr
400-800
400­
800
200­
400
>800 - - - - >800 >800
2 .3  C o n c lu s io n s
A set of dimers of aminoglycoside analogues has been synthesized from natural neomycin via a 
straightforward route. Cleavage of both diaminoglucose pyranoses was followed by installation of an N- 
propargylated morpholine. Subsequent selective oxidation of the primary alcohol and immediate 
conjugation to arylamine by reductive amination led to three different 2-deoxystreptamine conjugates. 
Dimerization of the resulting conjugates with a range of bisazides afforded a small library of potential 
RNA-binding ligands in a straightforward synthetic route involving minimal protecting group 
transformations. All compounds were evaluated for antibacterial activity employing a novel 
fluorescence-based cell viability essay and compared to kanamycin. Several of the compounds, dimers 
and monomers, showed antibacterial activity in the high micromolar range. Further lead optimization of 
the conjugates is therefore required, e.g. by introduction of longer spacers between the arylamines and 
the morpholine to allow cooperative binding. Screening against a larger panel of bacterials strains 
should provide better insight in the usefullness of the conjugates as antibiotics. Also, it remains to be 
established whether the conjugates are actually binding to A-site RNA or by another mode-of-action. 
Research along those lines is currently ongoing in our laboratories.
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2 .5  E x p e r im e n ta l  s e c tio n
General methods and materials
TLC analyses are performed on silica gel-coated plates (Merck 60 F254) with the indicated solvent 
mixture. Compounds were detected with ammonium molybdate or potassium permanganate staining, or 
UV light. Flash column chromatography was carried out using ACROS silica gel (0.035-0.070 mm, ca 6 
nm pore diameter). Solvents were distilled from appropriate drying agents prior to use. Unless stated 
otherwise, all chemicals were purchased and used as such.
IR spectra were recorded on an ATI Mattson Genesis Series FTIR spectrometer; absorption reported in 
cm-1. NMR spectra were recorded on a Bruker DMX 300 (300 MHz), and a Varian 400 (400 MHz) 
spectrometer. 1H NMR and 13C NMR spectra are reported in units of ppm on the 8 scale. Coupling 
constants are reported as J-values in Hz. Semipreparative RP-HPLC was performed using a C 18 column 
(10 x 250 mm, 5 |i) with HPLC grade MilliQ containing 0.1% TFA (eluant A) and acetonitril containing 
0.1% TFA (eluant B) with a gradient of 5 ^  50% of B in 30 min. Compounds were detected by UV 
absorption at 215 and 254 nm.
Hexa-Af-(terf-butoxycarbonyl) neomycin B (1)17
o ^ " n h
N H B o c
To a solution of neomycin B (2 g, 2.2 mmol) in a mixture of H2O/1,4- 
dioxane (30 mL, 1:1 v/v) was added Na2CO3 and di-tert- 
butyldicarbonate.The reaction mixture was stirred at room temperature for 
6 h. Dioxane was removed by evaporation and the residue was partitioned 
between EtOAc (100 mL) and H2O (100 mL). The aqueous layer was
B o c H N .
O H
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extracted with EtOAc (2 x50 mL) and the combined organic layers were washed with brine (100 mL), 
dried (Na2SO4) and concentrated in vacuo. Purification by column chromatography (MeOH/CH2Cl2 1/9) 
afforded 1 (2.2 g, 82%) as an amorphous white solid. RF 0.49 (MeOH/CH2Cl2 1/9). HRMS (ESI) m/z 
calcd for C53H94N 6O25 (M+Na)+: 1237.61, found: 1237.6.
5- ö-(ß-D-ribofuranosyl)-2-deoxystreptamine (2)
B o c H N ^ / ^ N H B o c  To a solution of 1 (1 g, 0.82 mmol) in 25 mL of MeOH, was added 25 mL of a H2O 
h o '  'o h  solution of NaIO4 (2.12 g, 9.8 mmol). The reaction mixture was stirred at room
O
V .,vOH temperature for 16 h. Methanol was removed by evaporation and the residue was 
f ' ‘'OH partitioned between EtOAc (100 mL) and H2O (50 mL). The aqueous layer was
HO
extracted with EtOAc (2 x 50 mL) and the combined organic layers were washed 
with brine (100 mL), dried (Na2SO4) and concentrated in vacuo. The residue was dissolved in MeOH 
(30 mL), and Et3N (2 mL) was added. The reaction mixture was stirred at room temperature for 16 h and 
then concentrated in vacuo. Purification by crystallization from CH2Cl2 (100 mL) afforded compound 2 
(212 mg, 52%) as a white amorphous solid. Rf 0.12 (MeOH/CH2Cl2 1/9).1H NMR (MeOD, 400 MHz): 
8 5.21 (s, 1H), 4.32 (dd, J=4.5, 7.7 Hz, 1H), 3.99 (d, J=4.5 Hz, 1H), 3.90 (dt, J=2.6, 7.7 Hz, 1H), 3.78 
(dd, J=2.3, 12.1 Hz, 1H), 3.60 (dd, J=2.6, 12.1 Hz, 1H), 3.40-3.15 (m, 10H), 2.02 (dt, J=4.2, 7.9 Hz, 
1H), 1.41 (s, 18H), 1.21 (m, 1H).13C NMR (MeOD, 75 MHz): 8 156.3, 107.8, 83.8, 82.3, 78.2, 74.7,
72.7, 68.6, 59.7, 50.6, 33.8,26.8. HRMS (ESI) m/z calcd for C21H38N2O11 (M+Na)+: 517.237, found: 
517.237.
tert-butyl (1R, 3S, 4R, 5r, &S)-4,6-dihydroxy-5-((£S, &S)-6-(hydroxymethyl)-4-(prop-2- 
ynyl)morpholin-2-yloxy)cyclohexane-1,3-diyldicarbamate (3)
BocHN^ \ v. NHBoc To a solution of 2 (830 mg, 1.68 mmol) in 20 mL of MeOH, was added 20 mL of a
ho' 'oh H2O solution of NaIO4 (431 mg, 2.016 mmol). The reaction mixture was stirred at 
)—\ f t  room temperature for 2 h. The methanol was removed by evaporation and the
O N —'
/ residue was partitioned between EtOAc (100 mL) and H2O (50 mL). The aqueous 
layer was extracted with EtOAc (2 x50 mL) and the combined organic layers were washed with brine 
(100 mL), dried (Na2SO4) and concentrated in vacuo.The residue was dissolved in 15mL of MeOH, and 
NaBH3CN (422 mg, 6.72 mmol) was added. To the resulting mixture was added drop-wise a solution of 
propargylamine (138 mL, 2.52 mmol) and AcOH (403 mL, 6.72 mmol) in MeOH (1 mL). The reaction
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mixture was stirred at room temperature for 2 h. The reaction was then quenched with 0.5mL of Et3N 
and concentrated in vacuo.The residue was taken up in EtOAc (100 mL), washed with saturated 
NaHCO3 (2 x 50mL) and brine (50mL).The organic layer was dried (Na2SO4), filtered and concentrated 
in vacuo.Purification by column chromatography (MeOH/CH2Cl2 1/9) afforded 1 (358 mg, 41%) as an 
amorphous white solid. Rf 0.34 (MeOH/CH2Cl2 1/9). 1H NMR (MeOD, 400 MHz): 8 4.85 (dd, J=2.3,
8.6 Hz, 1H), 3.70 (m, 1H), 3.57 (dd, J=1.7, 5.1Hz, 2H), 3.42-3.19 (m, 11H), 3.01 (d, J=10.5 Hz, 1H), 
2.70 (d, J=11.1 Hz, 1H), 2.65 (t, J=2.3 Hz, 1H), 2.13 (m, 2H), 2.02 (dt, J=3.9, 13.0 Hz, 1H), 1.41 (s, 
18H), 1.21 (dd, J= 12.5 Hz, 1H).13C NMR (MeOD, 75 MHz): 8 156.2, 99.7, 85.2, 78.1, 76.7, 74.1, 73.5,
72.5, 61.9, 54.1, 51.3, 50.6, 50.4, 45.1, 33.6, 26.8. HRMS (ESI) m/z calcd for C24H41N3O9 (M+H)+: 
516.292, found: 516.292.
2-(2-Aminoethylamino)-4-methylpyridine (5)
N n A solution of 2-chloro-4-methylpyridine (0.876 mL, 10 mmol) in 1,2-diaminoethane
rf V  ^ ^ n h 2
(6 mL) was heated at 150°C for 18 h. The volatiles were removed in vacuo. 
Purification by column chromatography (10% MeOH/CH2Cl2 to 20% MeOH/CH2Cl2) afforded 5 (700 
mg, 46%) as a yellow oil.1H NMR (MeOD, 300 MHz): 8 7.76 (d, J=4.8 Hz, 1H), 6.36 (m, 2H), 3.31 (t, 
J=6.2 Hz, 2H), 2.79 (t, J=6.2 Hz, 2H), 2.17 (s, 3H).13C NMR (MeOD, 75 MHz): 8 156.5, 145.0, 136.2,
121.1, 106.6, 40.1, 39.9, 15.5. HRMS (ESI) m/z calcd for C8H 3N3 (M+H)+: 152.119, found: 152.118.
2-(2-Aminoethylamino)-5-methylpyridine (6)
h A solution of 2-chloro-5-methylpyridine (0.434 mL, 5 mmol) in 1,2-diaminoethane (3
'  "  ^ ' ~ ' ' n h 2
mL) was heated at 150°C for 18 h. The volatiles were removed in vacuo. Purification by
column chromatography (10% MeOH/CH2Cl2 to 20% MeOH/CH2Cl2) afforded 6 (386 
mg, 51%) as a yellow oil.1H NMR (MeOD, 300 MHz): 8 7.72 (m, 1H), 7.27 (dd, J=2.5, 8.5 Hz, 1H), 
6.46 (d, J=8.5 Hz, 1H), 3.30 (t, J=6.2 Hz, 2H), 2.79 (t, J=6.2 Hz, 2H), 2.13 (s, 3H). 13C NMR (MeOD, 
75 MHz): 8 156.6, 145.3, 138.0, 120.3, 107.7, 43.5, 40.1, 15.5. HRMS (ESI) m/z calcd for C8H 13N3 
(M+H)+: 152.119, found: 152.118.
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2-(2-Aminoethylamino)-4-methylquinoline (7)
A solution of 2-chloro-4-methylquinoline (1.7 g, 10 mmol) in 1,2-diaminoethane (6
NH2
mL) was heated at 150°C for 18 h. The volatiles were removed in vacuo. 
Purification by column chromatography ( 10% MeOH/CH2Cl2 to 20% 
MeOH/CH2Cl2) afforded 7 (963 mg, 48%) as a yellow oil.1H NMR (MeOD, 300 MHz): 8 7.72 (dd, 
J=1.2, 8.1 Hz, 1H), 7.59 (dq, J=0.5, 1.2, 8.4 Hz, 1H), 7.45 (ddd, J=1.4, 6.9, 8.4 Hz, 1H), 7.17 (ddd, 
J=1.2, 6.9, 8.1 Hz, 1H), 6.59 ( d, J=1.0 Hz, 1H), 3.50 (t, J=6.2 Hz, 2H), 2.86 (t, J=6.2 Hz, 2H), 2.48 (d, 
J=1.0 Hz, 3H). 13C NMR (MeOD, 75 MHz): 8 156.9, 147.0, 144.2, 128.4, 124.5, 123.0, 122.8, 120.9, 
111.9, 42.6, 40.3, 16.9. HRMS (ESI) m/z calcd for C 12Ï Ï 15N3 (M+H)+: 202.133, found: 202.134.
tert-butyl(lÆ,35,4Æ,5r,Æ5)-4,6-dihydroxy-5-((Z5,fiÆ)-6-((2-(5-methylpyridm-2-
ylamino)ethylamino)methyl)-4-(prop-2-ynyl)morpholin-2-yloxy)cyclohexane-1,3-diyldicarbamate
To a solution of 3 (65 mg, 0.126 mmol) in DMF (1mL), was added Dess­
Martin periodinane (64 mg, 0.151mmol). The reaction mixture was stirred 
overnight at room temperature. The reaction was quenched with a saturated 
solution of NaHCO3 (20 mL) and extracted with EtOAc (3 x25mL). The 
combined organic layers were washed with H2O (2 x 25 mL) and brine (25 
mL), dried (Na2SO4) and concentrated in vacuo.The residue was dissolved in 
2 mL of MeOH, and NaBH3CN (12 mg, 0.189 mmol) was added. To the reaction mixture was added a 
solution of 5 (57 mg, 0.378 mmol) and AcOH (11 mL, 0.189 mmol) in MeOH (0.5 mL). The reaction 
mixture was stirred at room temperature for 4 h. The reaction was quenched with 0.1mL of Et3N and 
concentrated in vacuo. The residue was taken up in EtOAc (50 mL), washed with saturated NaHCO3 (2 
x 25mL) and brine (25mL).The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. 
Purification by column chromatography (MeOH/CH2Cl2 1/9) afforded 8a (32 mg, 39%) as awhite solid. 
Rf 0.22 (MeOH/CH2Cl2 1/9). 1H NMR (MeOD, 400 MHz): 8 7.89(d, J= 5.4 Hz, 1H), 6.52 (d, J= 5.4 
Hz, 1H), 6.47 (s, 1H), 5.03 (d, J= 7.5 Hz, 1H), 3.96 (m, 1H), 3.57 (q, J= 5.6, 10.3 Hz, 2H), 3.41-3.15 (m, 
12H), 2.94 (d, J= 10.3 Hz, 1H), 2.70 (m, 2H), 2.29 (dd, J= 7.7, 11.0 Hz, 1H), 2.22 (s, 3H), 1.99 (m. 1H), 
1.41 (d, J= 8.4 Hz, 18H), 1.24 (m, 1H).13C NMR (MeOD, 75 MHz): 8 156.3, 156.2, 149.1, 144.9, 126.9,
114.3, 109.2, 99.5, 83.2, 78.2, 76.4, 74.8, 73.7, 72.8, 69.1, 54.0, 51.5, 48.7, 45.0, 38.2, 33.8, 26.8, 19.2. 
HRMS (ESI) m/z calcd for C32H52N6O8 (M+H)+: 649.392, found: 649.392.
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tert-butyl (lÆ,35,4Æ,5r,&S)-4,6-dihydroxy-5-((Z5,fiÆ)-6-((2-(4-methylpyridm-2- 
ylamino)ethylamino)methyl)-4-(prop-2-ynyl)morpholin-2-yloxy)cyclohexane-1,3-diyldicarbamate
To a solution of 3 (80 mg, 0.155 mmol) in DMF (1 mL), was added Dess­
Martin periodinane (79 mg, 0.186 mmol). The reaction mixture was stirred 
overnight at room temperature. The reaction was quenched with a saturated 
solution of NaHCO3 (20 mL) and extracted with EtOAc (3 x 25 mL). The 
combined organic layers were washed with H2O (2 x 25 mL) and brine (25 
mL), dried (Na2SO4) and concentrated in vacuo.The residue was dissolved in 3 
mL of MeOH, and NaBH3CN (14 mg, 0.232 mmol) was added. To the 
resulting mixture was added a solution of 6 (70 mg, 0.465 mmol) and AcOH (14 mL, 0.232 mmol) in 
MeOH (0.5 mL). The reaction mixture was stirred at room temperature for 4 h. The reaction was 
quenched with 0.1 mL of Et3N and concentrated in vacuo. The residue was taken up in EtOAc (50 mL), 
washed with saturated NaHCO3 (2 x 25mL) and brine (25mL).The organic layer was dried (Na2SO4), 
filtered and concentrated in vacuo. Purification by column chromatography (MeOH/CH2Cl2 1/9) 
afforded 8b (41 mg, 41%) as a white solid. Rf 0.22 (MeOH/CH2Cl2 1/9). 1H NMR (MeOD, 400 MHz): 
8 7.74 (s, 1H),7.28 (dd, J= 2.3, 8.5 Hz, 1H), 6.5 (d, J= 8.5 Hz, 1H), 4.85 (dd, J= 2.3, 8.6 Hz, 1H), 3.80 
(m, 1H), 3.42-3.19 (m, 11H), 2.99 (d, J= 10.3 Hz, 1H), 2.18-2.00 (m, 5H), 1.40 (d, J= 7.2 Hz, 18H), 1.26 
(m, 1H).13C NMR (MeOD, 75 MHz): 8 156.6, 156.3, 156.1, 145.1, 138.2, 120.5, 108.1, 99.8, 85.2, 78.2,
76.6, 76.2, 74.2, 73.5, 72.6, 74.2, 73.5, 72.6, 71.7, 54.1, 52.5, 50.5, 50.0, 45.0, 39.9, 33.8, 26.8, 15.4. 
HRMS (ESI) m/z calcd for C32H52N6O8 (M+H)+: 649.392, found: 649.392.
tert-butyl (lÆ,35,4Æ,5r,Æ5)-4,6-dihydroxy-5-((£5,fiÆ)-6-((2-(4-methylqumolm-2-
ylamino)ethylamino)methyl)-4-(prop-2-ynyl)morpholin-2-yloxy)cyclohexane-1,3-diyldicarbamate
(8c)
To a solution of 3 (100 mg, 0.194 mmol) in DMF (1 mL), was added Dess­
Martin periodinane (99 mg, 0.232 mmol). The reaction mixture was stirred 
overnight at room temperature. The reaction was quenched with saturated 
solution of NaHCO3 (20 mL) and extracted with EtOAc (3 x 25 mL). The 
combined organic layers were washed with H2O (2 x 25 mL) and brine (25
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mL), dried (Na2SO4) and concentrated in vacuo. The residue was dissolved in 4mL of MeOH, and 
NaBH3CN (18 mg, 0.291 mmol) was added. To the resulting mixture was added a solution of 7 (116 mg,
0.582 mmol) and AcOH (17.5 mL, 0.291 mmol) in MeOH (0.5 mL). The reaction mixture was stirred at 
room temperature for 4 h. The reaction was quenched with 0.1 mL of Et3N and concentrated in vacuo. 
The residue was taken up in EtOAc (50 mL), washed with saturated NaHCO3 (2 x 25mL)and brine 
(25mL).The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. Purification by 
column chromatography (MeOH/CH2Cl2 1/9) afforded 8c (52 mg, 38%) as a white solid. RF 0.21 
(MeOH/CH2Cl2 1/9). 1H NMR (MeOD, 400 MHz): 8 7.84 (d, J= 8.1 Hz, 1H), 7.62 (d, J= 3.4 Hz, 1H),
7.30 (q, J= 4.1, 8.1 Hz, 1H), 6.72 (d, J= 1.0 Hz, 1H), 5.06 (d, J= 6.3 Hz, 1H), 3.97 (m, 1H), 3.75 (t, J=
5.0 Hz, 2H), 3.44-3.18 (m, 13H), 2.95 (d, J= 11.0 Hz, 1H), 2.72-2.65 (m, 2H), 2.57 (d, J= 1.0 Hz, 3H),
2.30 (dd, J= 7.7, 11.0 Hz, 1H), 2.17 (dd, J= 9.3, 11.1 Hz, 1H), 2.03 (dt, J= 3.8, 12.5 Hz, 1H), 1.42 (d, J=
9.1 Hz, 18H), 1.32 (m, 1H).13C NMR (MeOD, 75 MHz): 8 156.7, 145.9, 145.2, 129.4, 123.7, 123.3,
123.1, 122.0, 112.0, 99.6, 83.5, 78.2, 76.4, 74.7, 73.7, 72.8, 69.2, 54.0, 51.6, 49.1, 48.5, 45.0, 38.4, 26.9,
17.0. HRMS (ESI) m/z calcd for C36H 4N6O8 (M+H)+: 699.406, found: 699.408.
General procedure for Boc-protection 9a-c.
To a solution of 8a-c (0.15 mmol) in CH2Cl2 (2 mL) was added di-tert-butyl dicarbonate (0.18 mmol,
1.2 equiv.) and DMAP (5 mg). The reaction mixture was stirred at room temperature for 5 h. The 
volatiles were removed in vacuo. Purification by column chromatography (MeOH/CH2Cl2 1/9) gave the 
desired product.
Com pound 9a.
Yield 87%, white solid. Rf 0.43 (MeOH/CH2Cl2 1/9). HRMS (ESI) m/z calcd for C37H Ä O 10 (M+H)+: 
749.443, found: 749.443.
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Com pound 9b.
Yield 90%, white solid. Rf 0.43 (MeOH/CH2Cl2 1/9). HRMS (ESI) m/z calcd for C37H60N6O 10 (M+H)+: 
749.443, found: 749.443.
Com pound 9c.
BocHNn ^ ~ . N H B o c  
HO'' ''OH
JO N—'
r
a N NH
Yield 84%, white solid. Rf 0.46 (MeOH/CH2Cl2 1/9). HRMS (ESI) m/z calcd for C4Ä 2N6O10 (M+H)+: 
799.458, found: 799.459.
General procedure forthe synthesis of bis-azides A-D.
To a solution of a commercially obtained dibromide (2.5 mmol) in 10 mL of DMF was added NaN3 (6.0 
mmol). The reaction mixture was stirred at 60 °C for 5 h. The reaction was then quenched with H2O and 
extracted with Et2O. The organic layers were washed with H2O and brine, dried (Na2SO4) and 
concentrated in vacuo. Purification by column chromatography (EtOAc/heptane, 1/20) gave the pure 
product.
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1,4-bis(azidomethyl)benzene (A)
N-
N3
Yield 86%, oil. RF 0.34 (EtOAc/heptane, 1/8). 1H NMR (CDCl3, 300 MHz): 8 7.34 (s, 4H), 4.35 (s, 
4H).13C NMR (CDCl3, 75 MHz): 8 135.0, 128.1, 53.9.
1,2-bis(azidomethyl)benzene (B)
Yield 82%, oil. Rf 0.36 (EtOAc/heptane, 1/8). 1H NMR (CDCl3, 300 MHz): 8 7.38 (s, 4H), 4.43 (s, 
4H).13C NMR (CDCl3, 75 MHz): 8 133.4, 129.6, 128.5, 51.7.
1,5-diazidopentane (C)
Yield 91%, liquid. RF 0.49 (EtOAc/heptane, 1/8). 1H NMR (CDCl3, 300 MHz): 83.25 (t, J= 6.7 Hz, 4H),
1.60 (m, 4H), 1.42 (m, 2H).13C NMR (CDCl3, 75 MHz): 8 50.7, 27.9, 23.4.
1,4-diazidobutane (D)
Yield 86%, liquid. Rf 0.51 (EtOAc/heptane, 1/8). 1H NMR (CDCl3, 300 MHz): 8 3.27(t, J= 5.7 Hz, 4H),
1.61 (m, 4H). 13C NMR (CDCl3, 75 MHz): 8 50.4, 25.6.
4-azidomethyl-1-bromobenzene
n3^  To a solution of 1-bromo-4-(bromomethyl)benzene (200 mg, 0.80 mmol) in 1 mL of DMF was 
added NaN3 (52 mg, 0.80 mmol). The reaction mixture was stirred at 60 °Cfor 5 h. The reaction 
was then quenched with H2O and extracted with Et2O. The organic layers were washed with
Br
H2O and brine, dried (Na2SO4)and concentrated in vacuo. Purification by column chromatography 
(EtOAc/heptane, 1/20) gave 1-bromo-4-(azidomethyl)benzene (156 mg, 92%) as a colorless liquid. RF
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0.51 (EtOAc/heptane, 1/8). 1H NMR (C D O 3, 400 MHz): 87.47(d, J= 8.4 Hz, 2H), 7.15 (d, J= 8.4 Hz, 
2H), 4.24 (s, 2H). 13C NMR (C D O 3, 75 MHz): 8 133.9, 131.5, 129.3, 121.8, 53.6.
1-azido-4-bromobenzene
n 3 To a solution of NaN3 (1.5 g, 24.3 mmol) in a mixture of H2O/CH2Cl2 (7.5 mL, 1 :1  v/v) at 0 °C, 
Q  was added Tf2O (2.01 mL, 12.15 mmol). The reaction mixture was stirred at room temperature 
B r for 2  h. After quenching with aqueous NaHCO3, the layers were separated and the aqueous layer 
was extracted with CH2Cl2 (5.75 mL). The organic layers were combined to afford 9.5mL of TfN3 
solution. Then, to a solution of para-bromoaniline (700 mg, 4.06 mmol) and CuSO4 (5 mg) in H2O (9.5 
mL) was added the TfN3 solution, MeOH (31 mL) and Et3N (1.6 mL). The reaction mixture was stirred 
overnight at room temperature. Then solid NaHCO3 ( 1.0  g) was added carefully and the organic solvents 
were evaporated. The aqueous residue was extracted with EtOAc (3 x 100 mL), and the organic layers 
were combined, dried (Na2SO4), and concentrated in vacuo to give a yellow liquid. Purification by 
column chromatography (EtOAc/heptane, 1/20) afforded 1-azido-4-bromobenzene (630 mg, 78%) as a 
colorless liquid. RF 0.61 (EtOAc/heptane, 1/8). 1H NMR (CDCl3, 400 MHz): 8 7.44(d, J= 8.9 Hz, 2H),
6.89 (d, J= 8.9 Hz, 2H). 13C NMR (CDCl3, 75 MHz): 8 138.7, 132.3, 120.1, 117.2.
4-(azidomethyl)-1-methoxybenzene
n3. To a solution of 1-(chloromethyl)-4-methoxybenzene (400 mL, 2.9 mmol) in 2 mL of DMF 
rp 5^  was added NaN3 (188 mg, 2.9mmol). The reaction mixture was stirred at 60 °C for 5 h. The 
I I  reaction was then quenched with H2O and extracted with Et2O. The organic layers were
O M e
washed with H2O and brine, dried (Na2SO4) and concentrated in vacuo. Purification by column 
chromatography (EtOAc/heptane, 1/20) gave 1-(azidomethyl)-4-methoxybenzene (410 mg, 87%) as a 
colorless liquid. Rf 0.36 (EtOAc/heptane, 1/8). 1H NMR (CD O 3, 400 MHz): 8 7.23(d, J= 8.8 Hz, 2H),
6.90 (d, J= 8.8 Hz, 2H), 4.24 (s, 2H), 3.78 (s, 3H). 13C NMR (CDCl3, 75 MHz): 8 159.2, 129.2, 126.9,
113.7, 54.7, 53.9.
4-azido-1-methoxybenzene
To a solution of NaN3 (1.5 g, 24.3 mmol) in a mixture of H2O/CH2Cl2 (7.5 mL, 1:1 v/v) at 0 °C, 
was added Tf2O (2.01mL, 12.15 mmol). The reaction mixture was stirred at room temperature
O M e
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for 2 h. After quenching with aqueous NaHCO3, the layers were separated and the aqueous layer was 
extracted with CH2Cl2 (5.75 mL). The organic layers were combined to afford 9.5mL of TfN3 solution. 
Then, to a solution of para-methoxyaniline (500 mg, 4.06 mmol) and CuSO4 (5 mg) in H2O (9.5 mL) 
was added the TfN3 solution, MeOH (31 mL) and Et3N (1.6 mL). The reaction mixture was stirred 
overnight at room temperature. Then solid NaHCO3 (1.0 g) was added carefully and the organic solvents 
were evaporated. The aqueous residue was extracted with EtOAc (3 x 100 mL), and the organic layers 
were combined, dried (Na2SO4), and concentrated in vacuo to give a yellow liquid. Purification by 
column chromatography ((EtOAc/heptane, 1/20) afforded 1-azido-4-methoxybenzene (490 mg, 81%) as 
a colorless liquid. RF 0.42 (EtOAc/heptane, 1/8). 1H NMR (CDCl3, 400 MHz): 8 6.94 (m, 2H), 6.87 (m, 
2H), 3.78 (s, 3H).13C NMR (CDCl3, 75 MHz): 8 156.5, 131.8, 119.5, 114.6, 55.0.
1-(azidomethyl)-2-methoxybenzene
N3 To a solution of 1-(chloromethyl)-2-methoxybenzene (400 mL, 2.9 mmol) in 2 mL of DMF 
MeO^ ^*1 was added NaN3 (188 mg, 2.9 mmol). The reaction mixture was stirred at 60 °C for 5 h.
^  The reaction was then quenched with H2O and extracted with Et2O. The organic layers 
were washed with H2O and brine, dried (Na2SO4) and concentrated in vacuo. Purification by column 
chromatography (EtOAc/heptane, 1/20) gave 1-(azidomethyl)-2-methoxybenzene (406 mg, 86%) as a 
colorless liquid. RF 0.44 (EtOAc/heptane, 1/8). 1H NMR (CDCl3, 400 MHz): 8 7.29(m, 2H), 6.94 (m, 
2H), 4.35 (s, 2H), 3.84 (s, 3H).13C NMR (CDCl3, 75 MHz): 8 157.2, 129.6, 129.3, 123.4, 120.1, 110.1,
54.8, 49.7.
General Procedure for Copper (I)-Catalyzed Azido-Alkyne Cycloaddition (CuAAC). (9aA-10g), 
exemplified for compound 9aA.
To a solution of 9a (15 mg, 0.020 mmol) in a mixture of MeCN/H2O (2 mL, 20:1 v/v), was added 
linker A (1.8 mg, .010 mmol). The reactionmixture was stirred at room temperature in the presence of a 
Cu-wired stirringbar. After 3 h, the Cu-wire was removed and stirring wasprolonged until all starting 
material was consumed. The volatiles were removed in vacuo. Purification by column chromatography 
(MeOH/CH2Cl2 1/9) afforded 9aA (11 mg, 63%) as a white solid. HRMS (ESI) m/zcalcd for 
C52H80N 18O8 (M+H)+: 1085.6484, found: 1085.6464. RP-HPLC: tR = 15.42 min.
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Com pound 9aB
Yield 57%, white solid. HRMS (ESI) m/zcalcd for C52H80N 18O8 (M+H)+: 1085.6484, found: 
1085.6482. RP-HPLC: R  = 17.23 min.
Com pound 9aC
Yield 61%, white solid. 1H NMR (MeOD, 400 MHz): 8 7.95 (s, 2H), 7.78 (d, J= 6.4 Hz, 2H), 6.91 (s, 
2H), 6.81 (dd, J= 6.6, 1.4 Hz, 2H), 5.09 (d, J= 7.7 Hz, 2H), 4.36 (t, J= 7.0 Hz, 4H), 4.10 (m, 2H), 3.89 (s, 
2H), 3.77 (t, J= 6.0 Hz, 4H), 3.65 (t, J= 9.2 Hz, 2H), 3.48 (m, 6H), 3.35 (m, 4H), 3.21 (m, 6H), 2.39 (s, 
6H), 2.36 (dt, J= 8.2, 3.8 Hz, 2H), 1.91 (m, 4H), 1.72 (q, J= 12.4 Hz, 2H), 1.27 (m, 2H). HRMS (ESI) 
m/zcalcd for C49H82N 18O8 (M+H)+: 1051.6641, found: 1051.6577. RP-HPLC: R  = 16.33 min.
Com pound 9aD
Yield 60%, white solid. HRMS (ESI) m/zcalcd for C48H 80N 18O8 (M+H)+: 1037.6484, found: 
1037.6448. RP-HPLC: R  = 16.28 min.
Com pound 9aE
Yield 87%, white solid. HRMS (ESI) m/zcalcd for C29H43N9O4 (M+H)+: 582.3516, found: 582.3516. 
RP-HPLC: tR = 15.12 min.
Com pound 9bA
Yield 73%, white solid. HRMS (ESI) m/zcalcd for C52H 80N 18O8 (M+H)+: 1085.6412, found: 
1085.6419. RP-HPLC: R  = 16.72 min.
Com pound 9bB
Yield 65%, white solid. HRMS (ESI) m/zcalcd for C52H80N 18O8 (M+H)+: 1085.6484, found: 
1085.6442. RP-HPLC: R  = 16.44 min.
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Com pound 9bC
Yield 66%, white solid. HRMS (ESI) m/zcalcd for C49H82N 18O8 (M+H)+: 1051.6641, found: 
1051.6641. RP-HPLC: R  = 17.11 min.
Com pound 9bD
Yield 65%, white solid. HRMS (ESI) m/zcalcd for C48H80N 18O8 (M+H)+: 1037.6484, found: 
1037.6460. RP-HPLC: R  = 16.81 min.
Com pound 9bE
Yield 92%, white solid. HRMS (ESI) m/zcalcd for C29H43N9O4 (M+H)+: 582.3516, found: 582.3516. 
RP-HPLC: R  = 16.19 min.
Compound 9cA
Yield 60%, white solid. HRMS (ESI) m/zcalcd for C60H 84N 18O8 (M+H)+: 1185.6797, found: 
1185.6878. RP-HPLC: R  = 22.72 min.
Com pound 9cB
Yield 58%, white solid. HRMS (ESI) m/zcalcd for C60H 84N 18O8 (M+H)+: 1185.6797, found: 
1185.6781. RP-HPLC: R  = 24.13 min.
Com pound 9cC
Yield 69%, white solid. 1H NMR (CDCl3, 400 MHz): 8 8.09 (s, 2H), 7.96 (d, J= 8.1 Hz, 2H),7.82 (s, 
2H), 7.71 (t, J= 7.2 Hz, 2H), 7.49 (t, J= 8.1 Hz, 2H), 6.99 (s, 2H), 5.24 (d, J= 7.4 Hz, 2H), 4.44 (s, 2H), 
4.34 (t, J= 7.0 Hz, 4H), 3.95 (s, 4H), 3.65 (t, J= 9.1 Hz, 4H), 3.38-3.60 (m, 8H), 3.27 (t, J= 6.6 Hz, 4H),
3.16 (m, 4H), 2.95 (s, 2H), 2.63 (s, 4H), 2.32 (dt, J= 12.2, 4.1 Hz, 2H), 1.87 (m, 4H), 1.69 (q, J= 12.2 
Hz, 2H), 1.26 (m, 2H). HRMS (ESI) m/zcalcd for C57H86N 18O8 (M+H)+: 1151.6954, found: 1151.6945. 
RP-HPLC: R  = 21.61 min.
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Com pound 9cD
Yield 66%, white solid.HRMS (ESI) m/zcalcd for C56H84N 18O8 (M+H)+: 1137.6797, found: 
1137.6793. RP-HPLC: R  = 23.12 min.
Com pound 9cE
Yield 90%, white solid. HRMS (ESI) m/zcalcd for C33H45N9O4 (M+H)+: 632.3672, found: 632.3669. 
RP-HPLC: R  = 19.87 min.
Compound 10a
Yield 79%, white solid. 1H NMR (MeOD, 400 MHz): 8 8.04 (s, 1H), 8.02 (d, J= 8.4 Hz, 1H), 7.77 (t, 
J= 7.7 Hz, 1H), 7.55 (t, J= 7.7 Hz, 1H), 7.50 (d, J= 8.2 Hz, 2H), 7.24 (d, J= 8.2 Hz, 2H), 5.55 (s, 2H),
5.16 (d, J= 7.2 Hz, 1H), 4.17 (s, 3H), 3.98 (t, J= 6.0 Hz, 2H), 3.65 (t, J= 9.0 Hz, 1H), 3.56 (m, 1H), 3.48 
(t, J= 9.7 Hz, 4H), 3.37 (dd, J= 12.8, 2.3 Hz, 1H), 3.20 (m, 4H), 2.69 (s, 3H), 2.60 (m, 2H), 2.36 (dt, J=
8.1, 3.7 Hz, 1H), 1.71 (q, J= 12.4 Hz, 1H). HRMS (ESI) m/zcalcd for C33H44N9O4Br (M+H)+: 710.2777, 
found: 710.2761. RP-HPLC: R  = 20.43 min.
Com pound 10b
Yield 71%, white solid. HRMS (ESI) m/zcalcd for C32H42N9O4Br (M+H)+: 696.2621, found: 
696.2664. RP-HPLC: R  = 21.18 min.
Com pound 10c
Yield 77%, white solid. 1H NMR (MeOD, 400 MHz): 8 8.03 (s, 1H), 8.01 (d, J= 8.1 Hz, 1H), 7.76 (t, 
J= 7.7 Hz, 1H), 7.54 (t, J= 7.7 Hz, 1H), 7.28 (d, J= 8.7 Hz, 2H), 6.88 (d, J= 8.7 Hz, 2H), 5.49 (s, 2H), 
5.23 (d, J= 7.0 Hz, 1H), 4.36 (s, 2H), 4.28 (t, J= 9.5 Hz, 1H), 3.99 (t, J= 5.5 Hz, 2H), 3.74 (s, 3H), 3.66 
(t, J= 9.1 Hz, 1H), 3.63 (d, J= 11.5 Hz, 1H), 3.57 (dd, J= 12.8, 6.4 Hz, 1H), 3.36-3.55 (m, 4H), 3.31 (s, 
3H), 2.84 (m, 2H), 2.68 (s, 2H), 2.37 (dt, J= 12.0, 4.0 Hz, 1H), 1.73 (q, J= 12.5 Hz, 1H). HRMS (ESI) 
m/zcalcd for CMH47N9O5 (M+H)+: 662.3778, found: 662.3758. RP-HPLC: R  = 21.34 min.
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Com pound 10d
Yield 72%, white solid. HRMS (ESI) m/zcalcd for C33H45N 9O5 (M+H)+: 648.3621, found: 648.3600. 
RP-HPLC: R  = 20.63 min.
Com pound 10e
Yield 81%, white solid. 1H NMR (MeOD, 400 MHz): 8 8.02 (d, J= 8.2 Hz, 1H), 7.97 (s, 1H), 7.77 
(dd, J= 8.2, 7.2 Hz, 1H), 7.55 (dd, J= 8.2, 7.2 Hz, 1H), 7.33 (m, 1H), 7.23 (dd, J= 7.4, 1.6 Hz, 1H), 7.00 
(d, J= 8.3 Hz, 1H), 6.92 (dt, J= 7.5, 1.0 Hz, 1H), 5.55 (s, 2H), 5.19 (d, J= 8.3 Hz, 1H), 4.24 (s, 3H), 3.99 
(t, J= 5.9 Hz, 2H), 3.83 (s, 3H), 3.68 (t, J= 9.2 Hz, 1H), 3.35-3.60 (m, 5H), 2.84 (m, 3H), 2.69 (s, 4H), 
2.36 (dt, J= 12.1, 4.0 Hz, 1H), 1.71 (q, J=12.6 Hz, 1H). HRMS (ESI) m/zcalcd for C34H47N9O5 (M+H)+: 
662.3778, found: 662.3769. RP-HPLC: R  = 21.15 min.
Com pound 10f
Yield 70%, white solid. HRMS (ESI) m/zcalcd for C34H48N 10O4 (M+H)+: 661.3938, found: 661.3914. 
RP-HPLC: R  = 21.32 min.
Com pound 10g
Yield 68%, white solid. HRMS (ESI) m/zcalcd for C31H50N 10O4 (M+H)+: 627.4094, found: 627.4084. 
RP-HPLC: R  = 21.12 min.
FRET-based oxygen-sensitive assay27
A typical experiment using a 96-well U-bottom plate was performed as follows. Serial dilutions of a 
freshly grown cell culture were made in LB to achieve 109 to 102 colony-forming units (cfu, confirmed 
by colony plate counting). Wells were prepared in triplicate by filling each well with 180 ml of the cell 
dilution plus 20 ml of Cy3-labeled hemocyanin solution (0.5-1 mM end-concentration). To avoid 
evaporation and rapid oxygen diffusion, 50 ml of mineral oil was added on top of each well. For 
antibiotic resistance tests, the initial number of cells was 107 cfu/well. Kanamycin was added to a final 
concentration of 0.05 to 5000 mg/ mL. Controls were performed by adding Cy3 or Cy3-labeled BSA
54
2-Deoxystreptamine Conjugates by Truncation-Derivatization of Neomycin
instead of Cy3-labeled hemocyanin to the cell culture as well as by using unlabeled hemocyanin. The 
fluorescence of Cy3-labeled hemocyanin in LB without cells was also monitored as a control in the 
absence of oxygen consumption.. Fluorescence spectra and time traces were measured on a Cary Eclipse 
Fluorimeter (Varian) with a 96-well plate reader accessory. During the measurements, the temperature 
of the plate was kept constant using a thermostated water bath.
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CHAPTER 3
Fully Orthogonally Protected 2-Deoxystreptamine from Kanamycin
A concise route for the synthesis of a fully orthogonally protected and enantiopure 2-deoxystreptamine 
derivative from commercially available kanamycin is developed. Desymmetrization of the sterically 
hinderd diacetate by a Verenium esterase was employed as the key step in the synthesis. Subsequent 
chemoselective azide reduction further assisted to arrive at the fully orthogonally protected 2- 
deoxystreptamine. The resulting 2-deoxystreptamine can be employed for the synthesis of 
aminoglycoside analogues.
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3.1 I n t r o d u c t io n
Since the discovery of the first aminoglycoside, streptomycin, in 1944 different members of the 
aminoglycoside family are frequently used as antibiotics due to the strong bactericidal activity, low cost 
and synergistic effects in combination with other drugs1. The mode of action of aminoglycosides is by 
binding to the decoding site of prokaryotic ribosomal RNA, thereby interfering with the fidelity of 
translation, and ultimately causing bacterial cell death2. Apart from that, a number of aminoglycosides 
reveal antiviral activity as a consequence of specific interactions with viral RNA3. However, rapid 
emergence of resistance and high human toxicity4 has stimulated the development of new structural 
analogues5 of natural aminoglycosides devoid of such limitations. The plethora of hydroxy and amino 
functions in aminoglycosides, however, render chemistry aiming at structural analogues far from trivial 
and necessitate lengthy synthetic protective group schemes. Consequently, a more practical strategy 
involves the preparation of aminoglycoside type analogues based solely on the central aminohexitol,
2-deoxystreptamine. Modern research in the field of aminoglycosides substantiate the fundamental role 
of central aminocyclohexitol ring, commonly known as 2-deoxystreptamine, in binding to RNA6 and 
thus make it a key scaffold in the development of new structural analogues of natural aminoglycosides.
Despite the large number of synthetic efforts7, to date the most efficient method to obtain 2- 
deoxystreptamine is by acidic degradation of neomycin8. However, the meso 2-deoxystreptamine thus 
obtained again requires multiple protecting group manipulations before it can be used for the synthesis 
of novel RNA ligands. In contrast to neomycin, to date members of the 4,6-substituted aminoglycosides 
have not been used as starting material for 2-deoxystreptamine. Herein, we described a route towards 
fully orthogonally protected and enantiopure 2-deoxystreptamine starting from commercially available 
kanamycin A, a member of the 4,6-substituted aminoglycosides.
3 .2  R e s u lts  a n d  D iscu ss io n
Acid hydrolysis o f kanamycin
Since kanamycin belongs to the 4,6-linked 2-deoxystreptamine type of aminoglycosides, and 
consequently contains an unsubstituted 5-OH, it can be conveniently employed as starting material for 
the synthesis of selectively 5-O-protected 2-deoxystreptamine via global protection followed by
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hydrolysis of the glycosidic bonds (Scheme 1). Thus, the amino functionalities of kanamycin A were 
converted to azides via transition metal-catalyzed diazotransfer9, followed by global O-allylation or 
benzylation, to give the respective fully protected kanamycin derivatives 1a (R = allyl) or 1b (R = 
benzyl) in good yields (Scheme 1).
Scheme 1
kanamycin Ar- a.b
eHO*' Y ^ O H M
1a R = CH2CH=CH2 (59%) 
b R = Bn (57%)
RO Y  OM CT ' Y  "’OHMeO'1 ^  ' N3 
2a,b 3a R = CH2CH=CH2 (61 %) 4a,b
Reagents and conditions: a) TfN3, CuSO4, H2O, MeOH, CH2Cl2, 16 h. b) NaH, BnBr or CH2=CHCH2Br, DMF, 0°C rt,
16 h. c) 1N HCl, MeOH, reflux, 16 h. d) HMDS, TMSCl, MeCN, 3 h. e) 1N HCl, MeOH, 15 min.
Next, both glycosidic bonds of 1a were simultaneously hydrolyzed by refluxing compound 1a in 1 N 
HCl in MeOH for 16 hours to give an anomeric mixture of methyl glycosides 2a and 4a along with the 
desired 5-O-allylated 2-deoxysteptamine 3a. However, the separation of compound 3a from the methyl 
glycosides 2a and 4a was difficult due to near identical retention times on silica gel. Fortunately, a time­
consuming chromatographic separation could be readily avoided by transient trimethylsilylation of the 
free hydroxyls of 5-O-protected 2-deoxystreptamine 3a. After a fast chromatographic separation, rapid 
and quantitative hydrolysis of the silyl ethers with 1 N HCl in MeOH (15 min) gave 2-deoxystreptamine 
3a in pure form.
Scheme 2
3a or b
M3
AcO^ ^OAc 
X
5a X= OCH2CH=CH2 (86%) 
b X= OBn (81%) 
c X= H (70%)
Reagents and condtions: a) Pyridine, Ac2O, DMAP, 0 °C ^ , rt, 3h. b) i- Me3P, THF, 3 h; ii- CbzCl, Et3N, MeOH, 3 h; iii- 
Ac2O, pyridine, 0 °C ^  rt, 3 h.
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Thus 5-O-protected 2-deoxystreptamine 3a, or 3b by a similar sequence of events, was obtained from 
kanamycin A in five chemical steps and three chromatographic separations in an overall yield of 36%. 
Since compounds 3a and 3b are meso, enzymatic pathways were explored to convert 3a and 3b into 
building blocks suitable for the assembly of enantiopure aminoglycoside analogues. A well-established 
technology for the resolution of diols involves enzymatic hydrolysis10. To this end, 3a,b were acetylated 
to 5a,b with Ac2O and pyridine, which proceeded efficiently. An alternative test substrate 6 for 
enzymatic resolution was obtained by Staudinger reduction of azides followed by Cbz-protection and 
acetylation (Scheme 2). For reasons of comparison, the 5-deoxy derivative 5c was also prepared by a 
known route11. Initially, a number of lipases from a commercially available enzyme-kit were 
investigated but none of the enzymes demonstrated any hydrolytic activity on 5a or 5b. Steric hindrance 
of the 5-O-alkyl group may be responsible for the lack of reactivity, as it was found that subjecting the 
corresponding 5-deoxystreptamine derivative 5c led to rapid conversion (not depicted). As the 
commercially available enzymes failed to desymmetrize the 2-deoxystreptamine derivatives (entries 1­
4), we next screened a set of esterases provided by Verenium Corporation and selected for the capacity 
to hydrolyse sterically hindered substrates. Out of 17 enzymes, six were able to convert 5a and 5b, 
although four esterases (entries 5, 6, 8, 10) hydrolyzed both acetate groups and one esterase (entry 7) 
gave a mixture of monoacetate, diacetate, and diol. To our delight, in a mixture of acetonitrile and 
phosphate buffer (pH 7.5, 37 °C) Verenium esterase 5 (entry 9) was found to hydrolyze only a single 
acetate group of substrate 5a with more than 95% conversion and 92% isolated yield. The resulting 
monoacetate 7a was formed with excellent enantiomeric excess as judged by HPLC. Reaction of the 
same enzyme with the more sterically hindered benzylated substrate 5b (entry 11) gave only 22% 
isolated yield. Also, with substrate 6 less than 10% conversion was detected which further supports the 
notion of steric hindrance (entry 12). Further attempts to optimize the reaction conditions i.e. variation in 
temperature, pH, or co-solvents did not change matters. Finally, attempts to perform asymmetric 
acylation of 4a by subjection to Verenium esterase 5 in neat vinyl acetate were fruitless; no conversion 
was detected. At this point, the absolute configuration of 7a was established as depicted in Table 1 by 
comparison of optical rotation with a sample prepared by a degradative route from D-neamine12 (Scheme 
3).
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Table 1
N3 * ^ " \> N3
5a or 5b --------- ► I J
HO''' Y ^ ' vOAc
7a R = CH2CH=CH2 
b R = Bn
Entry Substrate Enzymea,b pH Time (d) Conversion Yield (% ) ee (% )c
1 5a CCL 7.5 6 - - -
2 5a CAL 7.5 6 - - -
3 5a PPL 7.5 6 - - -
4 5a PCL 7.5 6 - - -
5 5a Verenium 1 7.5 6 73 - -
6 5a Verenium 2 7.5 6 36 - -
7 5a Verenium 3 7.5 6 n.dd - -
8 5a Verenium 4 7.5 6 19 - -
9 5a Verenium 5 7.5 2 95 92 >99
10 5a Verenium 6 7.5 6 100 - -
11 5b Verenium 5 7.5 7 40 22 -
12 6 Verenium 5 7.5 10 - - -
aEnzyme, phosphate buffer, CH3CN, 37 °C.
b CCL = Candida Cylindracea Lipase; CAL = Candida Antarctica Lipase; PPL = Porcine Pancreas
Lipase; PCL = Pseudomonas Cepacia Lipase; Esterases obtained from Verenium corporation
(www.verenium. com).
cDetermined by chiral HPLC.
dMixture of monoacetate, diacetate and diol.
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Tetraazidoneamine derivative 10 was reacted with allyl bromide, TBAI and NaH to protect the 5-OH 
with an allyl group but upon deprotonation with NaH a partial acetyl shift occurred to afford an 
intractable mixture of regioisomers 11a and 11b. The mixture of 11a and 11b in MeOH was treated with 
KOt-Bu to give an inseparable mixture of diols 12a and 12b. Again, the mixture of regioisomers was 
further processed. Finally, oxidation of 12a and 12b using NaIO4 smoothly afforded a mixture of 
dialdehyde which upon treatment with ^-butylamine underwent ß-elimination to afford after 
chromatographic separation pure 7a. The analytical data of this compound 7a fully correspond to those 
of 7a obtained by enzymatic resolution.
Scheme 3
Reagents and conditions: (a) NaH, CH2=CHCH2Br, TBAI, DMF, 0°C rt, 16h (42%). b) KO‘Bu, MeOH, rt, 2 h (73%). 
(c) NaIO4, MeOH, rt, 16 h. d) ^-BuNH2, MeOH, rt, 16 h (20% over two steps).
To arrive at fully orthogonally protected 2-deoxystreptamine, differentiation between the two amino 
functionalities is also required. To this end, we turned our attention to chemoselective azide reduction13 
as recently explored by Wong and Chang. Since in compound 7a, the 6-O-Ac renders the vicinal azide 
more electron-deficient, compound 7a was subjected to one-pot Staudinger reduction/Boc protection14, 
affording compound 8 in a satisfactory 40% yield (Scheme 4). Thus, a fully orthogonally protected 
enantiopure 2-deoxystreptamine has been obtained in eight steps from kanamycin and with an overall 
yield of 12%.
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Scheme 4
7a a
\
b or c
\
8 R = Boc (40%)
9 R = p-BrCbz (27%)
Reagents and conditions: a) PMe3, THF, -78°C ®  rt, 2 h. b) Boc-ON, -78°C ®  r.t. c) p-BrCbzCl, -78°C ®  r.t.
By the same sequence of events, additional proof of the absolute configuration of 8 was individually 
obtained by X-ray crystallography. To this end (Scheme 4), the aza-ylide intermediate resulting from 
selective azide reduction of 7a was treated with p-BrCbzCl, in turn prepared by treating p-bromobenzyl 
alcohol with diphosgene, to give p-BrCbz-protected amine 9 in 27% yield. Crystallization from MeCN 
followed by X-ray diffraction gave the structure depicted in Figure 1.
Figure 1. PLUTON representation of the crystal structure of the orthogonally protected 2-DOS 9 showing the absolute 
stereochemistry.
3.3  C o n c lu s io n s
In conclusion, we obtained a fully orthogonally protected enantiopure 2-deoxystreptamine derivative in 
12% overall yield starting from 4,6-disubstituted aminoglycoside kanamycin. Desymmetrization of the 
sterically hinderd meso diol by enzymatic resolution was employed as the key step in the synthesis.
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Subsequent chemoselective azide reduction further assisted to arrive at the fully orthogonally protected
2-deoxystreptamine 8.
3 .4  A c k n o w le d g m e n ts
We thank Flash Bartnek and Jesal Patel (Verenium Corporation) for preparation and production of 
esterases and Dr. S. Weiner for kindly providing the esterases to us. Dr. R. de Gelder is kindly 
acknowledged for elucidation of the X-ray structure.
3 .5  E x p e r im e n ta l  S ec tio n
General methods and materials
Solvents were distilled from appropriate drying agents prior to use and stored under nitrogen. Chemicals 
were purchased from Sigma-Aldrich and used as received, unless stated otherwise. Reactions were 
carried out under inert atmosphere of dry nitrogen or argon. Standard syringe techniques were applied 
for the transfer of dry solvents and air- or moisture-sensitive reagents. Reactions were followed and RF 
values are obtained using thin layer chromatography (TLC) on silica gel-coated plates (Merck 60 F254) 
with the indicated solvent mixture. NMR spectra were recorded on a Bruker DMX 300 (300 MHz):, or a 
Varian 400 (400 MHz): spectrometer in CDCl3 solutions (unless otherwise reported). Chemical shifts 
are given in ppm with respect to tetramethylsilane (TMS) as internal standard. Coupling constants are 
reported as J-values in Hz. Peak assignment in 13C spectra are based on 2D-GHSQC and GHMBC 
spectra. Column or flash chromatography was carried out using ACROS silica gel (0.035-0.070 mm, ca 
6 nm pore diameter). High resolution mass spectra were recorded on a JEOL AccuTOF (ESI), or a 
MAT900 (EI, CI, and ESI).
1,3,6',3"-Tetraazido-1,3,6',3"-tetradeam inokanam ycin
T"1 _ _ _ _ 1 i* _ _ _ r * T W T _ T W T  / £■ '-> r _ i _ _ e
layers were separated and the aqueous layer was extracted with CH2Cl2 (200 mL). The organic layers
X *  .vL J.,. ✓L J.,  0.41 mol, 1.5 equiv./NH2). The reaction mixture was stirred at room 
Y  o ' n3 M y
OH OH OH temperature for 2 h. After quenching with aqueous NaHCO3, the
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were combined to afford 335 mL of TfN3 solution. Then, to a solution of kanamycin (20 g, 34.3 mmol) 
and CuSO4 (219 mg) in H2O (335 mL) was added the TfN3 solution, MeOH (1.1 L) and Et3N (43 mL). 
The reaction mixture was stirred overnight at room temperature. Then solid NaHCO3 (35 g) was added 
carefully and the organic solvents were evaporated. The aqueous residue was extracted with EtOAc (5 x 
300 mL), and the organic layers were combined, dried (Na2SO4), and concentrated in vacuo to give a 
yellow oil. Purification by column chromatography (pure EtOAc to 10% MeOH/EtOAc) afforded 
tetraazidokanamycin (17 g, 84%) as a colorless oil. RF 0.44 (MeOH/EtOAc, 1/9). 1H NMR (MeOD, 400 
MHz): 8 5.24 (d, J= 3.8 Hz, 1H), 5.18 (d, J= 3.8 Hz, 1H), 4.08-3.98 (m, 2H), 3.78-3.28 (m, 15H), 2.33 
(dt, J= 4.2, 12.6 Hz, 1H), 1.56 (q, J= 12.4 Hz, 1H). 13C NMR (MeOD, 75 MHz): 8 100.4, 98.0, 83.0,
80.2, 73.8, 72.9, 71.9, 71.5, 70.4, 70.1, 67.9, 66.4, 60.0, 58.8, 50.8, 31.5. HRMS (ESI) m /zcalcd for 
C 18H28N 12O 11 (M+Na)+: 611.201, found: 611.193.
1,3,6 ',3"-Tetraazido-1,3,6 ',3"-tetradeam ino-4,2 ',3 ',4 ',2",4",6"-hepta-0Lallylkanamycin (1a)
N3 OAll To a solution of tetraazidokanamycin derivative (517 m
3>S,ta ^
AllO J L  N3 N3 ^ \> O A ll mmol) in DMF (25 mL) was added, at 0 °C, NaH (545 mg, 7.85
_  ^  mmol) and then allyl bromide (1.0 mL, 12 mmol). The reaction
A llO ^ ^ ^ ^ O ' 'O ^ ^ ^  'N3
OAll OAll OAll mixture was allowed to warm to room temperature and stirred for
4 h. The reaction was then quenched with NH4Cl and extracted with EtOAc/i-PrOH (9/1). The organic
layer was washed with water, brine and then dried (Na2SO4) and concentrated in vacuo. Purification by
column chromatography (EtOAc/heptane, 1/6) afforded 1a (545 mg, 71%) as a yellow oil. RF 0.48
(EtOAc/heptane, 1/3). 1H NMR (CDCl3, 400 MHz): 8 6.01-5.72 (m, 7H), 5.55 (d, J= 3.7 Hz, 1H), 5.47
(d, J= 3.8 Hz, 1H), 5.36-5.07 (m, 14H), 4.45 (m, 1H), 4.35-3.86 (m, 14H), 3.85-3.62 (m, 2H), 3.58-3.22
(m, 14H), 2.35 (dt, J= 4.0, 13.19 Hz, 1H), 1.21 (m, 1H). 13C NMR (CDCl3, 75 MHz): 8 134.9, 134.5,
134.4, 134.3, 134.0, 133.9, 118.6, 117.7, 117.0, 116.5, 115.7, 97.3, 96.0, 82.6, 81.6, 79.0, 78.2, 75.9,
74.2, 74.0, 73.6, 72.6, 70.7, 69.9, 68.3, 65.2, 61.0, 59.3, 51.6, 32.7. HRMS (ESI) m/z calcd for
C39H56N 12O 11 (M+Na)+: 891.421, found: 891.412.
1,3,6',3"-TetraazidoL1,3,6',3"LtetradeaminoL4,2',3',4',2",4",6"Lhepta-OLbenzylkanamycin (1b)
N3^  /OBn To a solution of tetraazidokanamycin derivative (502 mg, 0.85
BnO/. ^^—■~N3^^^ '^s\ ^ N 3
N3^
)' A N
BnO^N-'-'So'"
OBn OBn OBn
OBn mmol) in DMF (20 mL) was added, at 0 °C, NaH (340 mg, 8.5 
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mmol) and then benzyl bromide (2 mL, 16.0 mmol). The reaction mixture was allowed to warm to room 
temperature and stirred for 4 h. The reaction was then quenched with NH4Cl and extracted with 
EtOAc/i-PrOH (9/1). The organic layer was washed with water, brine and then dried (Na2SO4) and 
concentrated in vacuo. Purification by column chromatography (EtOAc/heptane,1/6) afforded 1b (658 
mg, 63%) as white foam. Rf 0.35 (EtOAc/heptane, 1/3). 1H NMR (CDCl3, 400 MHz): 8 7.45-6.81 (m, 
35H), 5.56 (d, J= 3.7 Hz, 2H), 5.04 (d, J= 12 Hz, 1H), 4.89-4.47 (m, 9H), 4,42 (d, J= 12.0 Hz, 1H), 4.30 
(ddd, J= 2.4, 4.6, 9.9 Hz, 1H), 4.21-4.09 (m, 3H), 4.16 (t, J= 18.8 Hz, 1H), 3.77-3.22 (m, 14H), 3.11 (dd, 
J= 1.8, 11.0 Hz, 1H), 2.84 (dd, J= 2.4, 11.0 Hz, 1H), 2.39 (td, J= 4.4, 13.1 Hz, 1H), 1.65 (dd, J= 12.4, 25 
Hz, 1H). 13C NMR (CDCl3, 75 MHz): 8 138.0, 137.5, 137.2, 136.9, 128.1, 128.0, 127.9, 127.8, 127.6,
127.5, 127.4, 127.3, 127.1, 127.0, 126.8, 126.5, 125.2, 96.8, 95.5, 82.1, 81.3, 78.8, 77.9, 76.3, 75.5, 74.0,
69.5, 67.1, 65.0, 59.9, 58.9, 50.9, 31.7.
1,3LdiazidoL1,3LdideaminoL5L OLally^Ldeoxystreptamine (3a)
N3^ / \ > * N 3 AcCl (1.5 mL) was added to MeOH (15 mL) at 0 °C. The obtained 1 N HCl/MeOH
..■L J : .  solution was added to 1a (200 mg, 0.23 mmol) and the reaction mixture was refluxed 
HO 'OH
OAll overnight. The reaction was then quenched with NaHCO3, concentrated and extracted 
with EtOAc. The organic layer was washed with water, brine and then dried (Na2SO4) and concentrated 
in vacuo. The crude product was treated with HMDS (1 mL) and catalytic trimethylsilyl chloride (100 
mL) in acetonitrile (5 mL). After purification by column chromatography (EtOAc/heptane, 1/15), the 
resulting bis-TMS-ether was treated with 1 N HCl in MeOH to afford pure 3a as a white solid (58 mg, 
68%). Rf 0.14 (EtOAc/heptane, 1/3). 1H NMR (CDCl3, 400 MHz): 8 6.01-5.86 (m, 1H), 5.28 (qdd, J=
1.2, 1.4, 10.36, 21.2 Hz, 2H), 4.35 (m, 2H), 4.18 (dt, J= 1.4, 5.6 Hz, 2H), 3.50-3.34 (m, 4H), 3.15 (t, J=
8.9 Hz, 1H), 2.20 (dt, J= 4.6, 12.9 Hz, 1H), 1.38 (dt, J= 12.6, 13.2 Hz, 1H). 13C NMR (CDCl3, 75 MHz): 
8 134.1, 117.3, 82.5, 75.5, 73.9, 59.8.5, 31.3.
1,3LdiazidoL1,3LdideaminoL5L OLbenzy^Ldeoxystreptamine (3b)
N3^ /~ \> » N 3 AcCl (1.5 mL) was added to MeOH (15 mL) at 0 °C. The obtained 1 N HCl/MeOH 
H < O ' 'vOH solution was added to 1b (200 mg, 0.23 mmol) and the reaction mixture was refluxed 
OBn overnight. The reaction was then quenched with NaHCO3, concentrated and extracted 
with EtOAc. The organic layer was washed with water, brine and then dried (Na2SO4) and concentrated
66
Fully Orthogonally Protected 2-Deoxystreptamine from Kanamycin
in vacuo. The crude product was treated with HMDS (1 mL) and catalytic trimethylsilyl chloride (100 
mL) in acetonitrile (5 mL). After purification by column chromatography (EtOAc/heptane, 1/15) the 
resulting bis-TMS-ether was treated with 1 N HCl in MeOH to afford pure 3b as a white solid (58 mg, 
68%). Rf 0.11 (EtOAc/heptane, 1/3). 1H NMR (CDCh, 400 MHz): 7.49-7.28 (m, 5H), 4.83 (s, 2H), 
3.51-3.31 (m, 4H), 3.24 (t, J= 7.8 Hz, 1H), 2.19 (dt, J= 13.2, 3.9 Hz, 1H), 1.27 (dt, J= 13.2, 12.9 Hz, 
1H).13C NMR (CDCl3, 75 MHz): 8 128.3, 127.8, 127.5, 82.7, 75.0, 59.8, 31.3.
1,3 diazidoL1,3LdideaminoL5LOLallylL4,ÓLdiLOLacetylL2Ldeoxystreptamine (5a)
Ns Ns To a solution of 3a (205 mg) in pyridine (10 mL) was added DMAP (catalytic) and
white solid. RF 0.28 (EtOAc/heptane, 1/3). 1H NMR (CDCl3, 400 MHz): 8 5.75 (ddt, J= 17.3, 10.4, 5.7 
Hz, 1H), 5.17 (qdd, J= 1.2, 1.4, 10.3, 13.2 Hz, 2H), 5.01 (t, J= 9.9 Hz, 2H), 4.07 (dt, J= 1.4, 5.6 Hz, 2H), 
3.45 (m, 3H), 2.28 (dt, J= 13.3, 4.6 Hz, 1H), 2.13 (s, 6H), 1.54 (dt, J= 13.2, 12.6 Hz, 1H). 13C NMR 
(CDCl3, 75 MHz): 8 168.9, 133.4, 116.7, 78.5, 74.2, 73.1,57.8, 31.4, 20.3. HRMS (ESI) m/z calcd for 
C 13H 18N6O5 (M+Na)+: 361.131, found: 361.125.
1,3LdiazidoL1,3LdideaminoL5LOLbenzylL4,ÓLdiLOLacetylL2Ldeoxystreptamine (5b)
N3 N3 To a solution of 3b (900 mg) in pyridine (20 mL) was added DMAP (catalytic) and
white solid. RF 0.25 (EtOAc/heptane, 1/3). 1H NMR (CDCl3, 400 MHz): 8 7.38-7.18 (m, 5H), 5.06 (t, J=
9.9 Hz, 2H), 4.60 (s, 2H), 3.52-3.39 (m, 3H) 2.29 (dt, J= 13.5, 4.1 Hz, 1H), 2.02 (s, 6H), 1.57 (dt, J=
13.0, 12.1 Hz, 1H). 13C NMR (CDCl3, 75 MHz): 8 168.9, 128.0, 127.4, 127.2, 79.0, 74.3, 57.8, 31.3,
20.2. HRMS (ESI) m/z calcd for C 17H20N 6O5 (M+Na)+: 411.151, found: 411.136.
A . , acetic anhydride (1 mL) at 0 °C. The reaction mixture was allowed to warm to room
ACO OAC
OAll temperature and stirred for 2 hours. Solvents were evaporated under vacuum and the
residue was purified by column chromatography (EtOAc/heptane, 1/4) to afford 5a (235 mg, 86%) as a
a n' 'oa acetic anhydride (2 mL) at 0 °C. The reaction mixture was allowed to warm to roomACO O a C
OBn temperature and stirred for two2 hours. Solvents were evaporated under vaccum and
residue was purified by Column chromatography (EtOAc/heptane, 1/4) to afford 5b (935 mg, 81%) as a
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(1R, 3S, 4R, 5S, &S)L1,3LdiazidoL1,3LdideaminoL5L O ^ lly ^ L  OLacety^Ldeoxystreptamine (7 a) from 
1,3,2',6'-tetraazido-1,3,2',6'-tetradeamine-5,3',4'-tri-O-acetyl-D-neamine12.
temperature and stirred for 1 h. The reaction was then quenched with NH4Cl and extracted with 
EtOAc/i-PrOH (9/1). The organic layer was washed with water, brine and then dried (Na2SO4) and 
concentrated in vacuum. Purification by column chromatography (EtOAc/heptane,1/6) afforded an 
inseparable mixture of regioisomers 11a and 11b (45 mg). To a solution of the mixture of 11a and 11b 
(40 g, 0.067 mmol) in MeOH (1 mL) was added KOt-Bu (7.5 mg, 0.067 mmol, 1 equiv.) and the 
resulting mixture was stirred at rt for 2 h. The solution was neutralized with Amberlite IR-120, filtered, 
and concentrated in vacuum. The residue was purified by column chromatography (EtOAc/heptane,1:1) 
to afford an intractable mixture of 12a and 12b (25 mg). Again, the mixture of regioisomers was further 
processed. To a solution of the mixture 12a and 12b (25 mg, 0.049 mmol) in MeOH (2 mL) was added 
NaIO4 (78 mg, 7.5 equiv., 0.367 mmol) at 0 °C. The solution was allowed to warm to rt and stirred for 
16 h. A white precipitate was formed and filtered off, and the filtrate was concentrated in vacuum. The 
residue was taken up in EtOAc, washed with H2O and brine. The organic layer was dried (Na2SO4) and 
concentrated in vacuum. The residue was then dissolved in MeOH (2 mL), and butylamine (5 ^L, 3 
equiv.) was added dropwise. The mixture was stirred for 1h at rt, concentrated in vacuum and the 
residue was purified by column chromatography (EtOAc/heptane,1:6) to afford pure 7a (3 mg) as a 
yellow oil. [a]D0 +1.3 (EtOAc). The analytical data of this compound 7a fully correspond to those of 7a 
obtained by enzymatic resolution.
Selection o f enzymes for testing
Verenium has discovered over 500 unique microbial carboxylester hydrolases (esterases, EC 3.1.1.1; 
lipases EC 3.1.1.3). These enzymes were isolated by screening mixed population environmental DNA 
libraries obtained from diverse microenvironments around the world15. The enzymes are highly diverse 
in sequence and display a wide range of activities16. In the present work, we sought to select a subset of 
enzymes to screen first for the hydrolysis of compounds 5 and 6 before testing additional enzymes, if 
necessary. In a previous study, it was shown that many Verenium carboxylester hydrolases, containing 
a GGG(A)X-motif close to the active site, were active on sterically-hindered esters of tertiary alcohols17.
^N3 To a solution of tetraazidoneamine derivative 10 (100 mg, 0.181 mmol) in DMF (2 mL) 
vOAC was added, at 0 °C, allyl bromide (109 mL, 0.905 mmol), TBAI (100 mg, 0.271 mmol)
l and then NaH (8 mg, 0.199 mmol). The reaction mixture was allowed to warm to room
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Given the bulky nature of compounds 5 and 6, we reasoned that this set of enzymes represented an 
attractive starting point for screening. 17 enzymes from this set were chosen based on good activity and 
expression. These enzymes were produced recombinantly and, in order to simplify testing, they were 
available as lyophilized cell lysates.
( 1R, 3S, 4R, 5S, 6S)l 1,3LdiazidoL1,3LdideaminoL5L OLallyl-6- OLacetyl-2-deoxystreptamine (7 a) 
N3^ / \ ^ N 3 To a solution of 5a (30 mg, 0.088 mmol) in CH3CN (200 mL) was added phosphate 
buffer (pH 7.5, 2 mL) and enzyme Verenium 5 (20 mg). The reaction mixture was 
OAll shaken for 48 hours at 37 °C and then filtered over Celite (flush with excess of 
EtOAc). Solvents were evaporated under vacuum and residue was purified by column chromatography 
(EtOAc/heptane, 1/8 to 1/5) to afford 7a (24 mg, 91%) as a brownish oil. RF 0.26 (EtOAc/heptane, 1/3). 
1H NMR (CDCl3, 300 MHz): 8 5.9-5.78 (m, 1H), 5.22 (qdd, J= 1.25, 1.42, 10.37, 15.76 Hz, 2H), 4.94 (t, 
J= 9.9 Hz, 1H), 4.18 (d, J= 5.4 Hz, 2H), 3.49 (q, J= 9.6, 18.9 Hz, 1H), 3.47-3.34 (m, 2H), 3.26 (t, J= 9.3 
Hz, 1H), 2.22 (dt, J= 4.5, 13.3 Hz, 1H), 2.14 (s, 3H), 1.40 (m, 1H). 13C NMR (CDCl3, 75 MHz): 8 
169.8, 134.3, 117.8, 81.3, 76.2, 75.1, 74.2, 59.9, 58.7, 32.1, 21. HRMS (ESI) m/z calcd for C 11H 16N6O4 
(M+Na)+: 319.121, found: 319.112. . [a]D +1.3 (EtOAc).
(1R,3S,4R,5S,65)L1L^-BocL3LazidoL3LdeaminoL5-OLallylL6LOLacetylL2Ldeoxystreptamine (8a) 
N3^ / \ M H B oC Compound 7a (20 mg, 0.067 mmol) was dissolved in THF (1 mL) and was cooled
,.L to -78  °C. To this cooled solution was added 1 M THF solution of PMe3 (67 mL,
HO OAc
OAll 0.067 mmol) and the reaction mixture was stirred at -78 °C for 5 min. The reaction
was warmed to room temperature and stirred for 2 hours. The reaction was then quenched with Boc-ON 
(41 mg, 0.167 mmol) and stirred for 4 h. Solvents were then evaporated under vacuum and the residue 
was purified with column chromatography (EtOAc/heptane, 1/3) to afford 8a (10 mg, 40%) as a white 
solid. Rf 0.17 (EtOAc/heptanes, 1/3). 1H NMR (CDCl3, 300 MHz): 8 5.85 (m, 1H), 5.22 (qdd, J= 1.25, 
1.43, 10.37, 16.44 Hz, 2H), 4.73 (dd, J= 9.5, 10.6 Hz, 1H), 4.20 (ddd, J= 1.55, 2.97, 5.80 Hz, 2H), 3.41 
(m, 3H), 2.7 (d, J= 2.36 Hz, 1H), 2.26 (dt, J= 4.20, 12.83 Hz, 1H) 2.09 (s, 3H), 1.41 (s, 9H). 1.28 (m, 
1H). 13C NMR (CDCl3, 75 MHz): 8 170.6, 164.7, 133.8. 117.0, 80.8, 79.5, 76.7, 74.8, 73.7, 69.6, 48.8,
33.0, 27.7, 20. HRMS (ESI) m/z calcd for C16H26N4O6 (M+Na)+: 393.191, found: 393.177 . [a]D +1.6 
(EtOAc).
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18p-bromobenzyloxycarbonyl chloride
gr To a solution of 4-bromobenzyl alcohol (500 mg, 2.6 mmol) in a mixture of 1,4- 
dioxane/toluene (6 mL, 1:5 v/v) was added diphosgene (257 |iL, 1.3 mmol). The 
reaction mixture was stirred at room temperature for 24 h. The solvents were 
then evaporated under vacuum and the residue was purified by crystallization from hexane at -50 °C to 
afford the product (421 mg, 65%) as colorless needles. 1H NMR (CDCl3, 400 MHz): 5 7.52 (d, J= 8.1 
Hz, 2H), 7.29 (d, J= 8.1 Hz, 2H), 5.23 (s, 2H).
1-N(l^,J5,4^,55,^5)-1-^-(4-BrCbz)-3-azido-3-deam ino-5-ö-allyl-6-ö-acetyl-2-deoxystreptam ine
(9)
,Br Compound 7a (20 mg, 0.067 mmol) was dissolved in THF (1 mL) and
,3r r Y O was cooled to -78  °C. To this cooled solution was added 1 M THFO solution of PMe3 (67 mL, 0.067 mmol) and the reaction mixture was
HO oAc 3 v r  '
OAll stirred at -78  °C for 5 minutes. The reaction was warmed to room
temperature and stirred for 2 h. The reaction was then quenched with p-bromobenzyloxycarbonyl 
chloride (17 mg, 0.072 mmol) and stirred for 4 h. Solvents were then evaporated under vacuum and the 
residue was purified with column chromatography (EtOAc/heptane, 1/3) to afford 9a (10 mg, 40%) as a 
white crystalline solid. Rf 0.17 (EtOAc/heptane. 1/3). 1H NMR (CDCl3, 300 MHz): 5 7.47 (d, J= 8.2 Hz, 
2H), 7.19 (d, J= 8.2 Hz, 2H), 5.86 (tdd, J= 5.6, 10.3, 17.1 Hz, 1H), 5.21 (qdd, J= 1.2, 1.4, 10.3, 15.1 Hz, 
2H), 5.01 (m, 2H), 4.74 (dd, J= 9.4, 10.7 Hz, 1H), 4.20 (ddd, J= 1.4, 2.7, 5.8 Hz, 2H), 3.28-3.57 (m, 3H), 
2.65 (d, J= 1.8 Hz, 1H), 2.30 (dt, J= 3.9, 12.8 Hz, 1H), 1.9 (s, 3H), 1.31 (dd, J= 12.4, 25.1 Hz, 1H). 13C 
NMR (CDCl3, 75 MHz): 5 133.7, 131.2, 129.2, 117.0, 80.7, 75.7, 74.5, 73.8, 65.6, 59.4, 49.7, 32.9,
20.3.
X-ray analysis o f compound 9
A translucent colorless single crystal (rather rough rod) was mounted in air on a glass fibre. Intensity 
data were collected at -65 °C. A Nonius KappaCCD single-crystal diffractometer was used (9 and œ 
scan mode) using graphite monochromated Mo-Ka radiation. Unit cell dimensions were determined 
from the angular setting of 67 reflections. Intensity data were corrected for Lorentz and polarization 
effects. SADABS multiscan correction19 was applied.
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Table 2. Crystal data and structure refinement for compound 9.
Crystal size 0.19 x 0.07 x 0.04 mm
Empirical formula C 19 H23 Br N4 O6
Temperature 208(2)K
Radiation / Wavelength Mo-Ka (graphite mon.) / 0.71073 Â
Crystal system, space group Orthorhombic, P 2 12 121
Unit cell dimensions 
67 reflections 
2.060 < 0 < 24.960 )
a, a = 4.9910(3) Â, 90°
b, ß = 11.0159(15) Â, 90°
c, y = 39.504(3) Â, 90°
Volume 2171.9(4) Â3
Z, Calculated density 4, 1.478 Mg/m3
Absorption coefficient 1.935 mm -1
F(000) 992
Theta range for data collection 2.06 to 24.96°
Index ranges -5<=h<=5, -12<=k<=12, -45<=l<=45
Reflections collected / unique 25989 / 3428 [R(int) = 0.1124]
Reflections observed 1912 [Io > 2 a  (Io)]
Completeness to 20 = 24.96 94.6%
Absorption correction SADABS multiscan correction (Sheldrick, 1996)
Refinement method Full-matrix least-squares on F2
Computing SHELXL-97 (Sheldrick, 1997)
Data / restraints / parameters 3428 / 550 / 310
Goodness-of-fit on F2 1.071
SHELXL-97 weight parameters 0.045900 3.584900
Final R indices [I > 2 a  (I)] R1 = 0.0765, wR2 = 0.1231
R indices (all data) R1 = 0.1681, wR2 = 0.1476
Absolute structure parameter 0 .10 (2 )
Largest diff. peak and hole 0.468 and -0.528 e.Â-3
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The structure was solved by the program CRUNCH20 and was refined with standard methods using 
SHELXL 9721 with anisotropic parameters for the nonhydrogen atoms. All hydrogens were placed at 
calculated positions and were refined riding on the parent atoms. A PLUTON drawing22 is shown in Fig.
1.
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CHAPTER 4
A Thymine-Aminoglycoside Conjugate for Subtype-Selective 
Targeting of HIV Dimerization Initiation Site
The preparation of a conjugate of thymine to truncated neomycin was explored by two different 
strategies. A bottom-up approach (Strategy A) involved first attachment of thymine to
2-deoxystreptamine, followed by regioselective glycosylation to the envisaged tetrameric conjugate. 
Key to the second strategy B was chemoselective cleavage-reconstitution sequence to facilitate selective 
removal of ring I of neomycin before installation of thymine. Binding of the resulting conjugate to a 
range of RNA structures, in particular HIV DIS kissing-loop complexes, was evaluated by isothermal 
titration calorimetry and it was found to bind not only to the HIV DIS complex subtype F and the 
ribosomal A-site, but also to HIV DIS complex subtype C. No binding was observed to other RNA 
structures.
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4.1 I n t r o d u c t io n
As in all retroviruses, a vital event in the replication of human immunodeficieny virus (HIV-1) is the 
dimerization of genomic RNA. The formation of RNA dimer is a prerequisite for the packaging of viral 
RNA into virions and also plays an important role in reverse transcription. For example, a mutant Rous 
sarcoma (a retrovirus) containing only monomeric RNA genome exhibited a 100-fold decrease in the 
synthesis of viral cDNA1 and deletion of the HIV-1 DIS stem-loop led to a reduction of a 1000-fold of 
the viral infectivity.2 In HIV-1, dimerization is initiated by formation of a kissing-loop complex3 
between a highly conserved stem loop of viral RNA possessing an auto-complementary sequence called 
the dimerization initiation site4 (DIS). The conserved stem loop of HIV genomic RNA may serve as the 
potential target for antiviral therapy since it is essential for genomic RNA dimerization and also plays an 
efficient role in RNA packaging.2 Strikingly, there is large structural and sequence similarity between 
the HIV DIS5 and the aminoacyl-tRNA site (A-site)6 of bacterial 16S ribosomal RNA (Figure 1).
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Figure 1. (a) Formation of the DIS kissing-loop complex by dimerization and (b) similarity with the bacterial ribosomal 
A-site (similar regions are denoted in grey). (c) Structure of neomycin, rings are indicated with Roman numerals.
The large similarity between the DIS kissing-loop complex and the bacterial ribosomal A-site is also 
reflected in the binding of aminoglycoside antibiotics by HIV DIS.7 Aminoglycosides form a class of 
antibiotics exerting their antibacterial activity by binding to the 30S ribosome and thereby interfering 
with protein translation. A crystal structure of the HIV-1 subtype F kissing-loop bound to neomycin8 
revealed the interactions between the 6'-amino group of one of the glucosamine moieties of neomycin,
i.e. ring I, and the highly conserved purine base A280 flanking the self-complementary sequence at the
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3'-end. The symmetrical nature of the HIV dimer is also reflected in the fact that neomycin is in fact able 
to bind in both pockets of the complex.
The crystal structure of neomycin in the HIV DIS complex reveals that ring I of neomycin is involved in 
pseudo base-pairing with A280. Based on this observation, we hypothesized that replacing ring I of 
neomycin with a nucleobase (thymine) might lead to enhanced stabilization of the kissing-loop 
interactions by base-pairing of thymine with the complementary nucleobase adenosine A280. 
Stabilization of the dimerized complex may interfere with its isomerization into an extended duplex.9 
Over-stabilization of the kissing-loop complex may impede the reverse transcription of the genomic 
RNA, thereby interfering with viral replication. This hypothesis triggered us to prepare a synthetic 
aminoglycoside-nucleobase conjugate with ring I of neomycin replaced by thymine (Figure 2). Herein, 
we report the synthesis of such a modified neomycin and binding studies to the HIV dimerization 
initiation site.
Figure 2. Structure of the thymine-aminoglycoside conjugate with thymine replacing ring I of neomycin (middle). 
Retrosynthetic analysis by two strategies reveals a step-wise approach starting from 2-DOS (strategy A) or attachment to 2- 
DOS already containing the neobiosamine disaccharide (strategy B).
The envisaged nucleobase-aminoglycoside conjugate is depicted in the boxed area in Figure 2. A 
retrosynthetic analysis of the conjugate reveals that two distinctly different synthetic approaches could 
be followed to prepare the molecule. In strategy A, the thymine moiety is coupled onto a 1,3- 
diaminohexitol called 2-deoxystreptamine (2-DOS), by nucleophilic displacement (SN2-reaction) of a 
chloride. To this end, 2-DOS needs to be suitably protected and the 4-hydroxygroup converted into a 
chloromethyl ether. After thymine introduction, attachment of the disaccharide part is secured by 
glycosylation of O-5 of 2-DOS and the desired conjugate obtained after deprotection. In the second
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strategy B, the thymine moiety is introduced by the same nucleophilic displacement at a chloromethyl 
ether derivative of 2-deoxystreptamine that, however, already contains the bottom disaccharide part. 
Since we had already developed several routes to orthogonally protected 2-deoxystreptamine derivatives 
in our lab (see Chapter 3), we opted to investigate strategy A first.
4 .2  R e s u lts  a n d  D iscu ss io n
Synthesis
Our synthesis commences with the enantiopure, orthogonally protected 1,3-diazido-5-O-allyl-6-O- 
acetyl-2-deoxystreptamine building block 110, obtained by enzymatic desymmetrization of a meso diol 
precursor (see Chapter 3). As described above, strategy A relies on a route involving first introduction of 
thymine followed by subsequent glycosylation with a disaccharide donor. Scheme 1 summarizes the 
coupling of 2-deoxystreptamine 1 with thymine. To this end, compound 1 was converted into 
methylthiomethyl (MTM) ether 2 in high yield by treatment with Ac2O and DMSO in AcOH via 
Pummerer rearrangement11. Attempts to couple MTM ether 2 directly with bis(trimethylsilyl)thymine12 
by in situ activation of the thiomethyl ether with NBS13 or iodine14 were not successful. Therefore, we 
treated compound 2 first with sulfuryl chloride in dichloromethane in order to convert 2 into 
chloromethyl ether 3. However, it was found that under these conditions the olefin moiety of compound
2 reacted with the methanesulfenyl iodide15 i.e. a byproduct of the reaction of O,S-acetals with sulfuryl 
chloride. Gratifyingly, by repeating the same reaction in the presence of excess cyclohexene, to trap the 
methanesulfenyl iodide, compound 3 was obtained in high yield.
i----- 2 R = CH3S
b 3 R = Cl
Reagents and conditions: a) DMSO, Ac2O, AcOH, 16 h (91%). b) SO2Cl2, CH2Cl2, cyclohexene, 1 h (90%). c) 5-methyl- 
2,4-bis(trimethylsilyloxy)pyrimidine, TBAI, CH2Cl2, 16 h, reflux, (60%). d) AcOH, H2O, PdCl2, NaOAc, 16 h (87%).
Scheme 1
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In order to introduce thymine by SN2-reaction, chloromethyl ether 3 was refluxed overnight with 
bis(trimethylsilyl)thymine and n-Bu4NI in dichloromethane. We were happy to find that under these 
conditions, the desired thymine-substituted 2-deoxystreptamine 4 was formed in acceptable yield (60%). 
Next, several methods for the deprotection of 5-O-allyl ether of compound 4 were explored. The 
reaction of 4 with (Ph3P)3RhCl16 and DABCO in aq EtOH gave no conversion and only starting material 
was recovered. Efforts to deprotect the 5-O-allyl ether 4 using PdCl2/CuCl/O2 in DMF-H2O resulted in 
Wacker oxidation, with formation of a ketone, exclusively17. Finally we succeeded in cleaving the allyl 
ether using PdCl2 and NaOAc in a mixture of AcOH and H2O. Under these conditions, compound 5 was 
obtained in 87% yield18.
Table 1. Conditions explored for glycosylation of 5 with ribose-derived donors.
+ x conditions
q  N3 v / \ > N3
R N ^ N ^ O ' ' '  y ^ O A c
.*OAc
AcO
6a R = H
AcO
6b R =
AcO OAc
E ntry X Conditions 6a 6b
yield % yield %
AcO
OAc
AcO" "OAc
AcO
OAc
TMSOTf, CH2Cl2, 4 A MS
SnCl4, CH2Cl2, 4 A MS 30
AcO
BF3OEt2, CH2Cl2, 0 ° C ^  r.t., 4 A MS 13 25
1 0 0
02
3
Having compound 5 in hand, various conditions for glycosylation were investigated with ribose-derived 
sugar donors as model system (Table 1). First, glycosylation of 5 with 1,2,3,5-tetra-O-acetyl-a/ß-D- 
ribofuranoside with TMSOTf activation in dichloromethane was attempted (Entry 1), but did not lead to
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the desired coupling product. Replacing TMSOTf with SnCl4 (entry 2) afforded the desired 
glycosylation at O-5 leading to the pseudo-trisaccharide 6a, but in a disappointing 30% yield. In order to 
improve the yield we decided to utilize trichloroacetimidate methodology19 for glycosylation. Therefore, 
the trichloroacetimidate donor was synthesized from 1,2,3,5-tetra-O-acetyl-D-ribofuranose20 by selective 
deprotection of the 1-O-acetyl group under the influence of (Bu3Sn)2O in toluene, followed by 
subsequent reaction of the resulting 2,3,5-tri-O-acetyl-D-ribofuranose with Cl3CCN and DBU in CH2Cl2 
at 0 °C. Coupling13 of the imidate donor with compound 5 under the influence of BF3 OEt2 in CH2Cl2 
gave the expected 6a, but again in low yield and moreover as a mixture with doubly glycosylated 
compound 6b (entry 3).
Scheme 2
Reagents and conditions: a) PdCl2, NaOAc, AcOH, H2O, 16 h.
We hypothesized that glycosylation of a 2-deoxystreptamine derivative prior to its coupling with 
thymine could evade the problem of ^-glycosylation of thymine. Therefore, it was attempted to first 
remove the allyl protective group of MTM ether 2, by reaction with PdCl2 and NaOAc in a mixture of 
AcOH and H2O (Scheme 2). Indeed, the allyl ether was effectively removed, but unfortunately 
deprotection was accompanied by an acetyl shift, resulting in an inseparable mixture of the desired 
compound 7a as well as the regioisomeric 5-O-acetyled 7b. Although other options for clean 
deprotection of the allyl group were considered, at this stage no more of the requisite building blocks 2 
or its precursor 1 were available and too little of the desired conjugate 6a had been obtained. Also, we 
had to shift our strategy because our supply of Verenium esterase, essential to make more of the starting 
material 2, had run out and no more of the enzyme was available. Given the fact that the required 2- 
deoxystreptamine derivative could no longer be obtained by the chemoenzymatic route (Chapter 3), we 
had to resort to another approach reported by our group for the synthesis of orthogonally protected 2- 
deoxystreptamine21, with some adaptations (Scheme 3). Thus, 1,3,2',6'-tetraazido-tri-O-acetyl-D- 
neamine 9 was prepared by Lewis acid-promoted cleavage of peracetylated tetraazidoneomycin 822
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according to the procedure reported by Swayze23. In short, compound 8 was treated with 3 equiv. of 
BF3OEt2 and 1.1
Scheme 3
Reagents and conditions: a) TolSH (1.1 equiv), BF3 OEt2 (3.0 equiv), CH2Cl2, rt, 15 h. b) HMDS, TMSCl, CH3CN, 3 h. c) 1 
M HCl, THF, rt, 30 min. (9: 82%, 10: 74 %).
equiv. of p-CH3PhSH (TolSH) in CH2Cl2 to give compound 9 and per-O-acetylneobiosamine 10 
(Scheme 3). As will be shown later, the disaccharide 10 has the proper functionality at the ribose 
anomeric center for activation with thiophilic promoters and to allow glycosylation of 2- 
deoxystreptamine directly (Chapter 5) or after protective group interconversion (this Chapter). At this 
stage, attention was first focused on compound 9. Unfortunately, the RF difference between compound 9 
and 10 was too small to allow chromatographic separation, therefore the crude mixture was treated with 
hexamethyldisilazane and catalytic TMSCl in CH3CN to convert the free 5-OH of 9 to the more 
lipophilic TMS ether. After separation from compound 10, acid hydrolysis of the TMS ether afforded 
the desired compound 9 in good yield.
Our earlier report on the synthesis of orthogonally protected 2-deoxystreptamine relied on the 
introduction of a MOM protective group at O-5.17 However, it was envisioned that a late-stage 
deprotection of a MOM group would be incompatible with an O,S-acetal. Therefore, allyl protection of 9 
was attempted, but turned out to be cumbersome, because the requisite basic conditions induced 
migration of the acetyl group from O-6 to O-5 (not depicted). Based on these observations we opted for 
an allyloxymethyl group at the 5-hydroxyl: it was reasoned that an allyloxymethyl group could be
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incorporated under mildly acidic conditions, whereas cleavage should take place under the same Pd- 
catalyzed conditions as applied earlier (Scheme 1) for deallylation.
Scheme 4
9 +
Reagents and conditions: a) NaH, reflux, 16 h (84 %). b) CH2Cl2, P2O5, 16 h, rt (76%). c) KO‘Bu, MeOH, rt, 2 h (70%). d) i 
NaIO4, MeOH, rt, 16 h. ii w-BuNH2, MeOH, rt, 16 h (50% over two steps).
So, bis(allyloxy)methane 1124 was prepared by refluxing allyl alcohol with CH2Br2 and NaH for 16 h. 
As expected, reaction of 1,3-diazido-tri-0-acetyl-neamine 9 with 11 in the presence of P2O5 gave 1,3- 
diazido-5-0-allyloxymethyl-tri-0-acetyl-neamine 12 in high yield (Scheme 4). Selective deprotection17 
of the acetyl groups at the sugar ring of compound 12 with KOlBu in MeOH gave compound 13. When 
the diol 13 was subjected to oxidative cleavage and subsequent ß-elimination reaction, a mixture of the 
desired monoacetate 14 along with meso diol 14', with unprotected 6-O-acetyl, was obtained. However, 
chromatographic purification afforded the orthogonally protected 1,3-diazido-5-0-allyloxy-methyl-6-0- 
acetyl-2-deoxystreptamine 14 in 50% isolated yield.
Scheme 5
14
• i
'OAc
15 R = CH3S
16 R = Cl
Reagents and conditions: a) DMSO, Ac2O, AcOH, 16 h (83%). b) SO2Cl2, CH2Cl2, cyclohexene, 1 h. c) 5-methyl-2,4 
bis(trimethylsilyloxy)pyrimidine, TBAI, CH2Cl2, o.n., reflux (0%).
Following the earlier protocol, compound 14 was converted to MTM ether 15 through Pummerer
rearrangement11 (Scheme 5). Unfortunately, reaction of MTM ether 15 with SO2Cl2 in the presence of
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cyclohexene in CH2Cl2 gave a mixture of two compounds, NMR analysis of which suggested one 
compound had undergone a shift of the allyloxymethyl group. However, it was found impossible to 
unambiguously determine the structure of the two compounds obtained, therefore both were separated 
and refluxed separately with bis(trimethylsilyl)thymine and n-Bu4NI in dichloromethane to make the 
corresponding thymine conjugates. Much to our dissatisfaction, only minor amounts of product 17 were 
formed, together with a significant amount of starting alcohol 14, and 17 could not be obtained in pure 
form.
At this point we realized that instead of temporarily protecting the 5-OH group of triacetylneamine 9 
(Scheme 3), we could also attempt conversion of 8 into a neomycin derivative with a selectively 
deprotected diaminoglycoside ring I. However, except for the stereochemistry at C-5, rings I and IV are 
identical, which would make a selective protection or deprotection highly challenging. Instead, we 
argued that a differentially protected form of neomycin could also be obtained by glycosylation of the 5- 
hydroxyl of 9 with a derivative of neobiosamine 10 (Scheme 3), after a protective group interconversion 
before glycosylation. For example, conversion of acetyl-protected 10 into a benzyl-protected derivative 
would allow selective deacetylation of ring I after glycosylation and, subsequently, oxidative cleavage 
and elimination of the resulting diol of ring I.
Scheme 6
I-----  18 R = OH i----- 20 R = Ac 22
b l— * -1 9 R  = Bn d l— *■ 21 R = H
Reagents and conditions: a) KO‘Bu, MeOH, rt, 2 h (91%). b) NaH, BnBr, DMF, 0 °C,. rt, 3 h (81%). c) 9, NIS, AgOTf, 
CH2Cl2, MS 4Â, -4 0  °C ^  -1 0  °C, 1 h (51%). d) KO‘Bu, MeOH, rt, 2 h (60%). e) i- NaIO4, MeOH, rt, 16 h. ii- n-BuNH2, 
MeOH, rt, 16 h (70% over two steps).
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Accordingly (Scheme 6), per-O-acetylneobiosamine 10 was treated with KOlBu in MeOH to remove the 
acetyl groups, followed by conversion of the unprotected compound 18 into benzyl derivative 19, by 
treatment with NaH and BnBr. Next, glycosylation of 9 with thioglycoside donor 19 was attempted. 
After several attempts, it was found that NIS-promoted coupling of neamine acceptor 9 with 
thioglycoside donor 19 in dichloromethane gave the desired compound 20 in reasonable yield and with a 
favorable a/ß ratio of approximately 1:6.5. Since it was found impossible to separate the anomers at this 
stage, we continued with the mixture of anomers with the objective to separate them at a later stage of 
the synthesis. The next target was to remove ring I of the resulting neomycin derivative 20 so thymine 
could be introduced at 4-OH. As anticipated, reaction of compound 20 with KOlBu in MeOH resulted in 
the selective removal of the acetyl groups, affording monoacetate 21 in high yield. Oxidative cleavage 
of the resulting diol 21 with NaIO4 in MeOH and subsequent elimination of the resulting dialdehyde 
proceeded uneventfully to give pseudotrisaccharide 22 with the 4-OH free.
Finally (Scheme 7), compound 22 was treated with DMSO, Ac2O and AcOH to give the MTM ether 23. 
Reaction of compound 23 with SO2Cl2 in CH2Cl2 gave chlorinated compound 24 which was refluxed 
overnight with bis(trimethylsilyl)thymine and æ-Bu4NI in dichloroethane to afford the desired thymine- 
substituted derivative 25.
Scheme 7
Reagents and conditions: a) DMSO, Ac2O, AcOH, 16 h (60%). b) SO2Cl2, CH2Cl2, 1 h (70%). c) 5-methyl-2,4- 
bis(trimethylsilyloxy)pyrimidine, _n-Bu4NI, C2H4Cl2, 40 h, reflux (80%). d) i LiOH, MeOH, 1,4-dioxane, H2O, 48 h (79%), ii 
PMe3, THF, 0.1 M NaOH, 4 h (84%), iii Pd(OH)2, H2, AcOH, H2O, 4 h (94%), iv TFA, MeOH.
We then proceeded to remove all protecting groups. First, saponification of the acetyl ester of compound 
25 was attempted with KOlBu in MeOH, but the acetyl group was found unaffected. After exploring a 
range of conditions, we succeeded in removing the acetyl group by treating compound 25 with LiOH in
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a mixture of H2O and dioxane for 48 h. Next, azides were reduced by treating with PMe3 in a mixture of 
THF and aqueous NaOH. Finally, benzyl ethers were removed by hydrogenolysis in the presence of 
Pearlman’s catalyst25 in aqueous AcOH/MeOH to afford fully deprotected thymine-substituted 
neomycin analogue 26 as the tetraacetic acid salt. For analytical purposes, acetate counter-ions were 
exchanged for trifluoroacetates by lyophilization from 2% TFA in CH2Cl2.
Binding studies
With the desired thymine-aminoglycoside conjugate at hand, it was possible to evaluate the binding 
affinity of conjugate 26 to several viral subtype kissing-loop dimers. All HIV subtypes (except 
subtype C) have an unpaired adenine at position 280 and are therefore in principle binding partners for 
the thymine conjugate. In order to evaluate the binding affinity, isothermal titration calorimetry (ITC) 
experiments were performed at 25 °C with a nanocalorimeter (Microcal ITC200). RNA at 12 |iM 
concentration (in strands) was diluted in 200 mM KCl, 2 mM MgCl2 and 25 mM sodium cacodylate pH
7.0. Conjugate 26 was first dissolved into H2O (concentration ~40 mM) and then in the RNA buffer at a 
0.4 mM final concentration. Each titration consisted of twenty 2 |il injections of the solution containing 
conjugate 26 (at a 0.5 |il/min rate) into the cell containing 200 |il of RNA. Results are summarized in 
Table 2. In panel a of Table 2 are the ITC data obtained on binding of 26 (Kd=8.9 |iM, DH = -15.0 
kcal/mol, DS = -26.3 cal/mol/deg) to the wild-type HIV-1 subtype F DIS RNA kissing-loop complex (2 
x 23 nt RNA hairpin). Subtype F was used instead of subtype A because subtype F is the best 
characterized DIS sequence with X-ray structures in complex with all aminoglycosides. The fact that 
ITC-data are not the result of aspecific binding -and that adenine plays an essential role in recognition 
of 26- is corroborated by performing the same binding experiment with a A280U DIS mutant 
(corresponding to HIV-1 subtype C) that is lacking the adenine for base-pairing, as can be seen in 
panel b. Also compound 26 does not bind to a control 22 bp RNA duplex with the same sequence but 
deprived of bulges (panel c), the highly structure 23S rRNA sarcin-ricin loop (panel d) or to the HIV-1 
TAR RNA that is also known to bind neomycin (however with a 10-fold reduced affinity compared to 
the HIV-1 DIS RNA (panel e). Taken together, it is clear that binding to HIV-1 DIS is indeed taking 
place to subtype F and that the adenine at position 280 is essential. Importantly, compound 26 was also 
found to bind to DIS subtype B (Kd = 9.1 |iM, DH = -20.5 kcal/mol, DS = -44.7 cal/mol/deg), a subtype
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Table 2. ITC data of complexation of conjugate 26 (a) with the wild-type HIV-1 subtype F, (b) with a mutant DIS A280U 
(corresponding to HIV-1 subtype C), (c) with a control 22 bp RNA duplex with the same sequence but deprived of bulges, d) 
with 23S rRNA sarcin-ricin loop, (e) with the HIV-1 TAR RNA, (f) with HIV-1 DIS subtype B, (g) with 16S rRNA A-site.
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that does not bind natural aminoglycoside antibiotics (panel f). Subtype B is unable to bind neomycin 
because the complementary sequence is GCGCGC instead of GLGCAC and therefore lacks the
275 275essential O4 of U for aminoglycoside binding. Instead, steric hindrance between the NH2 of C is 
likely to occur.8 Finally, as expected, compound 26 also binds to the 16S rRNA A-site (panel g) that is 
similar to the HIV-1 subtype F DIS.
From these data, it can be concluded that a nucleobase-aminoglycoside conjugate indeed binds to HIV 
DIS structures, although with reduced affinity as determined for neomycin (Kd = 15 nM, DH = -12.5 
kcal/mol, DS = -6.1 cal/mol/deg for subtype F). However, replacing ring I by a base is clearly an 
interesting strategy because it offers the possibility to target subtype C HIV-1, a predominant subtype in 
Asia and Africa, with an unpaired uridine instead of an adenine at position 280. Because of this 
mutation, HIV subtype C is completely unable to bind neomycin.
Finally, in order to obtain structural insight in the mode of binding of 26 to HIV-1 DIS, it was attempted 
to co-crystallize the RNA structure in the presence of 26. RNA in 150 mM KCl, 5 mM MgCl2 and 20 
mM sodium cacodylate pH 7.0 was concentrated to 300-360 |iM. Crystals were obtained by mixing 7 |il 
of the RNA solution with 1.0 |il of a solution containing 5 mM of 26 in 30% (w/v) 2-methylpentane-2, 
4-diol (MPD). Sitting drops were equilibrated over 24 hours at 37 °C against a reservoir containing 40% 
MPD, 300 mM KCl, 50 mM sodium cacodylate pH 7.0, 20 mM MgCl2 and crystals were transferred at 
20 °C for stabilization. This procedure was used because it was successfully used to obtain co-crystals of 
HIV-1 DIS/aminoglycoside complexes. Five crystals were frozen in liquid ethane prior to data 
collection. Data were collected at 100 K on the X06DA beamline at the Swiss Light Source synchrotron 
(Villigen, Switzerland) and processed with the XDS package. Space group and cell parameters were 
similar to previously-reported HIV-1 DIS kissing-complexes crystal structures. The structure was solved 
by the molecular replacement method using the program MOLREP and already-known HIV-1 DIS 
kissing-complexes as models. Structures were refined with the program PHENIX. Unfortunately, none 
of these structures showed any presence of electron density indicating the presence of aminoglycoside 
conjugate in the expected HIV DIS binding pocket. Consequently, other crystallization conditions 
(variation of ligand concentration, incubation temperature or precipitant) need to be screened.
Further experiments include UV-melting experiments to precisely evaluate the stabilization of the HIV-1 
DIS loop-loop interaction following binding of 26.9 In addition, the effect of 26 on the viral replication 
should be tested on cell-based assays.
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4.3 C o n c lu s io n
For the first time, a conjugate of a truncated aminoglycoside to a single nucleobase (thymine) has been 
successfully prepared. Two different strategies were explored, one based on the attachment of thymine 
to 2-deoxystreptamine followed by conversion to the tetramer by glycosylation, the other strategy 
involving selective removal of ring I of neomycin after a cleavage-reconstitution sequence, followed by 
conjugation of the resulting trimer to thymine. The first strategy was found useful to explore a range of 
conditions to introduce the thymine-deoxystreptamine linkage but glycosylation of the resulting 
conjugate did not lead to the desired product in practical amounts. The second strategy was more 
rewarding, and led to the successful isolation of a O-5 conjugated thymine to neomycin lacking ring I. 
The resulting conjugate was evaluated for binding to a range of RNA structures by isothermal 
calorimetry and was found to bind selectively to the HIV DIS complex (subtype F), thereby 
corroborating the hypothesis that complementary nucleobase pairing can substitute the native 
nucleobase-aminoglucose pairing. Replacing ring I by a nucleobase is a promising strategy because of 
the possibility to target HIV-1 subtype C, a frequently occurring subtype in Asia and Africa, with an 
unpaired uridine instead of an adenine at position 280. Finally, it is not excluded that the thymine- 
neomycin conjugate may more readily penetrate into cells because it is more hydrophobic than natural 
neomycin. Further experiments along these lines are currently underway.
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4 .5  E x p e r im e n ta l  S ec tio n
General methods and materials
Solvents were distilled from appropriate drying agents prior to use and stored under nitrogen. Chemicals 
were purchased from Sigma-Aldrich and used as received, unless stated otherwise. Reactions were 
carried out under inert atmosphere of dry nitrogen or argon. Standard syringe techniques were applied 
for the transfer of dry solvents and air- or moisture-sensitive reagents. Reactions were followed and RF 
values are obtained using thin layer chromatography (TLC) on silica gel-coated plates (Merck 60 F254) 
with the indicated solvent mixture. NMR spectra were recorded on a Bruker DMX 300 (300 MHz): and 
a Varian 400 (400 MHz): spectrometer in CDCl3 solutions (unless otherwise reported). Chemical shifts 
are given in ppm with respect to tetramethylsilane (TMS) as internal standard. Coupling constants are 
reported as J-values in Hz. Peak assignment in 13C spectra are based on 2D-GHSQC and GHMBC 
spectra. Column or flash chromatography was carried out using ACROS silica gel (0.035-0.070 mm, ca 
6 nm pore diameter). High resolution mass spectra were recorded on a JEOL AccuTOF (ESI), or a 
MAT900 (EI, CI, and ESI).
(1R, 3S, 4R, 5S, 6R)-1,3-diazido-1,3-dideamino-4- O-methylthiomethyl-5- ö-allyl-6- O-acetyl-2- 
deoxystreptamine (2)
To a solution of 1 (105 mg, 0.354 mmol) in DMSO (2 mL) was added Ac2O (2 
mL) and AcOH (2 mL). The reaction mixture was stirred at room temperature for 
16 h. The reaction was then quenched with saturated solution of NaHCO3 (50 mL) 
and extracted with EtOAc (3 x 50 mL). The organic layer was washed with H2O 
(50 mL), brine (50 mL), dried (Na2SO4) and concentrated in vacuo. Purification by column 
chromatography (EtOAc/heptane, 1/4) afforded 2 (115 mg, 91%) as a colorless oil. RF 0.30 
(EtOAc/heptane, 1/3). 1H NMR (CDCl3, 300 MHz): 5 5.79 (m, 1H), 5.15 (m, 2H), 4.87 (t, J= 9.9 Hz, 
1H), 4.85 (s, 2H), 4.18 (ddt, J= 1.3, 5.6, 12.4 Hz, 1H), 4.04 (ddt, J= 1.3, 5.6, 12.4 Hz, 1H), 3.50-3.25 (m, 
4H), 2.19 (m, 1H), 2.18 (s, 3H), 2.03 (s, 3H), 1.40 (dd, J= 12.4 Hz, 1H). 13C NMR (CDCl3, 75 
MHz): 5 169.1, 133.5, 116.8, 80.8, 80.2, 74.6, 73.8, 67.6, 59.3, 57.7, 31.6, 20.3, 14.3.
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(1R, 3S, 4R, 5S, 6R)-1,3-diazido-1,3-dideamino-4- O-chloromethyl-5- O-allyl-6- O-acetyl-2- 
deoxystreptamine (3)
3^ N To a solution of 2 (70 mg, 0.196 mmol) in a mixture of CH2Cl2/cyclohexene (2 mL,
10:1 v/v) was added SO2Cl2 (32 mL, 0.393 mmol). The reaction mixture was stirred
C r  o ''' '''OAc
O\  at room temperature for 2 h. The volatiles were removed in vacuo. Purification by
V  column chromatography (EtOAc/heptane, 1/4) afforded 3 (60 mg, 90%) as a 
colorless oil. Rf 0.29 (EtOAc/heptane, 1/3). 1H NMR (CDCl3, 300 MHz): 5 5.82 (m, 1H), 5.70 (d, J= 5.8 
Hz, 1H), 5.64 (d, J= 5.8 Hz, 1H), 5.27 (d, J= 9.4 Hz, 1H), 5.18 (d, J= 11.2 Hz, 1H), 4.95 (t, J= 10.0 Hz, 
1H), 4.19 (dd, J= 5.5, 12.2 Hz, 1H), 4.08 (dd, J= 5.5, 12.2 Hz, 1H), 3.67 (t, J= 9.51, 1H), 3.50-3.25 (m, 
3H), 2.23 (dt, J= 8.7, 13.2 Hz, 1H), 2.13 (s, 3H), 1.44 (dd, J= 12.8 Hz, 1H). 13C NMR (CDCl3, 75 
MHz): 5 169.0, 133.2, 117.2, 81.6, 80.0, 74.5, 74.0, 58.3, 57.7, 31.5, 20.3.
(1R, 3S, 4R, 5S, 6R)-1,3-diazido-1,3-dideamino-4- O- [(1-thyminyl)methyl]-5- O-allyl-6- O-acetyl-2- 
deoxystreptamine (4)
n3^ / \ m 3 To a solution of 3 (50 mg, 0.145 mmol) in CH2Cl2 (5 mL) was added 5-methyl- 
h n ^ n '^ o ' ' 'L - J.''oa 2,4-bis(trimethylsilyloxy)pyrimidine (117 mg, 0.435 mmol) and TBAI (5 mg). 
O O\  The reaction mixture was refluxed overnight. The volatiles were removed in 
^  vacuo. Purification by column chromatography (EtOAc/heptane, 1/2) afforded 
4 (38 mg, 60%) as a white solid. 1H NMR (CDCl3, 400 MHz): 5 8.86 (s, 1H), 7.13 (d, J= 1.2 Hz, 1H), 
5.78 (m, 1H), 5.34 (s, 2H), 5.19 (ddq, J= 10.4, 1.5, 1.3 Hz, 2H), 4.9 (t, J= 9.9 Hz, 1H), 4.14 (ddt, J=
12.6, 5.4, 1.4 Hz, 2H), 3.60 (t, J= 9.5 Hz, 1H), 3.39 (m, 2H), 3.29 (t, J= 9.5 Hz, 1H), 2.23 (dt, J= 13.3, 
4.5 Hz, 1H), 2.12 (s, 3H), 1.92 (d, J= 1.2 Hz, 3H), 1.48 (dd, J= 12.5 Hz, 1H). 13C NMR (CDCl3, 75 
MHz): 5 169.0, 163.0, 150.2, 138.9, 133.3, 116.8, 110.9, 82.9, 80.0, 77.9, 74.6, 73.9, 59.3, 57.7, 31.4,
20.3, 11.7.
( 1R, 3S, 4R, 5S, 6R)-1,3-diazido-1,3-dideamino-4- O- [(1-thyminyl)methyl]-6- O-acetyl-2- 
deoxystreptamine (5)
To a solution of 4 (37 mg, 0.085 mmol) in a mixture of AcOH/ H2O (2 mL,
o  ” " 3
11 10:1 v/v) was added sodium acetate (160 mg) and PdCl2 (75 mg, 0.426 mmol).
HN N O 'OAc
O'
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The reaction mixture was stirred overnight at room temperature. The reaction was quenched with 
saturated solution of NaHCO3 (25 mL) and extracted with EtOAc (3 x 25 mL). The organic layer was 
washed with brine (25 mL), dried (Na2SO4) and concentrated in vacuo. Purification by column 
chromatography (EtOAc/heptane, 1/1 to pure EtOAc) afforded 5 (29 mg, 87%) as a white solid. 1H 
NMR (CDCl3, 400 MHz): 5 7.12 (d, J= 1.2 Hz, 1H), 5.36 (dd, J= 10.08 Hz, 2H), 4.90 (t, J= 9.7 Hz, 1H), 
3.48 (m, 4H), 2.21 (dt, J= 13.4, 4.5 Hz, 1H), 1.93 (d, J= 1.2 Hz, 3H), 1.48 (dd, J= 12.5 Hz, 1H).
1,3,2',6'-tetraazido-1,3,2',6'-tetradeamino-6,3',4'-tri-O-acetyl-D-neam ine (9)
,N3 To a solution of tetraazidohepta-0-acetylneomycin (530 mg, 0.5 mmol) in
’'O Ac CH2Cl2 (20 mL) was added 4-methylbenzenethiol (70 mg, 0.55 mmol) and the 
. . resulting mixture was cooled to 0 °C. To this cooled solution was added
AcO''' " 'N 3
OAc BF3OEt2 (200 mL, 1.5 mmol) and the reaction mixture was stirred at 0 °C for
20 minutes. The reaction was allowed to warm to room temperature and stirred for 16 h. The reaction 
was then quenched with 0.5 mL of Et3N and concentrated in vacuo. The residue was taken up in CH2Cl2 
(100 mL), washed with H2O (50 mL) and brine (50 mL).The organic layer was dried (Na2SO4), filtered 
and concentrated in vacuo. Crude product was treated with HMDS (2 mL) and trimethylsilyl (200 |iL) 
chloride in acetonitrile (10 mL) for 16 h. After separation from compound 10 (236 mg, 74%) by column 
chromatography (EtOAc/heptane, 1/15) the resulting TMS-ether was treated with 1 N HCl in THF for 
30 minutes to afford pure 9 (226 mg, 82%) as a white solid. RF 0.41 (EtOAc/heptane, 1/1). 1H NMR 
(CDCl3, 400 MHz): 8 5.48 (dd, J= 10.6, 9.2 Hz, 1H), 5.34 (d, J= 3.7 Hz, 1H), 5.04 (dd, J= 10.2, 9.3 Hz, 
1H), 4.92 (t, J= 9.9 Hz, 1H), 4.33 (ddd, J= 10.2, 5.0, 2.8 Hz, 1H), 3.68 (dd, J= 10.5, 3.6 Hz, 1H), 3.58 (d, 
J= 3.4 Hz, 1H), 3.54 (ddd, J= 12.5, 10.0, 4.6 Hz, 1H), 3.35-3.46 (m, 3H), 2.40 (dt, J= 13.1, 4.3 Hz, 1H), 
2.18 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 1.61 (q, J= 13.8 Hz, 1H). 13C NMR (CDCl3, 75 MHz): 8 169.9,
169.7, 169.2, 98.3, 83.4, 74.4, 73.9, 70.8, 69.0, 68.8, 61.3, 57.8, 57.4, 50.4, 31.5, 20.3, 20.2, 20.1. 
HRMS (ESI) m/z calcd for C ^ H ^ N ^  (M+Na)+: 575.1687, found: 575.1671.
1-p-tolylthio-2,5-di- O-acetyl-3- O-(2',6'-diazido-2',6'-dideamino-3',4'-di-O-acetyl-ß-L- 
idopyranosyl)ribofuranose (10)
TolS Rf 0.40 (EtOAc/heptane, 1/1). 1H NMR (CDCl3, 400 MHz): 8 7.38 (d, J= 8.2 Hz,
2H), 7.11 (d, J= 7.9 Hz, 2H), 5.64 (d, J= 4.6 Hz, 1H), 5.45 (t, J= 4.6 Hz, 1H), 5.04 (t, 
J= 2.8 Hz, 1H), 5.00 (d, J= 1.8 Hz, 1H), 4.70 (m, 1H), 4.46 (m, 2H), 4.44 (d, J= 2.0
OAcN3
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Hz, 1H), 4.23 (m, 1H), 4.11 (ddd, J= 8.4, 3.8, 1.8 Hz, 1H), 3.61 (dd, J= 13.1, 8.4 Hz, 1H), 3.40 (m, 1H), 
3.20 (dd, J= 13.1, 3.8 Hz, 1H), 2.32 (s, 3H), 2.17 (s, 6H), 2.15 (s, 3H), 2.06 (s, 3H). 13C NMR (CDCl3, 
75 MHz): 8 170.1, 169.7, 169.3, 167.9, 137.2, 131.6, 130.1, 129.3, 98.0, 89.0, 77.7, 75.2, 73.3, 72.0,
68.3, 65.3, 62.5, 55.9, 50.1, 20.6, 20.3, 20.27, 20.21, 20.1. HRMS (ESI) m/z calcd for C26H32N6O 11S 
(M+Na)+: 659.171, found: 659.174.
Bis(allyloxy)methane (11)
To a solution of allyl alcohol (2 mL, 30 mmol) in CH2Br2 (20 mL) was added NaH 
(1.32 g, 33 mmol) at 0° C. The reaction mixture was refluxed overnight. The reaction was then 
quenched with H2O (25 mL) and extracted with CH2Cl2 (3 x 25 mL). The organic layer was washed with 
water (3 x 25 mL), brine (50 mL), dried (Na2SO4) and concentrated in vacuo to give 6 as a colorless 
liquid. Rf 0.49 (EtOAc/heptane, 1/5). 1H NMR (CDCl3, 400 MHz): 5 5.96 (m, 1H), 5.31 (q, J= 1.6, 3.3 
Hz, 1H), 5.27 (q, J= 1.6, 3.3 Hz, 1H), 5.20 (m, 1H), 5.17 (m, 1H), 4.72 (m, 2H), 4.08 (m, 2H). (CDCl3, 
75 MHz): 5 133.8, 116.4, 93.2, 67.7.
1,3,2',6'-tetraazido-1,3,2',6'-tetradeamino-5-O-aHyloxymethyl-6,3',4'-tri-O-acetyl-D-neamme (12)
"■ n3 To a solution of 9 (390 mg, 0.706 mmol) in a mixture of 11 (0.5 mL) and CH2Cl2 
OAc (5 mL), was added P2O5 (400 mg, 2.81 mmol). The reaction mixture was stirred at
with EtOAc (2 x50 mL) and the combined organic layers were washed with brine (50 mL), dried 
(Na2SO4) and concentrated in vacuo. Purification by column chromatography (EtOAc/heptane, 1/4) 
afforded 12 (336 mg, 76%) as a colorless oil. RF 0.30 (EtOAc/heptane, 1/2). 1H NMR (CDCl3, 300 
MHz): 5 5.85 (m, 1H), 5.51 (d, J= 3.7 Hz, 1H), 5.46 (dd, J= 9.2, 10.7 Hz, 1H), 5.24 (m, 2H), 5.02 (dd, 
J= 9.2, 10.2 Hz, 1H), 4.94 (d, = 6.8 Hz, 1H), 4.72 (dd, J= 6.8 Hz, 1H), 4.49 (dq, J= 2.8, 4.8, 10.2 Hz, 
1H), 4.10 (m, 1H), 3.91 (ddt, J= 1.4, 5.8, 12.8 Hz, 1H), 3.58 (m, 2H), 3.50-3.25 (m, 4H), 2.37 (dt, J= 4.4,
13.2 Hz, 1H), 2.11 (s, 3H), 2.08 (s, 3H), 2.04 (s, 3H), 1.61 (dd, J= 12.5 Hz, 1H). 13C NMR (CDCl3, 75 
MHz): 5 169.5, 169.1, 133.3, 117.0, 97.4, 97.3, 83.5, 78.2, 74.0, 69.6, 69.5, 68.89, 68.82, 60.3, 58.0,
Site
room temperature for 16 h. The reaction was quenched with saturated solution of 
^  NaHCO3 (50 mL), and the layers were separated. The aqueous layer was extracted
OAc
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57.6, 50.2, 31.0, 20.7, 20.19, 20.16. HRMS (ESI) m/z calcd for C22H30N 12O 10 (M+Na)+: 645.208, found: 
645.210.
1,3,2',6'-tetraazido-1,3,2',6'-tetradeamino-5-O-aHyloxymethyl-6-O-acetyl-D-neamme (13)
To a solution of 12 (400 mg, 0.643 mmol) in MeOH (10 mL) was added KOlBu
solution was neutralized with Amberlite IR 120 plus, filtered, and concentrated in 
vacuo. Purification by column chromatography (EtOAc/heptane, 1/3) afforded 13 
(240 mg, 70%) as a colorless oil. RF 0.26 (EtOAc/heptane, 1/1).
(1R,3S,4R,5S,6R)-1,3-diazido-1,3-dideamino-5-O-aHyloxymethyl-6-O-acetyl-2-deoxystreptamine
(14)
To a solution of 13 (263 mg, 0.488 mmol) in MeOH (10 mL) was added NaIO4 (784 mg,
ho'' y ^^'oao 3.6 mmol) at 0 °C. The reaction mixture was allowed to warm and stirred overnight at 
O \^  room temperature. The formed white precipitate was filtered off, and the filtrate was 
concentrated in vacuo. The residue was dissolved in EtOAc (100 mL), washed with H2O 
(2 x 50 mL) and brine (50 mL), dried (Na2SO4) and concentrated in vacuo. The residue was then 
dissolved in MeOH (10 mL) and butylamine (110 ^L) was added. The reaction mixture was stirred at 
room temperature for 16 h and then concentrated in vacuo. Purification by column chromatography 
(EtOAc/heptane, 1/4) afforded 14 (80 mg, 50%) as a colorless oil. RF 0.49 (EtOAc/heptane, 1/1) 1H 
NMR (CDCl3, 300 MHz): 5 5.87 (m, 1H), 5.26 (ddq, J= 1.2, 1.4, 10.3 Hz, 1H), 4.91 (dd, J= 9.6, 10.0 
Hz, 1H), 4.86 (d, J= 7.0 Hz, 1H), 4.66 (d, J= 7.0 Hz, 1H), 4.19 (m, 1H), 4.06 (ddt, J= 1.3, 5.8, 12.8 Hz, 
1H), 3.54-3.30 (m, 4H), 2.19 (dt, J= 4.4, 13.2 Hz, 1H), 2.11 (s, 3H), 1.43 (dd, J= 12.5 Hz, 1H). 13C NMR 
(CDCl3, 75 MHz): 5 169.3, 132.5, 117.8, 95.8, 83.7, 74.9, 73.5, 69.1, 59.4, 58.0, 31.3, 20.3.
(1R, 3S, 4R, 5S, 6R)-1,3-diazido-1,3-dideamino-4- O-methylthiomethyl-5- O-allyloxymethyl-6- O- 
acetyl-2-deoxystreptamine (15)
N3^ \ > N3 To a solution of 14 (38 mg, 0.116 mmol) in DMSO (1 mL) was added Ac2O (1 mL) 
^ s ^ O'''^ f  OAc and AcOH (1 mL). The reaction mixture was stirred overnight at room temperature.
Ov| The reaction was then quenched with saturated solution of NaHCO3 (25 mL) and
O^ i
L extracted with EtOAc (3 x 25 mL). The organic layer was washed with H2O (50 mL),
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brine (50 mL), dried (Na2SO4) and concentrated in vacuo. Purification by column chromatography 
(EtOAc/heptane, 1/6) afforded 15 (37 mg, 83%) as a colorless oil. RF 0.34 (EtOAc/heptane, 1/2) 1H 
NMR (CDCl3, 300 MHz): 5 5.87 (m, 1H), 5.24 (ddq, J= 1.4, 1.5, 10.4 Hz, 2H), 4.91 (m, 3H), 4.82 (q, J=
6.7 Hz, 2H), 4.11 (ddt, J= 1.4, 5.7, 12.9 Hz, 1H), 4.00 (ddt, J= 1.4, 5.7, 12.9 Hz, 1H), 3.57 (t, J= 9.3 
Hz,1H), 3.52-3.34 (m, 3H), 2.26 (dt, J= 4.5, 11.6 Hz, 1H), 2.25 (s, 3H), 2.14 (s, 3H), 1.48 (dd, J= 12.5 
Hz, 1H). 13C NMR (CDCl3, 75 MHz): 5 169.4, 133.3, 116.9, 95.9, 80.6, 79.6, 74.2, 68.9, 59.4, 58.0,
31.6, 20.6, 14.5.
(1R, 3S, 4R, 5S, 6R)-1,3-diazido-1,3-dideamino-4- ö-chloromethyl-5- ö-allyloxymethyl-6- O-acetyl-2- 
deoxystreptamine (16)
N3 ^ ^ \ > N3 To a solution of 15 (37 mg, 0.096 mmol) in a mixture of C ^C h/cyclohexene (2 mL,
Ci^o'''^j^'"oA c 10:1 v/v) was added SO2Cl2 (16 mL, 0.192 mmol). The reaction mixture was stirred at
O\^  room temperature for 2 h. The volatiles were removed in vacuo. Purification by 
column chromatography (EtOAc/heptane, 1/6) afforded 16 as a colorless oil. RF 0.36 
(EtOAc/heptane, 1/2) 1H NMR (CDCl3, 300 MHz): 5 5.90 (m, 1H), 5.56 (dd, J= 2.2, 5.9 Hz, 2H), 5.29 
(dq, J= 1.6, 17.2 Hz, 1H), 5.20 (dq, J= 1.4. 2.8, 10.3 Hz, 1H), 4.92 (t, J= 9.9 Hz, 1H), 4.88 (q, J= 6.6 Hz, 
2H), 4.20 (ddt, J= 1.4, 5.4, 12.8 Hz, 1H), 4.11 (ddt, J= 1.4, 5.4, 12.8 Hz, 1H), 3.6 (t, J= 9.4 Hz, 1H), 
3.56-3.34 (m, 3H), 2.28 (dt, J= 4.5, 13.4 Hz, 1H), 2.15 (s, 3H), 1.46 (dd, J= 12.5 Hz, 1H).
1-Deoxy-1-p-tolylthio-3-0L(2',6'-diazido-2',6'-dideoxy-a-L-idopyranosyl)-a,ß-D-ribofuranose (18)
TolS To a solution of 10 (255 mg, 0.400 mmol) in MeOH (5 mL) was added KOlBu (45 mg,
0.400 mmol) and the resulting mixture was stirred at room temperature for 2 h. The 
solution was neutralized with Amberlite IR 120 plus, filtered, and concentrated in
N3 o h  mg, 91%) as a colorless oil. RF 0.22 (EtOAc/heptane, 3/1). H NMR (CDCl3, 400 
MHz): 5 7.39 (d, J= 8.1 Hz, 2H), 7.11 (d, J= 7.8 Hz, 2H), 5.59 (d, J= 5.5 Hz, 1H), 5.17 (d, J= 1.5 Hz, 
1H), 4.42 (m, 2H), 4.33 (dd, J= 5.9, 4.3 Hz, 1H), 4.11 (m, 2H), 4.04 (ddd, J= 8.8, 3.8, 1.8 Hz, 1H), 3.86 
(d, 2.5 Hz, 2H), 3.71 (dd, J= 13.1, 8.8 Hz, 1H), 3,43 (s, 1H), 3.35 (dd, J= 13.1, 3.8 Hz, 1H), 2.32 (s, 3H).
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13C NMR (CDCl3, 75 MHz): 5 137.3, 132.0, 130.3, 129.4, 98.6, 94.0, 82.7, 73.9, 71.5, 69.1, 68.8, 61.2,
60.6, 51.0, 20.6, 13.7. HRMS (ESI) m/z calcd for C 18H24N6O7S (M+Na)+: 491.130, found: 491.132.
3 -0 LBenzyl-1-deoxy-1-p-tolylthio-3-0L(3 ',4 '-d i-0Lbenzyl-2',6'-diazido-2',6'-dideoxy-a-L- 
idopyranosyl)-a,ß-D-ribofuranose (19)
TolS To a solution of 18 (220 mg, 0.470 mmol) in DMF (5 mL) was added, at 0 °C, NaH
,\OBn
(113 mg, 2.82 mmol) and then benzyl bromide (0.35 mL, 2.82 mmol). Reaction 
"O mixture was allowed to warm to room temperature and stirred for 3 h. The reaction
Bno ^3
0 I was then quenched with NH4Cl (50 mL) and extracted with EtOAc (3 x 50 mL).
f i 0Bn The organic layer was washed with water (2 x 50 mL), brine (50 mL) and then dried 
N3 OBn
(Na2SO4) and concentrated in vacuo. Purification by column chromatography 
(EtOAc/heptane, 1/2) afforded 19 (332 mg, 83%) as white foam. RF 0.53 (EtOAc/heptane, 1/2). 1H NMR 
(CDCl3, 300 MHz): 5 7.27 (m, 24H), 5.83 (d, J= 5.8 Hz, 1H), 5.21 (d, J= 1.8 Hz, 1H), 4.85 (d, J= 11.1 
Hz, 1H), 4.62 (d, J= 12.1 Hz, 1H), 4.51 (m, 5H), 4.35 (d, J= 12.1 Hz, 1H), 4.23 (m, 3H), 3.90 (ddd, J=
8.5, 3.7, 1.7 Hz, 1H), 3.78 (dd, J= 6.0, 3.4 Hz, 1H), 3.71 (m, 3H), 3.13 (s, 1H), 2.88 (dd, J= 12.9, 3.8 Hz, 
1H), 2.32 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 137.8, 137.2, 136.65, 136.64, 132.2, 131.4, 129.0,
128.1, 127.98, 127.93, 127.8, 127.4, 127.2, 127.0, 98.1, 90.6, 81.6, 78.9, 75.0, 74.1, 72.9, 72.3, 72.1,
71.4, 71.1, 68.9, 56.9, 50.6, 20.6. HRMS (ESI) m/z calcd for C46H48N6O7S (M+Na)+: 851.314, found: 
851.320.
1,3,2',6',2'M,6 'M-Hexaazido-1,3,2',6',2'M,6 'M-hexadeamino-6,3',4'-tri-OLacetyl-2M,5M3 'M,4 'M-tetra-OL 
benzyl-D-neomycin (20)
Compound 9 (125 mg, 0.226 mmol) and 19 (206 mg, 0.249 mmol) were 
dissolved in CH2Cl2 (10 mL) in the presence of 4Â MS. The suspension 
was stirred at -40 °C for 10 minutes before A/-iodosuccinamide (152 mg, 
0.678 mmol) was added in one portion. In another flask, AgOTf (58 mg, 
0.226 mmol) was dissolved in anhydrous toluene (1 mL) in the presence of 
small amount of 4Â MS. The suspension of AgOTf was then added 
dropwise to the reaction mixture at -40 °C. The reaction mixture was 
allowed to warm to -10 °C and stirred for 30 minutes. The reaction was then quenched with Et3N and 
stirred for 30 minutes. The reaction mixture was filtered off and the solvents were evaporated in vacuo.
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Purification by column chromatography (EtOAc/heptane, 1/1) afforded 20 (146 mg, 51%) as a colorless 
oil. Rf 0.29 (EtOAc/heptanes, 1/2). 1H NMR (CDCl3, 400 MHz): 5 7.30 (m, 20H), 6.21 (d, J= 3.9 
Hz,1H), 5.22 (dd, J= 10.6, 9.3 Hz, 1H), 5.15 (d, J= 4.3 Hz, 1H), 4.91 (m, 2H), 4.7 (dd, J= 10.0, 9.4 Hz, 
1H), 4.60 (m, 3H), 4.48 (t, J= 5.1 Hz, 3H), 4.43 (m, 1H), 4.34 (m, 2H), 4.26 (m, 2H), 3.92 (dd, J= 5.8, 
4.4 Hz, 1H), 3.83 (m, 1H), 3.76 (m, 2H), 3.64 (dd, J= 10.7, 2.6 Hz, 1H), 3.59 (dd, J= 12.8, 8.2 Hz, 1H), 
3.48 (d, J= 2.2 Hz, 1H), 3.45 (t, J= 2.6 Hz, 1H), 3.35 (m, 2H), 3.23 (dd, J= 13.3, 4.2 Hz, 1H), 3.12 (s, 
1H), 3.00 (dd, J= 12.8, 4.3 Hz, 1H), 2.36 (t, J= 3.5 Hz, 1H), 2.26 (dt, J= 12.6, 3.9 Hz, 1H), 2.03 (s, 3H), 
2.02 (s, 3H), 2.01 (s, 3H), 1.51 (dd, J=12.6 Hz, 1H). 13C NMR (CDCl3, 75 MHz): 5 169.5, 169.4, 169.1,
137.7, 136.6, 136.5, 128.3, 128.1, 128.0, 127.8, 127.7, 127.6, 127.2, 127.1, 102.8, 99.2, 95.7, 84.3, 83.5, 
79.9, 74.6, 73.7, 73.4, 73.1, 72.8, 72.4, 71.9, 71.0, 70.8, 70.0, 68.6, 68.0, 59.9, 59.7, 58.6, 58.3, 57.4,
50.7, 50.4, 30.4, 20.8, 20.2,13.7.
HC
'OAc
1,3,2',6',2'M,6 'M-Hexaazido-1,3,2',6',2'M,6 'M-hexadeam ino-6-0-acetyl-2",5"3M',4 'M-tetra- O-benzyl- 
D-neomycin (21)
To a solution of 20 (64 mg, 0.050 mmol) in MeOH (1 mL) was added 
KOlBu (6 mg, 0.050 mmol) and the resulting mixture was stirred at room 
temperature for 2 h. The solution was neutralized with Amberlite IR 120 
plus, filtered, and concentrated in vacuo. Purification by column 
chromatography (EtOAc/heptane, 1/1) afforded 21 (35 mg, 65%) as a 
colorless oil. RF 0.42 (EtOAc/heptane, 1/1). 1H NMR (CDCl3, 400 MHz): 
5 7.27 (m, 20H), 6.22 (d, J= 3.9 Hz, 1H), 5.18 (d, J= 4.3 Hz, 1H), 4.94 (d, 
J= 1.6 Hz, 1H), 4.63 (t, J= 11.3 Hz, 1H), 4.53 (dd, J= 11.3 Hz, 1H), 4.49 (s, 2H), 4.44 (d, J= 11.9 Hz, 
1H), 4.33 (d, J= 1.6 Hz, 1H), 4.28 (dd, J= 5.8, 1.6 Hz, 1H), 4.25 (d, J= 12.2 Hz, 1H), 4.08 (dt, J= 9.4, 3.2 
Hz, 1H), 3.93 (dd, J= 5.7, 4.4 Hz, 1H), 3.85 (dt, J= 5.4, 2.2 Hz, 1H), 3.77 (m, 2H), 3,61 (m, 2H), 3.49 
(m, 2H), 3.33 (ddd, J= 13.3, 9.8, 4.3 Hz, 2H), 3.23 (td, J= 9.4, 3.7 Hz, 1H), 3.11 (s, 1H), 2.98 (dd, 12.8, 
4.1 Hz, 1H), 2.33 (d, J= 3.7 Hz, 1H), 2.22 (d, J= 3.7 Hz, 1H), 2.01 (m, 4H), 1.51 (dd, J= 12.5 Hz, 1H).
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(lÆ,35,4Æ,J5,fiÆ)-1,3-Diazido-1,3-dideamino-5-0L[2',5 '-dibenzyl-3'-0L(2M,6M-diazido-2'',6M- 
dideamino-3M,4 ''-d i-0 Lbenzyl-a-L-idopyranosyl)-ß-D-ribofuranosyl]-6-0Lacetyl-2- 
deoxystreptamine (22)
To a solution of 21 (156 mg, 0.133 mmol) in MeOH (10 mL) was added NaIO4 (228 
mg, 1.06 mmol). The reaction mixture was stirred at room temperature for 16 h. The 
formed white precipitate was filtered off, and the filtrate was concentrated in vacuo. 
The residue was dissolved in EtOAc (100 mL) washed with H2O (50 mL) and brine 
(50 mL). The organic layer was dried (Na2SO4) and concentrated in vacuo. The 
residue was then dissolved in MeOH (10 mL), and butylamine (100 |iL) was added. 
The reaction mixture was stirred at room temperature for 16 h and then concentrated 
in vacuo. Purification by column chromatography (EtOAc/heptane, 1/2) afforded 22 (90 mg, 70%) as a 
colorless oil. HRMS (ESI) m/z calcd for C47H52N 12O11 (M+Na)+: 983.369, found: 983.377.
(lÆ,35,4Æ,J5,fiÆ)-1,3-Diazido-1,3-dideamino-5-OL[2',5'-dibenzyl-3'-OL(2M,6''-diazido-2M,6M- 
dideamino-3M,4M-di-OLbenzyl-a-L-idopyranosyl)-ß-D-ribofuranosyl]-5-OLmethylthiomethyl-6-OL 
acetyl-2-deoxystreptamine (23)
To a solution of 22 (15 mg, 0.015 mmol) in DMSO (1 mL) was added Ac2O 
(1mL) and AcOH (1 mL). The reaction mixture was stirred overnight at room 
temperature. The reaction was quenched with saturated solution of NaHCO3 and 
extracted with EtOAc. The organic layer was washed with H2O, brine, dried
2SO4)
(EtOAc/heptane, 1/3) afforded 23 (9 mg, 60%) as a colorless oil.
(lÆ,35,4Æ,J5,fiÆ)-1,3-Diazido-1,3-dideamino-5-OL[2',5'-dibenzyl-3'-OL(2M,6''-diazido-2M,6M- 
dideamino-3'',4''-di-OLbenzyl-a-L-idopyranosyl)-ß-D-ribofuranosyl]-5-OLchloromethyl-6-0-acetyl-
2-deoxystreptamine (24)
To a solution of 23 (11 mg, 0.010 mmol) in a mixture of CH2Cl2 was added SO2Cl2 
(2 mL, 0.016 mmol). The reaction mixture was stirred at room temperature for 2 h. 
The volatiles were removed in vacuo. Purification by column chromatography 
(EtOAc/heptane, 1/6) afforded 24 (7 mg, 70%) as a colorless oil. 1H NMR (CDCl3,
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400 MHz): 5 7.27 (m, 20H), 6.08 (d, J= 6.2 Hz, 1H), 5.19 (d, J= 6.2 Hz, 1H), 5.08 (d, J= 1.7 Hz, 1H), 
5.04 (d, J= 4.1 Hz, 1H), 4.89 (t, J= 9.6 Hz, 1H), 4.63 (d, J= 12.1 Hz, 1H), 4.56 (dd, J= 6.2, 5.2 Hz, 2H), 
4.45 (dd, 12.3, 6.8 Hz, 2H), 4.38 (dd, J= 6.0, 1.9 Hz, 1H), 4.31 (q, J= 4.3, 2.2 Hz, 1H), 4.22 (d, J= 12.2 
Hz, 1H), 3.83 (m, 3H), 3.69 (dd, J= 13.0, 8.5 Hz, 2H), 3.55 (m, 3H), 3.33 (m, 2H), 3.13 (s, 1H), 2.92 
(dd, J= 13.0, 3.8 Hz, 1H), 2.17 (dt, J= 8.4, 4.4 Hz, 1H), 2.03 (s, 3H), 1.45 (dd, J= 12.8 Hz, 1H).
(lÆ,35,4Æ,J5,fiÆ)-1,3-Diazido-1,3-dideamino-5-OL[2',5'-dibenzyl-3'-OL(2M,6M-diazido-2'',6M- 
dideamino-3'',4''-di-OLbenzyl-a-L-idopyranosyl)-ß-D-ribofuranosyl]-5-OL[(1-thyminyl)methyl]-6- 
ö-acetyl-2-deoxystreptamine (25)
HN
O
A .
'O "
BnO
N3
'OAc
vOBn
0
o ^ V ' N3
■'‘‘" ^ ^ ^ O B n
OBn
To a solution of 24 (10 mg, 0.009 mmol) in C2H4Cl2 (5 mL) was added 5- 
methyl-2,4-bis(trimethylsilyloxy)pyrimidine (13 mg, 0.045 mmol) and 
TBAI (5 mg). The reaction mixture was refluxed for 36 h. The volatiles 
were removed in vacuo. Purification by column chromatography 
(EtOAc/heptane, 1/2 to pure EtOAc) afforded 25 (5 mg, 80%) as a white 
solid. 1H NMR (CDCl3, 400 MHz): 5 7.91 (s, 1H), 7.25 (m, 20H), 6.62 (d, 
J= 1.2 Hz, 1H), 5.47 (d, J= 11.4 Hz, 1H), 5.09 (m, 2H), 4.97 (t, J= 9.6 Hz, 
1H), 4.73 (d, J= 11.4 Hz, 1H), 4.64 (dd, J= 11.5, 5.6 Hz, 2H), 4.52 (m, 4H), 4.39 (dd, J= 11.4, 8.9 Hz, 
3H), 4.28 (d, J= 12.0 Hz, 1H), 3.93 (dd, J= 5.6, 4.5 Hz, 1H), 3.86 (m, 2H), 3.72 (s, 1H), 3.65 (m, 2H), 
3.56 (dd, J= 8.3 Hz, 2H), 3.47 (t, J= 9.1 Hz, 1H), 3.29 (m, 2H), 3.17 (s, 1H), 3.02 (dd, J= 12.9, 4.3 Hz, 
1H), 2.14 (dt, J= 8.8, 4.6 Hz, 1H), 2.05 (s, 3H), 1.81 (d, J= 1.2 Hz, 3H), 1.40 (dd, J= 13.0, 1H). 13C 
NMR (CDCl3, 75 MHz): 5 169.3, 149.9, 139.4, 137.6, 136.5, 128.1, 128.0, 127.9, 127.8, 127.7, 127.5, 
127.0, 115.4, 109.9, 105.6, 103.4, 98.7, 83.3, 83.2, 82.7, 79.7, 79.0, 73.9, 73.6, 73.4, 72.8, 72.5, 71.7, 
71.2, 70.9, 68.8, 58.9, 58.2, 56.8, 50.7, 31.3, 20.7, 11.6.
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(lÆ,35,4Æ,J5,fiÆ)-4-0L[(1-Thyminyl)methyl]-5- ÖL(3'-ÖLa-L-idopyranosyl)-ß-D-ribofuranosyl-2- 
deoxystreptamine (26)
H N  ©h To a solution of 25 (21 mg, 0.019 mmol) in a mixture of H2O/dioxane (1
i X  mL, 1:1 v/v) was added 0.5 mL H2O solution of LiOH (10 mg). The
HN N O ' ' ' O H
reaction mixture was stirred for two days at room temperature. The 
volatiles were removed in vacuo and crude material was purified by 
© column chromatography using (EtOAc/heptane, 1/3). The intermediate
o ^ . , , NH3
I I was then dissolved in THF (1 mL), followed by the addtion of 0.1M 
i''" 'S ^ ^ ^ O H
Nh, 0 H NaOH (0.5 mL) and PMe3 (90 mL). The reaction mixture was stirred at
© 3
room temperature for 4 h. The volatiles were then removed in vacuo and 
crude material was purified by ion exchange (Isolute SCX-2) column chromatography using 7M NH3 in 
methanol. The resulting intermediate was dissolved in mixture of H2O and AcOH (1 mL, 1:1 v/v) and 
Pd(OH)2 on carbon (20 mg) was added. The reaction was stirred under H2 for 16 h. The mixture was 
filtered through celite and solvents were evaporated in vacuo. Purification by silica gel chromatography 
(25% NH4OH/ CH2Cl2/ n-BuOH/ EtOH, 6/ 2/ 4/ 5) afforded the compound 26 as white solid. 1H NMR 
(CDCl3, 400 MHz): 5 7.47 (d, J= 1.0 Hz, 1H), 5.43 (d, J= 9.7 Hz, 1H), 5.35 (d, J= 9.7 Hz, 1H), 5.31 (d, 
J= 1.1 Hz, 1H), 5.27 (d, J= 4.2 Hz, 1H), 4.36 (m, 2H), 4.23 (m, 1H), 4.15 (m, 1H), 3.81 (dd, J= 9.8, 9.0 
Hz, 1H), 3.64 (m, 5H), 3.46 (m, 2H), 3.34 (dd, J= 13.1, 8.2 Hz, 2H), 3.19 (m, 2H), 2.37 (dt, J= 8.2, 3.5 
Hz, 1H), 1.85 (d, 1.0 Hz, 3H), 1.52 (m, 1H). 13C NMR (CDCl3, 75 MHz): 5 162.4, 161.9, 141.2, 117.6,
113.7, 110.8, 102.5, 95.8, 82.2, 80.5, 79.4, 79.2, 75.9, 70.4, 69.8, 69.7, 67.1, 66.6, 60.1, 48.4, 46.7, 39.8,
35.9, 27.3, 10.6. HRMS (ESI) m/z calcd for C23H40N6O12 (M+H)+: 593.276, found: 593.278.
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RNA sample preparation
All RNAs were purchased from Dharmacon (Lafayette, CO, USA). For purification, RNAs were loaded 
on a Nucleopac PA-100 column (Dionex, Sunnyvale, CA, USA) heated at 70 °C and equilibrated in 4 M 
urea, 20 mM Mes [2-N-(morpholine)ethane sulfonic acid], pH 6.2, and eluted using a NaClO4 gradient. 
HIV-1 DIS kissing-loop complexes were obtained as follows: RNA was diluted to 2 |iM (maximum 
concentration to avoid significant amount of duplex species) in water, heat-denatured at 90 °C for 5 
minutes, and then cooled on ice. Other RNAs were heated at 90 °C for 5 minutes and slowly cooled to 
room temperature.
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Isothermal Titration Calorimetry (ITC)
ITC measurements were performed at 25 °C on a MicroCal ITC200 (MicroCal, Northampton, MA, 
USA). The buffer contained 25 mM potassium acetate, 2 mM magnesium acetate, 200 mM sodium 
cacodylate, pH 7.0. High-salt conditions were chosen to reduce unspecific binding due to electrostatic 
interactions. In a typical experiment, 2 ^l aliquots of conjugate 26 (400 |iM solution) were injected into 
a 12 |iM DIS kissing-complex (200 |il sample cell). The duration of each injection was 4 s and the delay 
between injections was 120 s. ITC titration curves were analyzed using the software Origin (OriginLab, 
Northampton, MA, USA). Data were fitted with a single binding site model. Standard free energies of 
binding and entropic contributions were obtained, respectively, as DG = -  RT ln(Ka) and TDS = DH -  
DG, from the Ka and DH values derived from ITC curve fitting.
X-ray data collection statistics
Crystal 1 Crystal 2 Crystal 3 Crystal 4 Crystal 5
Space group C2221 C2221 C2221 C2221 C2221
a (Â) 27.2 27.2 27.3 27.1 27.2
b (Â) 117.6 117.7 117.9 118.1 117.6
c (Â) 93.5 94.0 94.0 94.3 94.1
Beamline X06DA X06DA X06DA X06DA X06DA
Resolution range (Â) 30 -  2.4 30 -  2.4 30 -  2.2 30 -  2.5 30 -2.3
Average redundancy 38.0 6.7 9.9 7.3 7.8
Completeness 1 91.3 (67.2) 87.3 (55.6) 89.7 (70.2) 90.1 (70.6) 86.7 (58.1)
Rsym 1 6.5 (73.2) 4.2 (39.9) 4.0 (45.2) 3.8 (49.1) 4.5 (65.7)
Average I/a  1 42.3 (7.3) 28.7 (5.5) 31.8 (5.4) 33.2 (4.5) 26.0 (3.8)
1 Values for last resolution shell are shown in parentheses
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CHAPTER 5
Synthesis of C-6'Methylated Neamine and Neomycin to 
Attenuate Aminoglycoside Toxicity
This Chapter details investigations for the regio- and stereoselective methylation of the 4,5-di substituted 
aminoglycosides neamine and neomycin, with the objective to reduce toxicity. Partial hydrolysis of 
paromomycin and a protective group sequence facilitated the regioselective liberation of 6'-OH for 
stereoselective methyl addition. Nucleophilic addition of organometallics to C=N and C=O derivatives 
was explored and the 6'-(R)-amino diastereoisomer was obtained from both neamine and neomycin.
paromomycin
NH2 OH
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5.1 I n t r o d u c t io n
Aminoglycosides are a class of bactericidal compounds, the first member of which, streptomycin, was 
discovered in 1944 by isolation from Streptomyces griseus1. Other members of the aminoglycoside 
family were isolated from actinomycetes of either genus Streptomyces or Micromonospora2, such as 
neomycin (1948), kanamycin (1957) and gentamicin (1967). Several of the naturally occurring 
aminoglycosides, as well as some semi-synthetic analogues, have been clinically applied as antibiotics 
because of their rapid antibacterial activity, chemical stability and low cost of production by 
fermentation. The antibacterial activity of aminoglycosides is derived from their binding to the major 
groove of the prokaryotic ribosomal 16S aminoacyl A-site3. Upon binding, an energetically favorable 
conformational change in the A-site RNA is inflicted, leading to a decrease in translational accuracy 
and, subsequently, bacterial cell death4.
As with all antibiotics, the prolonged use of aminoglycosides in human antibacterial chemotherapy has 
led to the development of resistance in various clinically important bacterial strains. The most common 
mechanism of resistance is the structural modification of the aminoglycoside by modifying enzymes that 
lead to loss of the affinity of the aminoglycoside for its target RNA5. In addition to issues related to 
bacterial resistance, another reason for restricted application of aminoglycosides in the clinic relates to 
toxic side-effects such as nephrotoxicity6 and ototoxicity7. Nephrotoxicity (kidney) is a consequence of 
the accumulation of aminoglycosides in the renal cortical cells, resulting in tubular cell degeneration. 
Ototoxicity (ear) on the other hand occurs as a result of the progressive damage of sensory cells of the 
cochlea and vestibular apparatus, although the exact molecular mechanism of toxicity is still unclear. In 
spite of the fact that a large number of structural analogues of aminoglycosides have been synthesized 
over the years to counteract bacterial resistance or to augment binding affinity8, only few studies have 
addressed the toxicity issue9.
Recently, Sandoval and co-workers reported that the commonly used mixture of gentamicins obtained 
from the fermentation broth contains one non-nephrotoxic congener10. Gentamicin is isolated from 
Micromonospora and is a mixture of various congeners C1, C1a, C2 and C2a that differ only in 
stereochemistry and the methylation pattern at C-6' (Figure 1). By means of HPLC, the individual 
congeners of gentamicin were separated and the bactericidal effect and cytotoxicity of each congener 
was evaluated. First of all, it was established that all four congeners displayed a similar antibacterial
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Figure 1. A) Individual congeners of gentamicin. B) Toxicity (light gray) of different congeners of gentamicin to porcine 
proximal tubule (LLC-PK1) cells and cell density (dark gray) after treatment.
activity. However, cytotoxicity assays with cultured cells revealed that the C-6'(Æ)-methyl 
gentamicin C2 had markedly reduced nephrotoxicity after 24 h of continual exposure. The significant 
difference in toxicity between the different congeners is remarkable, as C2a only differs from C2 in 
stereochemistry at C-6' and Ci only in methylation at N-6'. Although the structure-activity relationship 
of the toxicity of the different congeners remains fully unclear, the finding that a single functionality can 
determine toxicity to such a large extent inspired us to design and synthesize potential non-toxic 
analogues of other aminoglycosides. In particular, we were interested in non-toxic variants of neomycin, 
potentially the best antibiotic of the aminoglycoside family but with severely restricted use due to 
significant toxicity. Herein, we report the synthesis of C-6'(Æ)-methyl neamine and C-6'(Æ)-methyl 
neomycin derivatives as potential non-toxic neomycin analogues.
5 .2 R e s u lts  a n d  d is c u ss io n
Retrosynthetic design of the potentially non-toxic analogues of neamine (1a) and neomycin (1b) is 
depicted in Figure 2. Neamine (neomycin A) is the smallest natural aminoglycoside, a dimeric structure 
consisting of 2-deoxystreptamine (the cyclohexitol ring), O-5 substituted with a 2,6-diaminoglycoside. 
Neamine itself can be isolated from Streptomyces in small amounts and possesses some antibacterial 
activity. More importantly, neamine is similarly toxic as neomycin and paromomycin, two 
aminoglycosides differing only in substitution at C-6' (X = NH2 or X = OH, respectively). Notably, both 
neomycin and paromomycin differ from gentamicin in the substitution pattern at 2-deoxystreptamine, 
with the former two belonging to the 4,5-substituted family and gentamicin to the 4,6-substituted family.
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Currently, there are no methylated C-6' variants of the 4,5-substituted family of aminoglycosides known, 
which served as an important stimulus to prepare such derivatives chemically.
H,N. ,NHp
. XX
HOv' Y  ''MHz ^
HoN
X = OH : paromomycin 
X = NH2 : neomycin
, - k A OH
0^.,N H 2
|''-''VV ^ vOH 
NH2 ÖH
NH2 OH
Figure 2. Retrosynthetic analysis of a C-6'-methylated derivative of neamine (1a) and neomycin (1b).
It was envisaged that both target structures 1a and 1b could be obtained by chemo- and stereoselective 
chemical modification of C-6' of commercially available paromomycin. It must be noted that 
paromomycin contains two primary hydroxyl functions (one at C-6' and one at C-5") and we discovered 
that differentiation of the two hydroxyls was extremely cumbersome or highly inefficient (not depicted). 
Therefore, instead of with a lengthy protective group sequence, our synthesis commences with partial 
hydrolysis of paromomycin (obtained as the chloride salt) by overnight refluxing with concentrated HCl, 
to give a mixture of paromamine 2 and O-1 methylated neobiosamine 2a (Scheme 1)11. Separation by
Scheme 1
H,N ©.NH3
paromomycin
XX
Y  "0H 3CI9
OH
Reagents and conditions: a) H2O/MeOH (1:1, v/v), conc. HCl, reflux, on (92%).
crystallization from methanol afforded the desired paromamine 2 in good yield (92%). It was envisaged 
that late-stage reconnection of paromamine and neobiosamine by application of a known glycosylation 
technology would eventually reconstitute the desired tetrameric paromo/neomycin structure. First 
(Scheme 2), the amino functionalities of paromamine 2 were converted to azides via a copper-catalyzed
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diazotransfer12 reaction followed by selective tritylation of the primary 6'-OH to give compound 4 in 
good yield. Subsequent protection of the remaining free hydroxyls of compound 4 with a benzyl or 
methoxymethyl (MOM) group gave the fully protected paromamine derivatives 5a and 5b, respectively. 
Next, selective detritylation of compound 5a and 5b with TFA and pyrrole in CH2Cl2 afforded the 
respective compounds 6a and 6b in high yields.
Scheme 2
Reagents and conditions: a) TfN3, CuSO4, H2O, MeOH, CH2Cl2, on (84%). b) C6H5N, Ph3CCl, 0 ° C ^  rt, on (70%). c) 
NaH, BnBr or CH3OCH2Cl, DMF, 0 °C ^  rt, 4 h ( 5a: 92%, 5b: 78%). d) pyrrole, TFA, CH2Cl2, rt, 3 h (6a: 83%, 6b: 75%).
Compounds 6a and 6b served as substrates for screening various conditions for diastereoselective 
methyl addition. We initially explored the well-known13 addition of organometallic reagents to the C=N 
bonds of imines for diastereoselective methyl introduction. Thus, benzyl-protected compound 6a was 
oxidized to the corresponding aldehyde 7a and the resulting crude aldehyde was condensed with 
benzylamine in the presence of MgSO4 in toluene to give imine 8. Next, various conditions for methyl 
addition to imine 8 were explored but were found unsuccessful, i.e. with different organometallic 
reagents (CH3MgBr or CH3Li) with or without activation of C=N bond by coordination to a Lewis acid 
(BF3 OEt2).
Scheme 3
Reagents and conditions: a) (COCl)2, DMSO, Et3N, -78 °C, 1 h. b) BnNH2, MgSO4, PhCH3, 0 ° C ^  rt, 16 h (73% for two 
steps).
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Because the nucleophilic additions to imines did not work in our hands, we decided to investigate 
another well-recognized two-step approach for the synthesis of secondary amines involving first 
nucleophilic addition of an organometallic to a carbonyl compound followed by nucleophilic 
substitution of the resulting alcohol. To this end, intermediate aldehyde 7a, obtained from compound 6a 
by Swern oxidation, was treated with various nucleophilic methylating reagents to optimize the 
conditions for stereoselective methyl addition (Scheme 4). For example, the reaction of aldehyde 7a 
with MeMgBr in THF or toluene gave only minor amount of product. Ultimately, reaction of aldehyde 
7a with AlMe3 in the presence of a stoichiometric amount of CuCN at low temperature14 proceeded most 
satisfactorily, giving the methylated compound 9a as an inseparable mixture in 68% yield and with a 
favourable diastereomeric ratio of 6:1 for 6'-(S):6'-(R). Stereochemistry of C-6' was assigned relative to 
C-6 methyl glucosamine derivative14 synthesized from glucosamine via Swern oxidation followed by 
nucelophilic methyl addition using AlMe3 and CuCN at low temperature. When the aldehyde derived 
from alcohol 6b, with methoxymethyl (MOM) protecting groups instead of benzyl groups, was treated 
with AlMe3 and CuCN at low temperature, we were happy to find that the reaction now proceeded 
completely diastereoselectively to give 9b as a single 6'-(S) diastereoisomer (determined by NMR 
analysis) in 41% isolated yield.
Scheme 4
6a or 6b
a, b XX,0 ,0" Y  "
OR
9a R = Bn
b R = MOM
10a R = Bn
b R = MOM
Reagents and conditions: a) (COCl)2, DMSO, Et3N, -78 °C, 1 h. b) CuCN, AlMe3, THF, -55 ° C ^  rt, 16 h. (9a: 68%, ratio 
R:S=1:6), 9b: 41%, ratio R:S=0:1). c) MeSO2Cl, C ^ N ,  rt, 16 h. d) NaN3, DMF, 100 °C, 16 h, (10a: 80%, 10b: 75% for two 
steps).
Next, the introduction of azide by nucleophilic substitution was explored. To this end, it was attempted 
to convert the alcohol function of 9a and 9b into a good leaving group by treatment with p- 
toluenesulfonyl chloride or triflic anhydride, but the reaction did not work under a variety of conditions. 
Fortunately, the secondary alcohols of compound 9a and 9b could be smoothly mesylated by reaction 
with methanesulfonyl chloride in pyridine. Finally, displacement of mesylated alcohols with azide gave,
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with inversion of configuration, compound 10a as a mixture of diastereoisomers (ratio of 6'-(S):6'-(R), 
1:5) and 10b (single diastereomer with R-configuration), respectively.
Scheme 5
Reagents and conditions: a) MeOH, HCl (5M), rt, 16 h, (82%) b) Me3P, THF, NaOH, rt, 4 h (70%).
Since benzyl-protected compound 10a was an inseparable mixture of diastereoisomers, only compound 
10b was employed for further synthesis. The methoxymethyl group of 10b proved beneficial, not only to 
improve the stereoselective outcome of the nucleophilic addition, but also in follow-up chemistry 
(Scheme 5). Unlike the benzyl group, the MOM group could be selectively removed without affecting 
the azides. Thus, compound 10b was subjected to 5 M HCl in methanol to remove the MOM groups, 
affording compound 11 in high yield. Finally, azides were reduced with PMe3 in a mixture of THF and 
aqueous NaOH, to give the desired 6'-(R)-methylated neamine derivative 1a.
Scheme 6
TolS
Reagents and conditions: a) Ac2O, pyridine, 0° C ^  rt, 2 h (70%). b) 16, NIS, AgOTf, CH2Cl2, MS 4Â, -40 ° C ^  -10 °C, 
1 h (60%). c) i KO‘Bu, MeOH, rt, 2 h (87%), ii Me3P, THF, NaOH, rt, 4 h (73%). iii TFA, MeOH.
For the synthesis of the tetrameric 6'-(R)-methyl neomycin, glycosylation of compound 11 with the 
thioglycosyl donor 14 (synthesis shown in Chapter 4) was required. The synthetic strategy for
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glycosylation is summarized in Scheme 6. First, regioselective acetylation15 of compound 11 with Ac2O 
in pyridine afforded triacetylated compound 12 with the expected free 5-hydroxyl group. Subsequently, 
NIS-promoted coupling of compound 12 with thioglycoside donor 14 in dichloromethane gave the 
desired compound 13 in a favorable a/ß-ratio of approximately 1:5, as determined by proton NMR of the 
crude mixture. After separation of anomers, deprotection of acetyl groups with KOlBu in MeOH, 
followed by reduction of azides using PMe3 in a mixture of THF and 0.1 M NaOH, gave the desired 6'- 
(R)-methyl neomycin derivative 1b.
5 .3 C o n c lu s io n s
A concise route for the synthesis of C-6'(R)-methyl neamine and C-6'(R)-methyl neomycin derivatives 
from commercially available paromomycin was developed. Regioselective differentiation of two 
primary alcohols was achieved by the partial hydrolysis of the paromomycin. Nucleophilic addition of 
an organometallic to a carbonyl compound proved to be an efficient method for stereoselective methyl 
addition. Finally, the glycosylation of the modified neamine with disaccharide restored the original 
tetramer. Toxicity evaluation of the modified neamine and neomycin derivatives will be executed in due 
course.
5 .4  A c k n o w le d g e m e n t
Rick Schuringa and Nicole Seegers are gratefully acknowledged for their synthetic contributions to this 
Chapter.
5 .5  E x p e r im e n ta l  S ec tio n
General methods and materials
Solvents were distilled from appropriate drying agents prior to use and stored under nitrogen. Chemicals 
were purchased from Sigma-Aldrich and used as received, unless stated otherwise. Reactions were 
carried out under inert atmosphere of dry nitrogen or argon. Standard syringe techniques were applied 
for the transfer of dry solvents and air- or moisture-sensitive reagents. Reactions were followed and RF
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values are obtained using thin layer chromatography (TLC) on silica gel-coated plates (Merck 60 F254) 
with the indicated solvent mixture. NMR spectra were recorded on a Bruker DMX 300 (300 MHz), and 
a Varian 400 (400 MHz) spectrometer in CDCl3 solutions (unless otherwise reported). Chemical shifts 
are given in ppm with respect to tetramethylsilane (TMS) as internal standard. Coupling constants are 
reported as J-values in Hz. Peak assignment in 13C spectra are based on 2D-GHSQC and GHMBC 
spectra. Column or flash chromatography was carried out using ACROS silica gel (0.035-0.070 mm, ca 
6 nm pore diameter). High resolution mass spectra were recorded on a JEOL AccuTOF (ESI), or a 
MAT900 (EI, CI, and ESI).
Parom am ine (2)
To a solution of paromomycin sulfate (5 g, 8.14 mmol) in a mixture of 
H2O/MeOH (160 mL, 1:1 v/v) was added concentrated HCl (16 mL) and the
oH concentrated, and the crude solid was poured into MeOH (160 mL).
Concentrated HCl (16 mL) was added and the resulting mixture was stirred for another 12 h at 75 °C. 
The mixture was concentrated to 30 mL, and the formed precipitate was filtered and washed with cold 
Et2O, affording 2 (3.21 g, 92%) as an off-white solid. 1H NMR (D2O, 400 MHz): 8 5.52 (t, J= 3.2 Hz, 
1H), 3.89-3.65 (m, 4H), 3.64- 3.50 (m, 2H), 3.45 (td, J= 9.8, 3.1 Hz, 2H), 3.38- 3.28 (m, 2H), 2.37 (m, 
1H), 1.73 (qd, J= 12.5, 3.1 Hz, 1H). 13C NMR (D2O, 75 MHz): 8 96.5, 79.8, 74.2, 73.1, 71.8, 68.9, 59.8, 
53.5, 49.1, 48.3, 27.8.
O
1,3,2'-triazido-1,3,2'-trideam ino-parom am ine (3)
N^ ^ V Nj To a solution of NaN3 (8.8 g, 136 mmol) in a mixture of H2O/CH2Cl2 (45 mL, 
o h  I I
O O, . - ' ' ' - OH 1: 1 v/v) at 0 °C, was added Tf2O (11.2 mL, 68 mmol). The reaction mixture was
. . OH stirred at room temperature for 2 h. After quenching with aqueous NaHCO3, the
h o " '  ' ' n 3
o h  layers were separated and the aqueous layer was extracted with CH2Cl2 (33
mL). The organic layers were combined to afford 55 mL of TfN3 solution. Then, to a solution of 
paromoamine (3.21 g, 7.55 mmol) and CuSO4 (36 mg) in H2O (55 mL) was added the TfN3 solution, 
MeOH (185 mL) and Et3N (10 mL). The reaction mixture was stirred at room temperature for 16 h. 
Then solid NaHCO3 (7 g) was added carefully and the organic solvents were evaporated. The aqueous 
residue was extracted with EtOAc (3 x 100 mL), and the organic layers were combined, dried (Na2SO4),
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and concentrated in vacuo to give a yellow oil. Purification by column chromatography (MeOH/ CH2Cl2 
1/9) afforded 3 (2.55 g, 84%) as a colorless oil. Rf 0.32 (EtOAc/ MeOH, 1/9). 1H NMR (MeOD, 400 
MHz): 8 5.62 (d, J= 3.7 Hz, 1H),3.92 (m, 1H), 3.87 (dd, J= 10.5, 8.8 Hz, 1H), 3.74 (qd, J= 11.8, 3.4 Hz, 
2H), 3.42 (m, 4H), 3.19 (m, 1H), 3.06 (dd, J= 10.5, 3.7 Hz, 1H), 2.18 (dt, J= 12.6, 4.2 Hz, 1H), 1.36 (q, 
J= 12.2 Hz, 1H). 13C NMR (MeOD, 75 MHz): 8 97.4, 78.6, 76.08, 76.02, 72.1, 70.5, 69.8, 62.9, 60.3, 
59.9, 59.1, 31.3.
1,3,2'-triazido-1,3,2'-trideam ino-6'-0Ltritylparom am m e (4)
To a solution of 3 (1.45 g, 3.6 mmol) in pyridine (10 mL) was added
amorphous white solid. RF 0.32 (EtOAc/heptane, 1/1). 1H NMR (MeOD, 400 MHz): 8 7.48 (m, 6H), 
7.21 (m, 9H), 5.77 (d, J= 3.7 Hz, 1H), 4.24 (ddd, J= 10.0, 6.3, 1.8 Hz, 1H), 3.89 (dd, J= 10.4, 8.7 Hz, 
1H), 3.64 (dd, J= 9.8, 9.2 Hz, 1H), 3.46 (m, 4H), 3.34 (dd, J= 10.0, 8.8 Hz, 1H), 3.26 (m, 2H), 3.16 (dd, 
J= 9.8, 6.4 Hz, 1H), 3.11 (dd, J= 10.4, 3.8 Hz, 1H), 2.22 (dt, J= 12.9, 4.4 Hz, 1H), 1.37 (q, J= 12.4 Hz, 
1H) 13C NMR (MeOD, 75 MHz): 8 143.7, 128.1, 126.8, 126.1, 97.1, 85.8, 77.9, 76.28, 76.21, 71.2, 
70.8, 70.7, 63.0, 62.9, 60.0, 59.3, 31.8.
1,3,2'LtriazidoLl,3,2'LtrideaminoL6'LOLtritylL3',4',5,6Ltetra-OLbenzylparomamine (5a)
To a solution of 4 (1.62 g, 2.52 mmol) in DMF (20 mL) was added, at 0 °C,
(9/1). The organic layer was washed with water, brine and then dried (Na2SO4) and concentrated in 
vacuo. Purification by column chromatography (EtOAc/heptane, 1/6) afforded 5a (2.32 g, 92%) as a 
yellow oil. RF 0.35 (EtOAc/heptane, 1/3).
'OH tritylchloride (1.2 g, 4.3 mmol). The reaction mixture was stirred at room 
temperature for 16 h. The volatiles were removed in vacuo. Purification by 
column chromatography (EtOAc/heptane, 1/1) afforded 4 (1.65 g, 70%) as anOH
'OBn NaH (604 mg, 15 mmol) and then benzyl bromide (1.8 mL, 15 mmol). The 
reaction mixture was allowed to warm to room temperature and stirred for 4 h. 
The reaction was then quenched with NH4Cl and extracted with EtOAc/i-PrOHOBn
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1,3,2'-triazido-1,3,2'-trideam ino-6'-0Ltrity l-3 ',4 ',5 ,6-tetra-0L(methoxymethyl)paromamine (5b)
To a solution of 4 (1.6 g, 2.48 mmol) in DMF (20 mL) was added, at 0 °C, 
NaH (600 mg, 15 mmol) and then methoxymethyl (MOM) chloride (1.13 
mL, 15 mmol). The reaction mixture was allowed to warm to room 
temperature and stirred for 4 h. The reaction was then quenched with 
NH4Cl and extracted with EtOAc/i-PrOH (9/1). The organic layer was washed with water, brine and 
then dried (Na2SO4) and concentrated in vacuo. Purification by column chromatography 
(EtOAc/heptane, 1/6) afforded 5b (1.6 g, 78%) as a yellow oil. RF 0.63 (EtOAc/heptane, 1/1). 1H NMR 
(CDCl3, 300 MHz): 8 7.51- 7.20 (m, 15H), 5.79 (d, J= 3.7 Hz, 1H), 4.92 (m, 4H), 4.79 (m, 2H), 4.48 (d, 
J= 2.1 Hz,1H), 4.26 (m, 1H), 4.00 (dd, J= 10.4, 8.8 Hz, 1H), 3.75 (dd, J= 11.1, 7.7 Hz, 1H), 3.60- 3.37 
(m, 15H), 3.23 (dd, J= 10.4, 3.6 Hz, 1H), 3.11 (dd, J= 10.1, 5.6 Hz, 1H), 3.00 (m, 2H), 2.32 (dt, J= 12.8, 
4.2 Hz, 1H), 1.48 (q, J= 12.3 Hz, 1H). 13C NMR (CDCl3, 75 MHz): 8 143.4, 128.3, 127.3, 126.5, 98.9, 
98.0, 97.7, 96.6, 94.1, 93.4, 92.8, 92.7, 92.5, 86.0, 81.9, 80.3, 70.6, 62.4, 62.3, 59.4, 59.2, 56.6, 55.8,
55.7, 34.9, 32.0, 25.9, 25.8, 22.4, 22.2, 13.6.
1,3,2'-triazido-1,3,2'-trideamino-3',4',5,6-tetra-OLbenzylparomamine (6a)
To a solution of 5a (2.45 g, 2.44 mmol) in CH2Cl2 (25 mL) were added pyrrole
was stirred at room temperature for 3 h. The reaction was then quenched with 
saturated NaHCO3 and extracted with CH2Cl2. The organic layer was washed 
with brine, dried (Na2SO4) and concentrated in vacuo. Purification by column chromatography 
(EtOAc/heptane, 1/3) afforded 6a (1.54 g, 83%) as a yellow oil. RF 0.34 (EtOAc/heptane 1/2). HRMS 
(ESI) m/z calcd for C40H43N9Oy (M+Na)+: 784.315, found: 784.318.
1,3,2'-triazido-1,3,2'-trideamino-3',4',5,6-tetra-OL(methoxymethyl)paromamine (6b)
To a solution of 5b (1.55 g, 1.9 mmol) in CH2Cl2 (25 mL) were added 
pyrrole (0.8 mL, 11.3 mmol) and TFA (0.3 mL, 3.8 mmol). The reaction 
mixture was stirred at room temperature for 3 h. The reaction was then 
quenched with saturated NaHCO3 and extracted with CH2Cl2. The organic 
layer was washed with brine, dried (Na2SO4) and concentrated in vacuo. Purification by column 
chromatography (EtOAc/heptane, 1/3) afforded 6b (821 mg, 75%) as a yellow oil. 1H NMR (CDCl3,
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400 MHz): 8 5.66 (d, J= 3.8 Hz, 1H), 4.92 (d, J= 6.6 Hz, 2H), 4.89 (m, 3H), 4.80 (d, J= 1.8 Hz, 1H). 
4.78 (d, J= 1.8 Hz, 1H), 4.03 (m, 2H), 3.90 (ddd, J= 12.5, 5.9, 2.9 Hz, 1H), 3.79 (ddd, J= 12.7, 7.2, 1.6 
Hz, 1H), 3.64 (dd, J= 10.1, 9.0 Hz, 1H), 3.53 (m, 2H), 3.49 (d, J= 2.6 Hz, 7H), 3.45 (d, J= 0.4 Hz, 7H), 
3.36 (m, 4H), 3.17 (dd, J= 10.4, 3.8 Hz, 1H), 2.62 (t, J= 7.0 Hz, 1H), 2.32 (dt, J= 13.2, 4.4 Hz, 1H), 1.49 
(q, J= 12.2 Hz, 1H). 13C NMR (CDCl3, 75 MHz): 8 99.0, 98.4, 98.0, 97.7, 97.2, 82.0, 80.2, 71.1, 62.3,
60.7, 59.2, 59.0, 56.2, 56.0, 55.7, 31.8.
NBn
Il
1,3,2'-triazido-1,3,2'-trideamino-6'-deoxy-6'-Aƒ-benzylimino-3',4',5,6-tetra-OLbenzylparomamine
(8)
n3^ / \ ^ n 3 A solution of oxalyl chloride (90 mL, 1.039 mmol) in CH2Cl2 (2 mL) at -78 °C 
*o >vO' ' ' ^ j ^ ' ,'OBn was treated with a solution of DMSO (147 mL, 2.076 mmol) in CH2Cl2 (0.5 
•.,,N OBn mL). The reagents were stirred for 15 min. A solution of primary alcohol 6a 
(262 mg, 0.344 mmol) in CH2Cl2 (2 mL) was added drop wise to the reagents 
soluion. After being stirred for 30 min, the reaction mixture was treated with Et3N (433 mL, 3.11 mmol) 
at -78 °C and allowed to reach 0 °C over 20 min. The reaction mixture was then diluted with CH2Cl2, 
washed with H2O, brine and dried (Na2SO4) and concentrated in vacuo. The residue was azeotroped 
with toluene (thrice) to afford the desired aldehyde in quantitative crude yield.
To the solution of crude aldehyde (262 mg, 0.344 mmol) in toluene (10 mL) was added, at 0 °C, MgSO4 
(103 mg, 0.86 mmol) and benzylamine (55 mL, 0.516 mmol). The reaction mixture was allowed to warm 
to room temperature and stirred for 16 h. The volatiles were removed in vacuo. Purification by column 
chromatography (EtOAc/heptane, 1/3, 1% Et3N) afforded 8 (214 mg, 73%) as a yellow oil.
1,3,2'-triazido-1,3,2'-trideamino-6'(5)-methyl-3',4',5,6-tetra-OLbenzylparomamine (9a)
n3 A solution of oxalyl chloride (90 mL, 1.039 mmol) in CH2Cl2 (2 mL) at -78 °C 
OBn was treated with a solution of DMSO (147 mL, 2.076 mmol) in CH2Cl2 (0.5 
mL). The reagents were stirred for 15 min. A solution of primary alcohol 6a 
(262 mg, 0.344 mmol) in CH2Cl2 (2 mL) was added drop wise to the reagents 
soluion. After being stirred for 30 min, the reaction mixture was treated with Et3N (433 mL, 3.11 mmol) 
at -78 °C and allowed to reach 0 °C over 20 min. The reaction mixture was then diluted with CH2Cl2, 
washed with H2O, brine and dried (Na2SO4) and concentrated in vacuo. The residue was azeotroped 
with toluene (thrice) to afford the desired aldehyde in quantitative crude yield.
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A suspension of crude aldehyde (262 mg, 0.346 mmol) and CuCN (31 mg, 0.346 mmol) in anhydrous 
THF (5 mL) was stirred at room temperature for 10 min, cooled to -55 °C, then treated with AlMe3 (76 
mL, 2 M solution in toluene) and allowed to reach room temperature overnight. The reaction mixture 
was diluted with CH2Cl2 (10 mL) and quenched with saturated NaHCO3/NH4Cl (1:1 v/v) solution at 0 
°C. The biphasic mixture was stirred for 30 min or until the aqueous phase turned blue. The reaction was 
then diluted with CH2Cl2 and washed with saturated NaHCO3 and brine, dried (Na2SO4) and 
concentrated in vacuo. Purification by column chromatography (EtOAc/heptane, 1/3) afforded 9a (182 
mg, 68%) as a yellow oil. HRMS (ESI) m/z calcd for C41H45N9O7 (M+Na)+: 798.330, found: 798.333.
1,3,2',6'-tetraazido-1,3,2',6'-tetradeamino-6'(R)-methyl-3',4',5,6-tetra-OLbenzylneamine (10a)
N3^ / \ > . n 3 To a solution of 9a (130 mg, 0.163 mmol) in pyridine (3 mL) was added 
J L v 3 >v0'''’^ f  ''oBn methanesulfonyl chloride (56 mL, 0.48 mmol). The reaction mixture was
N3 I* A
BnO" " ^ r  "'N n stirred at room temperature for 16 h. The volatiles were removed in vacuo and 
OBn crude material was purified by column chromatography using
(EtOAc/heptane, 1/3). The intermediate was then dissolved in DMF (5 mL), followed by the addtion of 
NaN3 (31 mg, 0.48 mmol). The reaction mixture was stirred at 100 °C for 16 h. The volatiles were then 
removed in vacuo. Purification by column chromatography (EtOAc/heptane, 1/3) afforded 10a (104 mg, 
80%) as an oil. R f 0.67 (EtOAc/heptane, 1/2).
1,3,2'-triazido-1,3,2'-trideamino-6'(S)-methyl-3',4',5,6-tetra-OL(methoxymethyl)paromamine (9b)
N3^ / ' " w n3 A solution of oxalyl chloride (90 mL, 1.039 mmol) in CH2Cl2 (2 mL) at -78
* 0 ^ 0 " '  'OMOM °C was treated with a solution of DMSO (147 mL, 2.076 mmol) in CH2Cl2
OMOM
M0M0'' 'Y ' ''”'N3 (0 5 mL). The reagents were stirred for 15 min. A solution of primary
omom alcohol 6b (200 mg, 0.346 mmol) in CH2Cl2 (2 mL) was added drop wise to
the reagents soluion. After being stirred for 30 min, the reaction mixture was treated with Et3N (433 mL, 
3.11 mmol) at -78 °C and allowed to reach 0 °C over 20 min. The reaction mixture was then diluted with 
CH2Cl2, washed with H2O, brine and dried (Na2SO4) and concentrated in vacuo. The residue was 
azeotroped with toluene (thrice) to afford the desired aldehyde in quantitative crude yield.
A suspension of crude aldehyde (200 mg, 0.346 mmol) and CuCN (31 mg, 0.346 mmol) in anhydrous 
THF (5 mL) was stirred at room temperature for 10 min, cooled to -55 °C, then treated with AlMe3 (76
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mL, 2 M solution in toluene) and allowed to reach room temperature overnight. The reaction mixture 
was diluted with CH2Cl2 (10 mL) and quenched with saturated NaHCO3/NH4Cl (1:1 v/v) solution at 0 
°C. The biphasic mixture was stirred for 30 min or until the aqueous phase turned blue. The reaction was 
then diluted with CH2Cl2 and washed with saturated NaHCO3 and brine, dried (Na2SO4) and 
concentrated in vacuo. Purification by column chromatography (EtOAc/heptane, 1/3) afforded 9b (84 
mg, 41%) as a yellow oil. Rf 0.22 (EtOAc/heptane, 1/1). 1H NMR (CDCl3, 400 MHz): 8 5.76 (d, J= 3.7 
Hz, 1H), 5.06 (m, 1H), 4.91 (m, 3H), 4.88 (m, 2H), 4.79 (dd, J= 6.5, 2.8 Hz, 2H), 4.72 (m, 2H), 4.14 (m, 
1H), 4.03 (dd, J= 10.2, 8.4 Hz, 1H), 3.86 (ddd, J= 10.1, 2.5, 1.5 Hz, 1H), 3.63 (q, J= 8.3 Hz, 1H), 3.55­
3.35 (m, 18 H), 3.14 (dt, J= 10.4, 4.4 Hz, 1H), 2.73 (dd, 5.1, 4.9 Hz, 1H), 2.32 (dt, J= 7.9, 4.2 Hz, 1H), 
1.43 (q, J= 12. 1 Hz, 1H), 1.30 (d, J= 6.6 Hz, 3H). 13C NMR (CDCl3, 75 MHz): 8 98.9, 98.5, 97.9, 97.8, 
96.6, 96.5, 93.6, 92.7, 92.2, 82.0, 80.1, 72.7, 63.7, 62.2, 59.3, 59.2, 56.7, 56.2, 56.1, 55.7, 55.3, 32.1, 
18.2. HRMS (ESI) m/z calcd for C21H37N9O11 (M+Na)+: 614.249, found: 614.251.
n3
Nó ^ T °
MOMO''' "'N;
OMOM
OMOM 
OMOM
1,3,2',6'-tetraazido-1,3,2',6'-tetradeamino-6'(R)-methyl-3',4',5,6-tetra-OL(methoxymethyl)neamine
(10b)
To a solution of 9b (22 mg, 0.037 mmol) in pyridine (1 mL) was added 
methanesulfonyl chloride (9 mL, 0.11 mmol). The reaction mixture was 
stirred at room temperature for 16 h. The volatiles were removed in vacuo 
and crude material was purified by column chromatography using 
(EtOAc/heptane, 1/2). The intermediate was then dissolved in DMF (1 mL), followed by the addition of 
NaN3 (8 mg, 0.11 mmol). The reaction mixture was stirred at 100 °C for 16 h. The volatiles were then 
removed in vacuo. Purification by column chromatography (EtOAc/heptane, 1/2) afforded 10b (17 mg, 
75%) as an oil. Rf 0.50 (EtOAc/heptane, 1/1). 1H NMR (CDCl3, 400 MHz): 8 5.71 (d, J= 3.7 Hz, 1H), 
4.91 (m, 4H), 4.78 (dd, J= 11.3, 5.2 Hz, 2H), 4.63 (m, 1H), 4.34 (ddd, J= 10.3, 3.2, 1.8 Hz, 1H), 3.99 (m, 
1H), 3.70- 3.35 (m, 15H), 3.13 (m, 1H), 2.34 (dt, J= 7.7, 4.0 Hz, 1H), 1.53 (q, J= 12.5 Hz, 1H), 1.34 (d, 
J= 6.9 Hz, 3H). 13C NMR (CDCl3, 75 MHz): 8 98.9, 98.0, 97.9, 97.7, 96.6, 96.4, 93.4, 93.3, 92.9, 92.7, 
92.4, 82.0, 80.3, 72.3,62.2, 62.1, 59.4, 58.9, 56.6, 56.2, 56.0, 55.8, 55.3, 55.1, 31.8, 11.0.
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1,3,2',6'-tetraazido-1,3,2',6'-tetradeamino-6'(.R)-methylneamine (11)
N3 To a solution of 10b (14 mg, 0.022 mmol) in MeOH (1 mL) was added 5M 
OH HCl (0.5 mL). The reaction mixture was stirred at room temperature for 16 h. 
The volatiles were removed in vacuo. Purification by column chromatography 
(EtOAc/heptane, 2/1) afforded 11 (8 mg, 82%) as an oil. 1H NMR (MeOD, 400 
MHz): 8 5.67 (d, J= 3.8 Hz, 1H), 4.1 (dd, J= 4.5, 2.2 Hz, 1H), 3.83 (dd, J= 10.5, 8.6 Hz, 1H), 3.61 (qd, 
J= 6.9, 1.9 Hz, 1H), 3.43 (m, 4H), 3.21 (dd, J= 8.04 Hz, 1H), 3.04 (dd, J= 10.5, 3.8 Hz, 1H), 2.21 (dt, J=
12.7, 4.3 Hz, 1H), 1.34 (q, J= 12.6 Hz, 1H), 1.29 (d, J= 6.9 Hz, 3H). 13C NMR (MeOD, 75 MHz): 8 
97.4, 78.7, 76.1, 73.3, 70.9, 70.4, 62.6, 59.9, 59.1, 55.8, 31.4, 10.8.
6'(Æ)-methyl-neamine (1a)
To a solution of 11 (16 mg, 0.036 mmol) in THF (1 mL) was added 0.5 
mL of 0.1M NaOH (0.5 mL) and PMe3 (100 mL of 2 M solution in 
toluene). The reaction mixture was stirred at room temperature for 16 h. 
oh The volatiles were then removed in vacuo and crude material was purified
by ion exchange (Isolute SCX-2) column chromatography using 7M NH3 in methanol. The resulting 
compound was dissolved in MeOH (2 mL) and 5drops of TFA were added. The volatiles were then 
removed in vacuo to afford the compound 1a as a sticky solid (20 mg, 70%).1H NMR (MeOD, 400 
MHz): 8 6.04 (d, J= 3.9 Hz, 1H), 3.95 (m, 3H), 3.72 (dd, J= 6.7, 2.4 Hz, 1H), 3.59 (t, J=9.1 Hz, 1H), 
3.41 (m, 2H), 3.31 (dd, J= 9.9, 8.9 Hz, 1H), 3.21 (dd, J= 10.8, 3.9 Hz, 1H), 3.15 (m, 1H), 2.43 (dt, J= 
12.3, 4.1 Hz, 1H), 1.94 (q, J= 12.5 Hz, 1H), 1.28 (d, J= 6.8 Hz, 3H). 13C NMR (MeOD, 75 MHz): 8
94.8, 76.2, 75.3, 72.5, 71.2, 69.9, 68.2, 53.5, 49.5, 48.4, 27.8, 9.9.
1,3,2',6 '-tetraazido-1,3,2',6 '-tetradeam ino-6'(R)-m ethyl-3',4 ',6-tri-0Lacetylneamine (12)
N3 ^ / \ ^ N3 To a solution of 11 (40 mg, 0.90 mmol) in a mixture of CH2Cl2/pyridine (4 
" 1  J , ,  mL, 1:1 v/v) at 0 °C, was added Ac2O (2 mL). The reaction mixture was
O A c
I I  o h  stirred at room temperature for 2h. The reaction mixture was diluted with
A c O ' ' " ^ f  'N 3
OA c CH2Cl2 (25 mL) and quenched with aqueous NaHCO3. The layers were
separated and the organic layer was washed with H2O and brine, dried (Na2SO4) and concentrated in 
vacuo. Purification by column chromatography (EtOAc/heptane, 1/1) afforded 12 (36 mg, 70%) as a 
white solid. 1H NMR (CDCl3, 400 MHz): 8 5.48 (dd, J= 9.9, 9.7 Hz, 1H), 5.41 (d, J= 3.6 Hz, 1H), 4.99
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(t, J= 9.7 Hz, 1H), 4.91 (t, J= 9.9 Hz, 1H), 4.35 (dd, J= 10.3, 2.5 Hz, 1H), 3.67 (td, J= 9.2, 3.2 Hz, 1H), 
3.56 (m, 3H), 3.42 (m, 3H), 2.40 (dt, J= 8.4, 3.9 Hz, 1H), 2.17 (d, J= 0.7 Hz, 3H), 2.09 (d, J= 0.7 Hz, 
3H), 2.05 (d, J= 0.7 Hz, 3H), 1.62 (q, J= 12.6 Hz, 1H), 1.32 (d, J= 6.9 Hz, 3H).
1,3,2',6',2'M,6 'M-hexaazido-1,3,2',6',2'M,6M'-hexadeamino-6'(Æ)-methyl-6,3',4',2M,5M3 'M,4 'M-hepta-
Compound 12 (30 mg, 0.053 mmol) and 14 (51 mg, 0.079 mmol) were 
dissolved in CH2Cl2 (2 mL) in the presence of 4Â MS. The suspension 
was stirred at -40  °C for 10 minutes before A/-iodosuccinamide (36 mg, 
0.159 mmol) was added in one portion. In another flask, AgOTf (14 mg, 
0.053 mmol) was dissolved in anhydrous toluene (0.5 mL) in the 
presence of small amount of 4Â MS. The suspension of AgOTf was then
|v 'Y ’ 'OAc
n 3 O ac  added dropwise to the reaction mixture at -40 °C. The reaction mixture 
was allowed to warm to -10 °C and stirred for 30 minutes. The reaction was then quenched with Et3N 
and stirred for 30 minutes. The reaction mixture was filtered off and the solvents were evaporated in 
vacuo. Purification by column chromatography (EtOAc/heptane, 1/1) afforded 20 (34 mg, 60%) as a 
white solid.
O-acetylneomycin (13)
O \ . „ 'O
N3
OAc
O
N3 | |
A cO ''’ ' ' Y ' '  ''N 3 ^ ^ , ' ' OAc 
OAc O I
AcO
Y  ' 3
N3
6’(R)-methyl-neomycin (1b)
To a solution of 13 (34 mg, 0.043 mmol) in MeOH (2 mL) was added 
KOlBu (10 mg, 0.086 mmol) and the resulting mixture was stirred at 
room temperature for 4 h. The solution was neutralized with 
Amberlite IR 120 plus, filtered, concentrated in vacuo and the crude 
material was purified by column chromatography using 
(EtOAc/heptane, 1/1). The intermediate was then dissolved in THF (2 
MU mL), followed by the addtion of 0.1M NaOH (1 mL) and PMe3 (250
N H 3 O H
mL of 2 M solution in toluene). The reaction mixture was stirred at room temperature for 16 h. The 
volatiles were then removed in vacuo and crude material was purified by ion exchange (Isolute SCX-2) 
column chromatography using 7M NH3 in methanol. The resulting compound was then dissolved in 
MeOH (2 mL) and 10 drops of TFA were added. The volatiles were then removed in vacuo to afford 
the compound 1b as a white solid (41 mg, 73%).1H NMR (CDCl3, 400 MHz): 8 5.84 (d, J= 3.8 Hz, 1H),
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5.35 (d, J= 1.8 Hz, 1H), 5.09 (d, J= 1.6 Hz, 1H), 4.36 (dd, J= 6.6, 4.7 Hz, 1H), 4.26 (dd, J= 4.4, 1.9 Hz, 
1H), 4.18 (dd, J= 10.1, 1.8 Hz, 1H), 4.10 (td, J= 6.3, 2.8 Hz, 1H), 3.98 (ddd, J= 7.9, 4.6, 1.8 Hz, 1H), 
3.89 (t, J= 3.2 Hz, 1H), 3.82 (m, 2H), 3.64 (m, 4H), 3.39 (m, 3H), 3.05 (dd, J= 10.5, 3.8 Hz, 1H), 2.18 
(dt, J= 8.8, 3.9 Hz, 1H), 1.31 (q, J= 12.2 Hz, 1H), 1.29 (d, J= 6.9 Hz, 3H). 13C NMR (MeOD, 75 MHz): 
8 108.1, 97.8, 96.2, 83.3, 81.5, 75.7, 75.5, 75.2, 73.6, 73.2, 73.1, 70.8, 70.4, 69.2, 67.6, 62.6, 62.0, 60.0,
59.8, 59.3, 55.8, 50.5, 31.3, 10.6.
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Aminoglycosides are a family of structurally related, broad-spectrum bactericidal compounds that bind 
to 16S ribosomal RNA at the tRNA acceptor A-site (aminoacyl site). Upon binding, aminoglycosides 
thwart the ability of the ribosome to decode mRNA correctly during protein synthesis. Unfortunately, 
toxic side-effects and growing bacterial resistance have narrowed the significance of aminoglycosides as 
antibiotics. Due to these limitations, extensive research on aminoglycosides has resulted in the 
development of a wide range of synthetic strategies in an attempt to improve the overall characteristics 
of aminoglycosides.
In the introductory chapter of this Thesis (Chapter 1), an overview is provided of the various approaches 
reported in the literature to (a) enhance binding affinity, (b) overcome resistance and (c) reduce the 
toxicity of the aminoglycosides.
In Chapter 2  the synthesis of a small set of aminoglycoside analogues is described, employing a 
combination of approaches including heteroconjugation and dimerization (Figure 1). Both 
diaminosugars of natural neomycin B were cleaved to obtain an aminoglycoside-type scaffold less 
susceptible to bacterial resistance. Next, the residual ribose ring was converted into a morpholine and 
the resulting truncated neomycin (5-0-morpholino-2-deoxystreptamine) was conjugated with non­
aminoglycoside type RNA ligands in order to restore RNA affinity. Dimerization of the resulting 
conjugates with a range of bisazides afforded a small library of potential RNA-binding ligands in a 
straightforward synthetic route involving minimal protecting group transformations. All compounds 
were evaluated for antibacterial activity employing a novel fluorescence-based cell viability essay and 
compared to kanamycin. Several of the compounds, dimers and monomers, showed some but low 
antibacterial activity, with values in the high micromolar range. Interestingly, activity was higher against 
a kanamycin-resistant strain, which may validate the hypothesis that removal of heteroatoms from 
aminoglycosides is a useful strategy improve efficacy against resistant strains.
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neomycin B
Figure 1. Dimeric 5-O-morpholino derivatives of 2-deoxystreptamine as potential novel antibiotics.
Chapter 3 describes the synthesis of fully orthogonally protected and enantiopure 2-deoxystreptamine 
starting from commercially available kanamycin A (Figure 2). Key step of the route is the 
desymmetrization of a meso 2-deoxystreptamine intermediate by enzymatic resolution, under the action 
of an esterase obtained from Verenium. Subsequent chemoselective azide reduction completed the 
synthesis of an enantiopure 2-deoxystreptamine derivative. The latter compound may be utilized as 
scaffold in the development of novel structural analogues of natural aminoglycosides, given the fact that 
2-deoxystreptamine is highly conserved and plays a fundamental role in the binding of aminoglycosides 
to RNA.
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Figure 2. Synthetic path from kanamycin A, via meso 2-deoxystreptamine, to an enantiopure 2-deoxystreptamine analog.
It is known that aminoglycosides, known A-site ligands, can also bind to the HIV DIS kissing loop 
complex. The crystal structure of neomycin bound to HIV DIS kissing loop complex illustrates that ring 
I of neomycin is involved in pseudo base-pairing with A280. In Chapter 4 we describe a strategy to 
replace ring I of neomycin with a nucleobase (thymine), with the objective to enhance neomycin affinity 
and selectivity for the kissing-loop complex due to complementary base-pairing of thymine with 
adenosine A280. Thus, a conjugate of truncated neomycin to thymine was prepared (Figure 4). 
Chemoselective cleavage of neomycin, followed by reconstitution after protecting group 
interconversion, proved to be effective for the selective removal of ring I of neomycin before installation
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of thymine. The resulting conjugate was evaluated for binding to a range of RNA structures by 
isothermal titration calorimetry and was found to bind selectively to the HIV DIS complex (subtype F).
PGHN
PGHN OPG
Figure 4. Synthesis of thymine-conjugate via truncation of neomycin.
Chapter 5 describes the synthesis of C-6'(R)-methyl neamine and C-6'(R)-methyl neomycin derivatives 
from commercially available paromomycin with the objective to reduce aminoglycoside toxicity 
(Figure 3). Regioselective differentiation of two primary alcohols was achieved by the partial hydrolysis 
of the paromomycin and subsequent protective group manipulation. Oxidation was followed by 
stereoselective methyl addition to the resulting aldehyde with AlMe3 and CuCN at low temperature. 
Nucleophilic substitution of the resulting alcohol, with inversion of configuration, and deprotection 
yielded the desired C-6'(R)-methyl neamine. Ultimately, glycosylation of the modified neamine with a 
disaccharide donor gave C-6'(R)-methyl neomycin.
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Figure 3. Potentially non-toxic C-6'(R)-methylated analogs of neamine and neomycin in a synthetic route starting from 
paromomycin.
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De aminoglycosiden vormen een familie van breed-spectrum antibiotica met grote structurele 
overeenkomst die binden aan de tRNA bindingsplaats (A-plaats of aminoacyl plaats) van het 16S 
ribosomale RNA. Door te binden aan het rRNA, verstoort het aminoglycoside de betrouwbaarheid van 
de translatie van mRNA naar het eiwit die op het ribosoom plaatsvindt. Helaas is de klinische relevantie 
van aminoglycosiden als antibiotica tanende als gevolg van toxische bijwerkingen en een groeiende 
bacteriële resistentie. Vanwege deze beperkingen is er al uitgebreid en divers onderzoek gedaan naar de 
ontwikkeling van nieuwe aminoglycoside-type antibitioca met verbeterde eigenschapen.
In het inleidende hoofdstuk van dit proefschrift (Hoofdstuk 1) wordt een overzicht gegeven van de 
synthetische routes die in de literatuur zijn gerapporteerd om verbeterde aminoglycoside-analoga te 
maken, met als doel om (a) de bindingsaffiniteit te verhogen, (b) resistentie te omzeilen en (c) toxiciteit 
te reduceren.
In Hoofdstuk 2  wordt de synthese beschreven van een panel aan aminoglycoside analoga via een 
combinatie van technieken zoals heteroconjugatie en dimerisatie (Figuur 1). Hiertoe werden eerst beide 
diaminosuikers van natuurlijk neomycine B afgesplitst, met als doel om een aminoglycoside-type 
bouwsteen te verkrijgen die minder gevoelig is voor bacteriële resistentie. De ribose ring die hierna 
overbleef werd omgezet in een morpholine ring en om de RNA affiniteit te herstellen werd het hierdoor 
verkregen, gekortwiekte neomycine (5-0-morpholino-2-deoxystreptamine) vervolgens geconjugeerd 
aan andere RNA liganden die niet tot het aminoglycoside-type behoren. Zo ontstond door middel van 
dimerisatie van de resulterende conjugaten met een reeks aan bisaziden, een klein assortiment aan 
mogelijk RNA-bindende liganden in een over het geheel genomen efficiënte synthetische met daarin een 
minimum aan beschermgroep-transformaties. Alle verbindingen werden getest op anti-bacteriële 
activiteit en vergeleken met kanamycine met behulp van een nieuwe, fluorescentie-gebaseerde bio­
assay. Diverse verbindingen, zowel dimeren als monomeren, vertoonden inderdaad enige bacteriële 
activiteit, met hoog micromolaire activiteit. Een hoopgevende bevinding betrof de enigszins verhoogde 
activiteit van enkele verbindingen tegen een kanamycine-resistente stam, wat een aanwijzing kan
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betekenen dat het verwijderen van heteroatomen van aminoglycosiden inderdaad een succesvolle 
strategie kan zijn om activiteit tegen resistente stammen te verhogen.
Hoofdstuk 3 beschrijft de chemische omzetting van het commercieel verkrijgbare kanamycine tot een 
volledig orthogonaal beschermd en enantiomeer zuiver 2-deoxystreptamine (Figuur 2). De belangrijkste 
stap van de route omvat de enzymatische desymmetrisatie van een meso 2-deoxystreptamine 
intermediair, onder invloed van een esterase van Verenium. De synthese van het enantiomeer zuivere 2- 
deoxystreptamine werd vervolgens voltooid door een chemoselectieve azide reductie. Gezien het feit dat 
2-deoxystreptamine onderdeel uitmaakt van nagenoeg alle aminoglycosiden, en daarnaast een 
belangrijke rol speelt in de binding met RNA, ligt het in de lijn der verwachting dat een zuivere 
2-deoxystreptamine als bouwsteen kan dienen voor de ontwikkeling van geheel nieuwe structurele 
analoga van de natuurlijke aminoglycosiden.
hydrolyse
Figuur 2. Synthetische route van kanamycin A, via meso 2-deoxystreptamine, naar een enantiomeer zuiver 
2-deoxy streptamine-analo gon.
met het HIV DIS kissing loop. De kristalstructuur van neomycine gebonden aan het HIV DIS kissing
beschrijven we een strategie om deze ring I van neomycin te vervangen door een nucleobase (thymine),
neomycine B
C D
O ' S  #
\
r a
Figuur 1. Dimere 5-O-morpholino derivativen van 2-deoxystreptamine als mogelijk nieuwe antibiotica.
Het is bekend dat aminoglycosiden, die zoals gezegd binden op de A-plaats, ook een complex vormen
loop complex laat zien dat ring I van neomycine een pseudo base-paar vormt met A280. In Hoofdstuk 4
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met als doen om de affiniteit en de selectiviteit van neomycine met het kissing loop complex te 
verhogen als gevolg van base-paar vorming van thymine met het complementaire adenosine A280. 
Daartoe werd een neomycine, waarvan een ring selectief verwijderd was, synthetisch geconjugeerd aan 
thymine (Figuur 4). Een effectieve route werd gevonden in de chemoselectieve hydrolyse van 
neomycine tot neamine en neobiosamine. Van het neamine kon ring I nu afgesplitst worden, na enkele 
beschermgroep-interconversies gevolgd door herintroductie van het dimere neobiosamine en chemische 
binding van de thymine-ring. Binding van het resulterende conjugaat aan een reeks RNA structuren 
werd bepaald met isothermale titratie-caloriemetrie, waarbij selectiviteit voor binding aan het HIV DIS 
complex (subtype F) werd vastgesteld.
Figuur 4. Synthese van een thymine-conjugaat door kortwieken van neomycine en vorming van een N,O-acetaal.
Chapter 5 behandelt de synthese van C-6'(R)-methyl neamine en C-6'(R)-methyl neomycin derivaten 
vanuit het commercieel verkrijgbare paromomycine met als doel om de toxiciteit van aminoglycosiden 
te reduceren (Figuur 3). Door middel van een partiële hydrolyse van paromomycine en een aantal 
beschermgroep-manipulaties werd een regioselectieve differentiatie van de twee primaire alcoholen 
bereikt. Na oxidatie tot een aldehyde vond een stereoselectieve methyl-additie plaats, onder invloed van 
AlMe3 en CuCN op lage temperatuur. Het gewenste C-6'(R)-methyl neamine werd vervolgens verkregen 
door nucleofiele substitutie van het alcohol product, met inversie van configuratie. Na een 
ontschermingsstap, vond glycosylering van dit gemodificeerd neamine plaats met een disaccharide 
donor, wat resulteerde in het gewenste C-6'(R)-methyl neomycine.
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Figuur 3. Mogelijk niet-toxische C-6'(R)-gemethyleerde analoga van neamine en neomycine worden verkregen door middel 
van een synthetische route vanuit paromomycine.
126
Outlook
Outlook
Despite the discovery of various antibiotics bacterial infection remains a serious threat to human lives 
because of emerging resistance to existing antibiotics. Hence the circumstances necessitate the 
development of new antibacterial compounds to counter the growing bacterial resistance. However, 
history demonstrates a low interest of the pharmaceutical industry in the development of novel 
antibiotics. So the improvement of the existing drugs by synthetic diversification provides an 
opportunity to match the persistent need of new antibacterial compounds.
Aminoglycosides, a family of structurally related broad spectrum bactericidal compounds, have been 
used for several years for the treatment of aerobic Gram-negative bacterial infections due to the strong 
bactericidal activity, low cost and synergistic effects in combination with other drugs. However, toxic 
side-effects and growing bacterial resistance have narrowed the significance of aminoglycosides as 
antibiotics. Inactivation of aminoglycosides by bacterial enzymes is one of the most important resistance 
mechanisms and renders the fight against resistance difficult since evading or transforming the target 
sites of modification (amine or alcohol) of bacterial enzymes reduces the antibacterial activity as well, 
because the same heteroatoms are responsible for RNA binding. Conjugation of the modulated 
aminoglycosides with another RNA ligand could be a practical strategy to manage the resistance issue. 
Apart from this, aminoglycosides are naturally occurring organic molecules with high RNA affinity, 
which may serve as basis for RNA drug development. Synthesis of various derivatives of 
aminoglycosides could be a versatile strategy to increase both the affinity and the selectivity for a 
specific RNA construct. Since 2-deoxystreptamine is the most conserved element of aminoglycosides, 
the 2-DOS precurser synthesized in Chapter 3 of this Thesis could be employed as a scaffold for the 
development of various symmetrical and unsymmetrical aminoglycoside derivatives.
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